Treprostinil prodrug dry powder compositions and methods of use thereof
Patent Information
- Application Number
- JP2023526131
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-10-28
- Filing Date
- 2021-10-28
- Publication Date
- 2024-11-07
- Estimated Expiration
- 2041-10-28
AI Technical Summary
There is a need for novel treatment options for pulmonary hypertension (PH), particularly for conditions such as portopulmonary hypertension (PPH) and PH associated with interstitial lung disease, as current treatments are limited and ineffective for many patients.
A dry powder composition comprising treprostinil prodrugs, specifically formulated with compounds of formula (I) and leucine, mannitol, and optionally trehalose, administered via inhalation using a dry powder inhaler, providing a direct route to treat PH.
The dry powder composition effectively delivers treprostinil to the lungs, achieving therapeutic plasma concentrations and improving symptoms of PH, offering a more efficient and targeted treatment approach compared to existing methods.
Smart Images

Figure 2022094100000001 
Figure 2022094100000002
Abstract
Description
[Background technology]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 63 / 106,818, filed October 28, 2020, the disclosure of which is incorporated herein by reference in its entirety.
[0002] Pulmonary hypertension (PH) is characterized by abnormally high blood pressure in the pulmonary vasculature. It is a progressive, fatal disease leading to heart failure and can occur in the pulmonary arteries, pulmonary veins, or pulmonary capillaries. Symptomatic patients experience shortness of breath, dizziness, syncope, and other symptoms, all of which are worsened by exercise. It has multiple causes and can be idiopathic, with unknown etiology, or can lead to hypertension in other systems, such as portopulmonary hypertension, in which patients have both portal vein and pulmonary hypertension.
[0003] Pulmonary hypertension is classified into five groups by the World Health Organization (WHO). Group 1, referred to as pulmonary arterial hypertension (PAH), includes idiopathic (unknown cause), hereditary PAH (i.e., familial PAH or FPAH), drug- or toxin-induced PAH, and PAH caused by conditions such as connective tissue disease, HIV infection, liver disease, and congenital heart disease. Group 2 pulmonary hypertension is characterized as pulmonary hypertension associated with left heart disease. Group 3 pulmonary hypertension is characterized as PH associated with lung diseases such as chronic obstructive pulmonary disease and interstitial lung disease, and PH associated with sleep-related breathing disorders (e.g., sleep apnea). Group 4 PH is PH due to chronic thrombotic and / or embolic diseases, such as PH caused by pulmonary blood clots or blood coagulation disorders. Group 5 includes PH caused by other disorders or conditions, such as hematological disorders (e.g., polycythemia vera, essential thrombocythemia), systemic disorders (e.g., sarcoidosis, vasculitis), and metabolic disorders (e.g., thyroid disease, glycogen storage disease).
[0004] Pulmonary arterial hypertension (PAH) affects approximately 200,000 people worldwide, with approximately 30,000-40,000 of those in the United States. PAH patients experience constriction of the pulmonary arteries, which increases pulmonary artery blood pressure and makes it difficult for the heart to pump blood to the lungs. Patients often suffer from shortness of breath and fatigue, which severely limits their ability to engage in physical activity.
[0005] The New York Heart Association (NYHA) classifies PAH patients into four functional classes to assess the severity of their disease. NYHA Class I PAH patients have no physical activity limitations because ordinary physical activity does not cause excessive dyspnea or fatigue, chest pain, or near-syncope. NYHA Class II PAH patients have slight physical activity limitations. These patients are comfortable at rest, but ordinary physical activity causes excessive dyspnea or fatigue, chest pain, or near-syncope. NYHA Class III PAH patients have significant physical activity limitations. Despite being comfortable at rest, Class III PAH patients experience excessive dyspnea or fatigue, chest pain, or near-syncope as a result of less than ordinary physical activity. NYHA Class IV PAH patients are unable to perform physical activity without symptoms. Class IV PAH patients may experience dyspnea and / or fatigue at rest, and discomfort increases with physical activity. Signs of right heart failure are often evident in patients with class IV PAH.
[0006] PAH patients are treated with endothelin receptor antagonists (ERAs), phosphodiesterase type 5 (PDE-5) inhibitors, guanylate cyclase stimulators, prostanoids (e.g., prostacyclin), or combinations thereof. ERAs include ambrisentan (Letairis®), sitaxsentan, bosentan (Tracleer®), and macitentan (Opsumit®). PDE-5 inhibitors indicated for the treatment of PAH include sildenafil (Revatio®) and tadalafil (Adcirca®). Prostanoids indicated for the treatment of PAH include iloprost, epoprocentre, and treprostinil (Remodulin®, Tyvaso®). One approved guanylate cyclase stimulator is riociguat (Adempas®). In addition, patients are often treated with combinations of the aforementioned compounds.
[0007] The present invention addresses the need for new treatment options for pulmonary hypertension (PH) (including pulmonary arterial hypertension (PAH) and PH associated with interstitial lung disease), portopulmonary hypertension (PPH), and pulmonary fibrosis by providing dry powder compositions of treprostinil prodrugs useful for pulmonary administration and methods of administering the same to patients in need of treatment. Summary of the Invention
[0008] In one aspect, the present disclosure provides a composition comprising: (a) about 0.5 wt % to about 5 wt % of Formula (I); [ka] In the formula, R 1The present invention relates to a dry powder composition comprising a compound of Formula (I), its stereoisomer, or a pharmaceutically acceptable salt thereof, wherein (a) is tetradecyl, pentadecyl, hexadecyl, heptadecyl, or octadecyl; (b) about 10 wt% to about 61 wt% leucine; and the remainder (c) a sugar selected from the group consisting of trehalose and mannitol. The total of (a), (b), and (c) is 100 wt%. In a further embodiment, the composition comprises about 29 wt% to about 61 wt% leucine. In yet another embodiment, the composition comprises 0.5 wt% to about 4 wt% of the compound of Formula (I), its stereoisomer, or a pharmaceutically acceptable salt thereof.
[0009] In one embodiment, the stereoisomer is a diastereomer of a compound of formula (I), or a pharmaceutically acceptable salt thereof. In a further embodiment, the stereoisomer is a diastereomer of a compound of formula (I). In another embodiment, the stereoisomer is a diastereomer of a pharmaceutically acceptable salt of a compound of formula (I).
[0010] In one embodiment, R 1 is tetradecyl. In a further embodiment, R 1 is a linear tetradecyl.
[0011] In one embodiment, R 1 is pentadecyl. In a further embodiment, R 1 is a linear pentadecyl.
[0012] In one embodiment, R 1 is heptadecyl. In a further embodiment, R 1 is a linear heptadecyl.
[0013] In one embodiment, R 1 is octadecyl. In a further embodiment, R 1 is linear octadecyl.
[0014] In one embodiment, R 1 is hexadecyl. In a further embodiment, R 1is a linear hexadecyl.
[0015] In one embodiment, the compound of formula (I), its stereoisomer, or its pharmaceutically acceptable salt is present in about 0.5 wt% to about 4 wt% of the total weight of the dry powder composition. 1 is hexadecyl. In yet another embodiment, R 1 is linear hexadecyl. In yet another embodiment, the compound of formula (I), or a pharmaceutically acceptable salt thereof, is present in about 2 wt% to about 4 wt% of the total weight of the dry powder composition.
[0016] In one embodiment, the compound of formula (I), its stereoisomer, or its pharmaceutically acceptable salt is present in about 1 wt% to about 4 wt% of the total weight of the dry powder composition. 1 is hexadecyl. In yet another embodiment, R 1 is a linear hexadecyl.
[0017] In one embodiment, the compound of formula (I), its stereoisomer, or its pharmaceutically acceptable salt is present in about 1 wt% to about 3.5 wt% of the total weight of the dry powder composition. 1 is hexadecyl. In yet another embodiment, R 1 is a linear hexadecyl.
[0018] In one embodiment, the compound of formula (I), its stereoisomer, or its pharmaceutically acceptable salt is present in about 1 wt% to about 3 wt% of the total weight of the dry powder composition. 1 is hexadecyl. In yet another embodiment, R 1 is a linear hexadecyl.
[0019] In one embodiment, the compound of formula (I), its stereoisomer, or its pharmaceutically acceptable salt is present in about 1.5 wt% to about 4 wt% of the total weight of the dry powder composition. 1 is hexadecyl. In yet another embodiment, R 1is a linear hexadecyl.
[0020] In one embodiment, the compound of formula (I), its stereoisomer, or its pharmaceutically acceptable salt is present in about 0.8 wt% to about 4 wt% of the total weight of the dry powder composition. 1 is hexadecyl. In yet another embodiment, R 1 is a linear hexadecyl.
[0021] In one embodiment, the compound of formula (I), its stereoisomer, or its pharmaceutically acceptable salt is present in about 0.8 wt% to about 3.3 wt% of the total weight of the dry powder composition. 1 is hexadecyl. In yet another embodiment, R 1 is a linear hexadecyl.
[0022] In one embodiment, the compound of formula (I), its stereoisomer, or its pharmaceutically acceptable salt is present in about 1 wt% to about 2 wt% of the total weight of the dry powder composition. 1 is hexadecyl. In yet another embodiment, R 1 is a linear hexadecyl.
[0023] In one embodiment, the compound of formula (I), its stereoisomer, or its pharmaceutically acceptable salt is present in about 1 wt% to about 1.5 wt% of the total weight of the dry powder composition. 1 is hexadecyl. In yet another embodiment, R 1 is a linear hexadecyl.
[0024] In one embodiment, the compound of formula (I), its stereoisomer, or its pharmaceutically acceptable salt is present in about 1 wt% of the total weight of the dry powder composition. 1 is hexadecyl. In yet another embodiment, R 1 is a linear hexadecyl.
[0025] In one embodiment, the compound of formula (I), its stereoisomer, or its pharmaceutically acceptable salt is present in about 2 wt% of the total weight of the dry powder composition. 1 is hexadecyl. In yet another embodiment, R 1 is a linear hexadecyl.
[0026] In one embodiment, the compound of formula (I), its stereoisomer, or its pharmaceutically acceptable salt is present in about 3 wt% of the total weight of the dry powder composition. 1 is hexadecyl. In yet another embodiment, R 1 is a linear hexadecyl.
[0027] In one embodiment, the compound of formula (I), its stereoisomer, or its pharmaceutically acceptable salt is present in about 4 wt% of the total weight of the dry powder composition. 1 is hexadecyl. In yet another embodiment, R 1 is a linear hexadecyl.
[0028] In one embodiment, leucine is present at about 20 wt% to about 40 wt% of the total weight of the dry powder composition. 1 is hexadecyl. In yet another embodiment, R 1 is linear hexadecyl. In yet another embodiment, the compound of formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof is present in about 1 wt% to about 4 wt% of the total weight of the dry powder composition.
[0029] In another embodiment, leucine is present at about 29 wt% to about 61 wt% of the total weight of the dry powder composition. 1 is hexadecyl. In yet another embodiment, R 1 is linear hexadecyl. In yet another embodiment, the compound of formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof is present in about 1 wt% to about 4 wt% of the total weight of the dry powder composition.
[0030] In another embodiment, leucine is present at about 25 wt% to about 35 wt% of the total weight of the dry powder composition. 1 is hexadecyl. In yet another embodiment, R 1 is linear hexadecyl. In yet another embodiment, the compound of formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof is present in about 1 wt% to about 4 wt% of the total weight of the dry powder composition.
[0031] In another embodiment, leucine is present at about 40 wt% to 61 wt% of the total weight of the dry powder composition. 1 is hexadecyl. In yet another embodiment, R 1 is linear hexadecyl. In yet another embodiment, the compound of Formula (I), its stereoisomer, or its pharmaceutically acceptable salt is present at about 1 wt% to about 4 wt% of the total weight of the dry powder composition. In a further embodiment, leucine is present at about 45 wt% to 61 wt% of the total weight of the dry powder composition. In yet another embodiment, leucine is present at about 55 wt% to 61 wt% of the total weight of the dry powder composition.
[0032] In another embodiment, leucine is present at about 28 wt% to about 33 wt% of the total weight of the dry powder composition. 1 is hexadecyl. In yet another embodiment, R 1 is linear hexadecyl. In a further embodiment, the compound of formula (I), or a pharmaceutically acceptable salt thereof, is present in about 1 wt% to about 4 wt% of the total weight of the dry powder composition.
[0033] In another embodiment, leucine is present at about 25 wt% to about 33 wt% of the total weight of the dry powder composition, e.g., about 27 wt% to about 33 wt%, about 27 wt% to about 31 wt%, about 27 wt% to about 30 wt%, about 28 wt% to about 30 wt%, or about 30 wt% of the total weight of the dry powder composition. 1 is hexadecyl. In yet another embodiment, R 1is a linear hexadecyl.
[0034] In one embodiment, the dry powder compositions provided herein have a leucine to mannitol weight ratio of about 0.40 to 1 (leucine to mannitol) to about 0.50 to 1 (leucine to mannitol). In another embodiment, the dry powder compositions provided herein have a leucine to mannitol weight ratio of about 0.75 to 1 (leucine to mannitol) to about 0.90 to 1 (leucine to mannitol). In yet another embodiment, the dry powder compositions provided herein have a leucine to mannitol weight ratio of about 0 to about 1.5 to 1 (leucine to mannitol) to about 1.7 to 1 (leucine to mannitol).
[0035] In one embodiment, the sugar is mannitol. 1 is hexadecyl. In a further embodiment, R 1 is a linear hexadecyl.
[0036] In one embodiment, the dry powder composition comprises (a) about 1 wt% of the compound of Formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, (b) about 29.3 wt% or about 29.6 wt% of leucine, and the balance (c) mannitol. 1 is hexadecyl. In a further embodiment, R 1 is a linear hexadecyl.
[0037] In one embodiment, the dry powder composition comprises (a) about 3 wt% of the compound of formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, (b) about 29.3 wt% or about 29.6 wt% of leucine, and the balance (c) mannitol. 1 is hexadecyl. In a further embodiment, R 1 is a linear hexadecyl.
[0038] In another aspect of the present invention, there is provided a method of treating pulmonary hypertension (PH) in a patient in need thereof, the method comprising administering to the patient's lungs by inhalation via a dry powder inhaler an effective amount of a dry powder composition disclosed herein.
[0039] In one embodiment, the PH is Group 1 PH as characterized by the World Health Organization (WHO).
[0040] In one embodiment, pulmonary hypertension is pulmonary arterial hypertension (PAH). In one embodiment, PAH is Class I PAH as characterized by the New York Heart Association (NYHA). In another embodiment, PAH is Class II PAH as characterized by the NYHA. In another embodiment, PAH is Class III PAH as characterized by the NYHA. In another embodiment, PAH is Class IV PAH as characterized by the NYHA.
[0041] In another embodiment, the PH is WHO Group 2 PH. In another embodiment, the PH is WHO Group 3 PH. In a further embodiment, the Group 3 PH is PH associated with interstitial lung disease (ILD). In another embodiment, the PH is WHO Group 4 PH. In another embodiment, the PH is WHO Group 5 PH.
[0042] In one embodiment of the methods of treatment described herein, administration is performed once daily or twice daily.
[0043] In yet another aspect, the present disclosure relates to a system for treating PH. The system includes one of the dry powder compositions disclosed herein and a dry powder inhaler (DPI), which may be a single-dose or multi-dose inhaler. In another embodiment, the DPI is pre-metered or device-metered.
[0044] Yet another embodiment of the present invention relates to a method for treating PH (e.g., PAH or PH-ILD) in an adult human patient in need thereof, comprising administering from about 80 μg to about 675 μg of a compound of Formula (I), [ka] In the formula, R 1 is tetradecyl, pentadecyl, hexadecyl, heptadecyl, or octadecyl, its stereoisomer, or a pharmaceutically acceptable salt thereof, into the patient's lungs by inhalation; During the administration period, the patient has at least one of the following characteristics: (a) Treprostinil maximum plasma concentration (C) in the range of about 80% to about 125% of the range of about 17 pg / mL to about 1150 pg / mL max ),or (b) Approximately 475pg * h / mL~about 8000pg * The area under the treprostinil plasma concentration curve (AUC) ranged from approximately 80% to approximately 125% of the normal range (h / mL). 0-inf In a further embodiment, R 1 is hexadecyl, for example, linear hexadecyl.
[0045] In further embodiments, the composition comprises a dose selected from the group consisting of 80 μg, 160 μg, 240 μg, 320 μg, 400 μg, 480 μg, and 640 μg of a compound of Formula (I). The dose may be present, for example, in a single dry powder capsule or in multiple capsules.
[0046] In another aspect, the present disclosure provides a pharmaceutical composition comprising a pharmaceutical composition comprising about 80 μg to about 675 μg of Formula (I), [ka] In this aspect, the dry powder composition provides at least one of the following characteristics: (a) About 80% to about 125% of the maximum treprostinil plasma concentration (C) in the range of about 17 pg / mL to about 1150 pg / mL max ),or (b) Approximately 475pg * h / mL~about 8000pg * The area under the plasma concentration curve (AUC) in the range of approximately 80% to approximately 125% of h / mL 0-inf ).
[0047] In further embodiments, the composition comprises a dose selected from the group consisting of 80 μg, 160 μg, 240 μg, 320 μg, 400 μg, 480 μg, and 640 μg of a compound of Formula (I). The dose may be present, for example, in a single dry powder capsule or in multiple capsules.
[0048] In some embodiments, the dry powder compositions described herein and used in the methods described herein comprise about 1 wt% to about 5 wt% of a compound of Formula (I) or (II), or a pharmaceutically acceptable salt thereof, with the remainder being one or more pharmaceutically acceptable excipients suitable for use in a dry powder inhaler. In some embodiments, the one or more pharmaceutically acceptable excipients suitable for use in a dry powder inhaler comprise a sugar, an amino acid, and optionally distearoylphosphoethanoamine-polyethylene glycol 2000 (DPSE-PEG2000). In some embodiments of the dry powder compositions or methods described herein, the dry powder composition comprises about 25 wt% to about 61 wt% leucine, with the remainder being one or more sugars. In some embodiments, the one or more sugars are selected from trehalose and mannitol. In some embodiments of the dry powder compositions or methods described herein, the dry powder composition does not comprise distearoylphosphoethanoamine-polyethylene glycol 2000 (DPSE-PEG2000). [Brief explanation of the drawings]
[0049] [Figure 1] FIG. 1 is a graph showing the concentration of treprostinil palmityl (TP) in the lungs after inhalation of TPIP-A or TPIP-B.
[0050] [Figure 2] FIG. 2 is a graph showing the concentration of TRE in the lung after inhalation of TPIP-A or TPIP-B.
[0051] [Figure 3] FIG. 3 is a graph showing the concentration of treprostinil palmityl (TP) equivalents in the lungs after inhalation of TPIP-A or TPIP-B.
[0052] [Figure 4] FIG. 4 is a graph showing plasma TRE concentrations after inhalation of TPIP-A or TPIP-B.
[0053] [Figure 5] FIG. 5 is a graph showing the concentration of TP in BAL cell fractions after inhalation of TPIP-A or TPIP-B.
[0054] [Figure 6] FIG. 6 is a graph showing the concentration of TRE in BAL cell fractions after inhalation of TPIP-A or TPIP-B.
[0055] [Figure 7] FIG. 7 is a graph showing the concentration of TP equivalents in BAL cell fractions after inhalation of TPIP-A or TPIP-B.
[0056] [Figure 8] FIG. 8 is a graph showing the concentration of TP in BAL fluid after inhalation of TPIP-A or TPIP-B.
[0057] [Figure 9] FIG. 9 is a graph showing the concentration of TRE in BAL fluid after inhalation of TPIP-A or TPIP-B.
[0058] [Figure 10]FIG. 10 is a graph showing the concentration of TP equivalents in BAL fluid after inhalation of TPIP-A or TPIP-B.
[0059] [Figure 11] FIG. 11 is a graph showing the response of ΔRVPP to hypoxic challenge in rats exposed to TPIP-B at 6 μg / kg by inhalation.
[0060] [Figure 12] FIG. 12 is a graph showing the ΔRVPP response to hypoxic challenge in rats exposed to 23 μg / kg inhaled TPIP-B.
[0061] [Figure 13] FIG. 13 is a graph showing the response of RVPP to hypoxic challenge in rats exposed to 57 μg / kg inhaled TPIP-B.
[0062] [Figure 14] FIG. 14 is a graph showing the response of RVPP to hypoxic challenge in rats exposed to 138 μg / kg inhaled TPIP-B.
[0063] [Figure 15] FIG. 15 is a graph showing plasma TRE concentrations after TPIP-B inhalation.
[0064] [Figure 16] FIG. 16 is a graph showing TP concentrations in the lungs after TPIP-B inhalation.
[0065] [Figure 17] FIG. 17 is a graph showing TRE concentrations in the lung after TPIP-B inhalation.
[0066] [Figure 18] FIG. 18 is a graph showing TP equivalent concentrations in the lungs after TPIP-B inhalation.
[0067] [Figure 19] Figure 19 is a schematic diagram of the study design to examine the pharmacokinetic (PK) profile of single and multiple daily doses of TPIP-B in healthy adults. D: day, PK: pharmacokinetic, QD: once daily, Scn: screening, TPIP: treprostinil palmityl inhalation powder.
[0068] [Figure 20A] FIG. 20A is a graph showing the PK results of TPIP-A in healthy adults (single dose).
[0069] [Figure 20B] FIG. 20B is a graph showing the PK findings of TPIP-A in healthy adults (multiple doses).
[0070] [Figure 21] The top of Figure 21 shows one embodiment of a dose titration schedule for a compound of Formula (I) or (II). The bottom of Figure 21 shows the capsule doses used according to the titration schedule in the top of Figure 21. DETAILED DESCRIPTION OF THE INVENTION
[0071] Throughout this disclosure, the term "about" may be used in conjunction with numerical values and / or ranges. The term "about" is understood to mean those values that are close to the recited value. For example, "about 40 units" may mean within ±25%, ±20%, ±15%, ±10%, ±9%, ±8%, ±7%, ±6%, ±5%, ±4%, ±3%, ±2%, ±1%, within ±1%, less than ±1%, or any other value or range of values therein or below 40 (e.g., 30-50).
[0072] The term "pharmaceutically acceptable salt" refers to a salt prepared from a pharmaceutically acceptable non-toxic base or acid, including inorganic or organic bases and inorganic or organic acids. The nature of the salt is not critical, provided that it is pharmaceutically acceptable. Suitable pharmaceutically acceptable acid addition salts may be prepared from inorganic or organic acids. Exemplary pharmaceutical salts are described in Stahl, PH, Wermuth, CG, Eds. Handbook of Pharmaceutical Salts: Properties, Selection and Use; Verlag Helvetica Chimica Acta / Wiley-VCH: Zurich, 2002, the contents of which are incorporated herein by reference in their entirety. Specific, non-limiting examples of inorganic acids are hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, carbonic acid, sulfuric acid, and phosphoric acid. Suitable organic acids include, but are not limited to, aliphatic acids, alicyclic acids, aromatic acids, aryl aliphatic acids, and heterocyclyl containing carboxylic and sulfonic acids, such as formic acid, acetic acid, propionic acid, succinic acid, glycolic acid, gluconic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, glucuronic acid, maleic acid, fumaric acid, pyruvic acid, aspartic acid, glutamic acid, benzoic acid, anthranilic acid, mesylic acid, stearic acid, salicylic acid, p-hydroxybenzoic acid, phenylacetic acid, mandelic acid, embonic (pamoic acid), methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, pantothenic acid, toluenesulfonic acid, 2-hydroxyethanesulfonic acid, sulfanilic acid, cyclohexylaminosulfonic acid, algenic acid, 3-hydroxybutyric acid, galactaric acid, or galacturonic acid. Suitable pharmaceutically acceptable salts of the free acid-containing compounds disclosed herein include, but are not limited to, metal salts and organic salts.Exemplary metal salts include, but are not limited to, suitable alkali metal (group Ia) salts, alkaline earth metal (group IIa) salts, and other physiologically acceptable metal salts.Such salts can be made from aluminum, calcium, lithium, magnesium, potassium, sodium, and zinc.Exemplary organic salts can be made from primary amines, secondary amines, tertiary amines, and quaternary ammonium salts, such as tromethamine, diethylamine, tetra-N-methylammonium, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine), and procaine.
[0073] As used herein, the term "stereoisomer" refers to two molecules that have the same molecular formula and sequence of bonded atoms, but differ in the three-dimensional orientation of their atoms in space. One preferred stereoisomer according to the present invention is a diastereomer. The stereoisomer, in one embodiment, is a diastereomer of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In a further embodiment, the stereoisomer is a diastereomer of a compound of Formula (I). In another embodiment, the stereoisomer is a diastereomer of a pharmaceutically acceptable salt of a compound of Formula (I). In yet another embodiment, the stereoisomer is a diastereomer of a compound of Formula (II). In yet another embodiment, the stereoisomer is a diastereomer of a pharmaceutically acceptable salt of a compound of Formula (II).
[0074] Throughout this specification, numerical ranges are provided for specific quantities. These ranges should be understood to include all subranges therein. Thus, the range "50 to 80" includes all possible ranges therein (e.g., 51 to 79, 52 to 78, 53 to 77, 54 to 76, 55 to 75, 60 to 70, etc.). Furthermore, all values within a given range may be endpoints for the range encompassed thereby (e.g., the range 50 to 80 includes ranges with endpoints such as 55 to 80, 50 to 75, etc.).
[0075] Throughout this specification, numerical ranges are described as encompassing "about 80% to about 125%" or "about 80-125%" of the range of values. These should be understood to include 80% at the lowest endpoint of the range through 125% at the highest endpoint of the range, including all values therein.
[0076] The term “C max " means the maximum (or peak) treprostinil serum concentration measured after a compound of Formula (I) or (II), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof is administered to the lungs of a subject via a dry powder composition described herein. Additionally, C max may be measured after a single dose of a compound of Formula (I) or (II), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof described herein, or treprostinil C max may be measured at steady state. Unless otherwise stated, C max is the mean treprostinil C measured after a single dose in a target population (e.g., a population of PH patients). max Refers to...
[0077] The term "AUC" refers to the area under the plasma concentration-time curve of treprostinil measured from time 0 to a time after administration to the lungs of a subject and calculated using a combination of linear and logarithmic trapezoidal methods (linear up / log down method). In some embodiments, AUC may be measured from time 0 to 24 hours after administration ("AUC"). 0-24」 ), or the AUC may be measured from time 0 until extrapolated to infinity ("AUC 0-inf "). Additionally, treprostinil AUC may be measured after a single dose or at steady-state values. Unless otherwise specified, AUC refers to the mean AUC measured after a single dose in a subject population (e.g., a population of PH patients).
[0078] The term "trough plasma concentration" refers to the treprostinil plasma concentration before administration of a subsequent dose of a compound of Formula (I) or (II), a stereoisomer, or a pharmaceutically acceptable salt thereof. For example, the trough plasma concentration of treprostinil can be measured within 2 hours, 1 hour, or 30 minutes after administration of the subsequent dose. The trough plasma concentration can be measured after a single dose or at steady state. Unless otherwise specified, the trough plasma level refers to the average trough treprostinil level measured in a subject population (e.g., a population of PH patients).
[0079] The term "adult" refers to a human subject, e.g., a human patient, at least 18 years of age. In some embodiments, an adult is between 18 and 100 years of age, including all values and ranges therebetween, e.g., 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 1 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100.
[0080] In one aspect of the present invention, a dry powder composition of a treprostinil prodrug is provided. The dry powder composition comprises: (a) a compound of Formula (I), present in about 0.5 wt% to about 5 wt% of the total weight of the dry powder composition; [ka] In the formula, R 1 is tetradecyl, pentadecyl, hexadecyl, heptadecyl, or octadecyl, or a pharmaceutically acceptable salt thereof; (b) about 10 wt% to about 61 wt% leucine, the remainder and (c) a sugar selected from the group consisting of trehalose and mannitol, wherein the total of (a), (b), and (c) is 100 wt %.
[0081] In a further embodiment, the composition comprises about 25% to about 61% by weight of leucine. In yet another embodiment, the composition comprises about 25% to about 45% by weight of leucine. In another embodiment, the composition comprises about 45% to about 61% by weight of leucine.
[0082] In some embodiments, the compound of Formula (I), its stereoisomer, or its pharmaceutically acceptable salt is present at about 0.4 wt%, about 0.5 wt%, about 1 wt%, about 1.1 wt%, about 1.2 wt%, about 1.3 wt%, about 1.5 wt%, about 1.7 wt%, about 2.0 wt%, about 2.3 wt%, about 2.5 wt%, about 2.6 wt%, about 2.7 wt%, about 2.8 wt%, about 2.9 wt%, about 3 wt%, about 3.1 wt%, about 3.2 wt%, about 3.3 wt%, about 3.4 wt%, about 3.5 wt%, about 4 wt%, about 3.5 wt%, or about 5 wt% of the total weight of the dry powder composition.
[0083] The compound of Formula (I) and its pharmaceutically acceptable salts are treprostinil prodrugs disclosed in International Application Publication No. WO2015 / 061720, the disclosure of which is incorporated herein by reference in its entirety. In some embodiments, leucine is present at about 25 wt%, about 30 wt%, about 35 wt%, about 40 wt%, about 45 wt%, about 50 wt%, about 55 wt%, or about 60 wt% of the total weight of the dry powder composition.
[0084] In one embodiment of a compound of Formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, R 1 is tetradecyl. In a further embodiment, R 1 is a linear tetradecyl.
[0085] In another embodiment of the compound of Formula (I), its stereoisomer, or its pharmaceutically acceptable salt, R 1 is pentadecyl. In a further embodiment, R 1 is a linear pentadecyl.
[0086] In another embodiment of the compound of Formula (I), its stereoisomer, or its pharmaceutically acceptable salt, R 1 is heptadecyl. In a further embodiment, R 1 is a linear heptadecyl.
[0087] In another embodiment of the compound of Formula (I), its stereoisomer, or its pharmaceutically acceptable salt, R1 is octadecyl. In a further embodiment, R 1 is linear octadecyl.
[0088] In another embodiment of the compound of Formula (I), its stereoisomer, or its pharmaceutically acceptable salt, R 1 is hexadecyl. In a further embodiment, R 1 is a linear hexadecyl, i.e., a compound of formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and [ka] In a further embodiment, the compound of formula (I) is a compound of formula (II): 1 The compound of formula (I) where R is linear hexadecyl is also referred to herein as C16TR or its international non-proprietary name, treprostinil palmityl. In this application, C16TR and treprostinil palmityl are used interchangeably. Similarly, the compound of formula (II) is equivalent to the compound of formula (I), wherein R 1 is a linear hexadecyl.
[0089] In one embodiment, (a) is a compound of formula (I) or a pharmaceutically acceptable salt thereof. In a further embodiment, (a) is a compound of formula (II) or a pharmaceutically acceptable salt thereof. In a further embodiment, (a) is a compound of formula (II).
[0090] In one embodiment, the compound of Formula (I) or (II), or a pharmaceutically acceptable salt thereof, is present at about 1 wt% to about 5 wt% of the total weight of the dry powder composition. In some embodiments, the compound of Formula (I) or (II), or a pharmaceutically acceptable salt thereof, is present at about 1 wt% to about 4.5 wt% of the total weight of the dry powder composition. In some embodiments, the compound of Formula (I) or (II) is present at about 1 wt% to about 4 wt% of the total weight of the dry powder composition.
[0091] In one embodiment, the compound of Formula (I) or (II), or a pharmaceutically acceptable salt thereof, is present in about 1 wt% to about 3.5 wt% of the total weight of the dry powder composition. In another embodiment, the compound of Formula (I) or (II), or a pharmaceutically acceptable salt thereof, is present in about 1 wt% to about 3 wt% of the total weight of the dry powder composition.
[0092] In one embodiment, the compound of Formula (I) or (II), or a pharmaceutically acceptable salt thereof, is present at about 1 wt% to about 5 wt%, about 1 wt% to about 4.5 wt%, about 1 wt% to about 4 wt%, about 2 wt%, about 3 wt%, about 4 wt%, or about 5 wt% of the total weight of the dry powder composition. In some embodiments, the compound of Formula (I) or (II), or a pharmaceutically acceptable salt thereof, is present at about 1 wt% to about 5 wt%, about 1 wt% to about 4.5 wt%, about 1 wt% to about 4 wt%, about 1 wt% to about 2 wt%, about 2 wt%, or about 4 wt% of the total weight of the dry powder composition.
[0093] In one embodiment, the compound of Formula (I) or (II), or a pharmaceutically acceptable salt thereof, is present in about 0.8 wt% to about 3.3 wt%, or about 1 wt% to about 3 wt%, or about 1 wt% to about 2 wt%, or about 1 wt% to about 1.5% of the total weight of the dry powder composition.
[0094] In one embodiment, the compound of Formula (I) or (II), or a pharmaceutically acceptable salt thereof, is present at about 1 wt% of the total weight of the dry powder composition. In another embodiment, the compound of Formula (I) or (II), or a pharmaceutically acceptable salt thereof, is present at about 1.5 wt% of the total weight of the dry powder composition.
[0095] In one embodiment, the compound of Formula (I) or (II), or a pharmaceutically acceptable salt thereof, is present in about 0.8 wt% to about 1.5 wt% of the total weight of the dry powder composition. In another embodiment, the compound of Formula (I) or (II), or a pharmaceutically acceptable salt thereof, is present in about 2.7 wt% to about 4 wt% of the total weight of the dry powder composition. In one embodiment, the compound of Formula (I) or (II), or a pharmaceutically acceptable salt thereof, is present in about 2.7 wt% to about 3.5 wt%, e.g., about 2.8 wt% to about 3.2 wt%, or about 2.9 wt% to about 3.1 wt% of the total weight of the dry powder composition.
[0096] In one embodiment, leucine is present at about 25 wt% to about 61 wt% of the total weight of the dry powder composition. In a further embodiment, leucine is present at about 25 wt% to about 50 wt% of the total weight of the dry powder composition. In a further embodiment, leucine is present at about 25 wt% to about 40 wt% of the total weight of the dry powder composition. In a further embodiment, leucine is present at about 20 wt% to about 33 wt% of the total weight of the dry powder composition, e.g., about 20 wt%, about 25 wt%, about 26 wt%, about 27 wt%, about 28 wt%, about 29 wt%, about 30 wt%, about 31 wt%, about 32 wt%, or about 33 wt%. In a further embodiment, leucine is present at about 25 wt% to about 33 wt% of the total weight of the dry powder composition. In further embodiments, leucine is present at about 27 wt% to about 33 wt% of the total weight of the dry powder composition. In further embodiments, leucine is present at about 27 wt% to about 31 wt% of the total weight of the dry powder composition. In further embodiments, leucine is present at about 27 wt% to about 30 wt% of the total weight of the dry powder composition. In further embodiments, leucine is present at about 28 wt% to about 30 wt% of the total weight of the dry powder composition.
[0097] In another embodiment, the leucine is present at about 30 wt% of the total weight of the dry powder composition.
[0098] In yet another embodiment, leucine is present at about 45 wt% to about 61 wt%, e.g., about 45 wt% to about 55 wt%, or about 50 wt% to about 55 wt% of the total weight of the dry powder composition. In a further embodiment, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is present at about 3 wt% to about 4 wt% of the total weight of the dry powder composition. In yet another embodiment, R 1 is hexadecyl, for example, linear hexadecyl.
[0099] In some embodiments, the sugar in the dry powder composition is trehalose, hi other embodiments, the sugar in the dry powder composition is mannitol.
[0100] In one embodiment, the composition has the weight percentages shown in Table A below. In another embodiment, the composition has the weight percentages shown in Table A below, ±5% for each component. In yet another embodiment, the composition has the weight ratio of leucine to mannitol ("leucine:mannitol" or "leucine to mannitol") shown in Table A. [Table 1]
[0101] In one embodiment, the dry powder composition has the ingredients and weight percentages shown in Table B. [Table 2]
[0102] The weight ratio of leucine to sugar (i.e., mannitol or trehalose) in the compositions provided herein is, in one embodiment, about 0.4 to 1 (leucine to mannitol or trehalose) to about 1.7 to 1 (leucine to mannitol or trehalose). In a further embodiment, the composition comprises a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in about 1 wt% to about 4 wt% of the total weight of the dry powder composition. In a further embodiment, the weight ratio of leucine to sugar is about 0.4 to 1 (leucine to mannitol or trehalose) to 0.9 to 1 (leucine to mannitol or trehalose). In yet another embodiment, the weight ratio of leucine to sugar is about 0.4 to 1 (leucine to mannitol or trehalose) to 0.5 to 1 (leucine to mannitol or trehalose). In a further embodiment, the sugar is mannitol. The leucine, in one embodiment, is L-leucine.
[0103] In another embodiment, the sugar is mannitol and the weight ratio of leucine to mannitol is about 0.75 to 1 (leucine to mannitol) to 0.9 to 1 (leucine to mannitol). In a further embodiment, the composition comprises a compound of Formula (I), or a pharmaceutically acceptable salt thereof, at about 1 wt% to about 4 wt% of the total weight of the dry powder composition. In a further embodiment, the weight ratio of leucine to mannitol is about 0.8 to 1 (leucine to mannitol) to 0.9 to 1 (leucine to mannitol). In another embodiment, the sugar is trehalose and the weight ratio of leucine to trehalose is about 0.75 to 1 (leucine to trehalose) to 0.9 to 1 (leucine to trehalose). In a further embodiment, the composition comprises a compound of Formula (I), or a pharmaceutically acceptable salt thereof, at about 1 wt% to about 4 wt% of the total weight of the dry powder composition. In a further embodiment, the weight ratio of leucine to trehalose is about 0.8:1 (leucine to trehalose) to 0.9:1 (leucine to trehalose). The leucine, in one embodiment, is L-leucine.
[0104] In yet another embodiment, the sugar is mannitol and the weight ratio of leucine to mannitol is about 1.5:1 (leucine to mannitol) to 1.7:1 (leucine to mannitol). In a further embodiment, the composition comprises a compound of Formula (I), or a pharmaceutically acceptable salt thereof, at about 1 wt% to about 4 wt% of the total weight of the dry powder composition. In a further embodiment, the weight ratio of leucine to mannitol is about 1.6:1 (leucine to mannitol) to 1.7:1 (leucine to mannitol). In yet another embodiment, the sugar is trehalose and the weight ratio of leucine to trehalose is about 1.5:1 (leucine to trehalose) to 1.7:1 (leucine to trehalose). In a further embodiment, the composition comprises a compound of Formula (I), or a pharmaceutically acceptable salt thereof, at about 1 wt% to about 4 wt% of the total weight of the dry powder composition. In a further embodiment, the weight ratio of leucine to mannitol is about 1.6:1 (leucine to trehalose) to 1.7:1 (leucine to trehalose).
[0105] In another embodiment, the dry powder composition comprises (a) about 1-2 wt% of a compound of Formula (I) or (II), its stereoisomer, or a pharmaceutically acceptable salt thereof, (b) about 29 wt% of leucine, and the remainder (c) mannitol. In a further embodiment, about 1 wt% of a compound of Formula (I) or (II), or a pharmaceutically acceptable salt thereof, is present in the (a) dry powder composition. In another embodiment, about 2 wt% of a compound of Formula (I) or (II), or a pharmaceutically acceptable salt thereof, is present in the (a) dry powder composition.
[0106] In another embodiment, the dry powder composition comprises (a) about 1.5 wt% of a compound of Formula (I) or (II), or a pharmaceutically acceptable salt thereof, (b) about 29.6 wt% of leucine, and the balance (c) mannitol. 1 is a linear hexadecyl in compounds of formula (I).
[0107] In another embodiment, the dry powder composition comprises (a) about 3 wt% of a compound of Formula (I) or (II), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, (b) about 29 wt% of leucine, and the balance (c) mannitol. 1 is a linear hexadecyl in compounds of formula (I).
[0108] In another embodiment, the dry powder composition comprises (a) about 3 wt% of a compound of Formula (I) or (II), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, (b) about 29 wt% of leucine, and the balance (c) mannitol. 1 is a linear hexadecyl in compounds of formula (I).
[0109] In another embodiment, the dry powder composition comprises (a) about 1 wt. % of a compound of Formula (I) or (II), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, (b) about 29 wt. % of leucine, and the balance (c) mannitol. 1 is a linear hexadecyl in compounds of formula (I).
[0110] In another embodiment, the dry powder composition comprises (a) about 1 wt. % of a compound of Formula (I) or (II), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, (b) about 29.6 wt. % of leucine, and the balance (c) mannitol. 1 is a linear hexadecyl in compounds of formula (I).
[0111] In some embodiments, the dry powder composition does not include distearoylphosphoethanoamine-polyethylene glycol 2000 (DPSE-PEG2000).
[0112] In one embodiment, the dry powder composition comprises about 80 μg to about 700 μg of a compound of Formula (I) or (II), for example, about 80 μg, about 100 μg, about 110 μg, about 112.5 μg, about 120 μg, about 130 μg, about 140 μg, about 150 μg, about 160 μg, about 170 μg, including all values and ranges therein. , about 180μg, about 190μg, about 200μg, about 210μg, about 220μg, about 225μg, about 230μg, about 240μg, about 250μg, about 260μg, Approximately 270μg, approximately 280μg, approximately 290μg, approximately 300μg, approximately 310μg, approximately 320μg, approximately 330μg, approximately 340μg, approximately 350μg, approximately 360μg, approximately 370μg, about 380μg, about 390μg, about 400μg, about 410μg, about 420μg, about 430μg, about 440μg, about 450μg, about 460μg, about 4 70μg, about 480μg, about 490μg, about 500μg, about 510μg, about 520μg, about 530μg, about 540μg, about 550μg, about 560μg, about 57 The dry powder composition may comprise about 0 μg, about 580 μg, about 590 μg, about 600 μg, about 610 μg, about 620 μg, about 630 μg, about 640 μg, about 650 μg, about 660 μg, about 670 μg, about 675 μg, about 680 μg, about 690 μg, or about 700 μg of a compound of Formula (I), its stereoisomer, or a pharmaceutically acceptable salt thereof. In one embodiment, the dry powder composition comprises about 80 μg to about 640 μg of a compound of Formula (I) or (II). In one embodiment, the composition comprises about 80 μg, about 160 μg, about 240 μg, about 320 μg, about 400 μg, about 480 μg, or about 640 μg of a compound of Formula (I). The composition, in one embodiment, may be present in a single dry powder capsule or multiple (two or more) dry powder capsules. When present in multiple capsules, one of the aforementioned doses of the compound of formula (I) is divided among the capsules, which in one embodiment are size #3 HPMC capsules.
[0113] Embodiments of TPIP compositions at different unit strengths are provided below in Table C. It should be understood that the unit strengths of the components provided herein can be calculated based on the weight percent of the component and the desired dosage. For example, for an 80 μg dose of TP, multiply each component by 80 to obtain the unit strength of each component. [Table 3]
[0114] In one embodiment, the dry powder composition comprises about 80 μg of a compound of formula (I) or a pharmaceutically acceptable salt thereof. 1 is hexadecyl. In yet another embodiment, R 1 is a linear hexadecyl.
[0115] In one embodiment, the dry powder composition comprises about 160 μg of a compound of formula (I) or a pharmaceutically acceptable salt thereof. 1 is hexadecyl. In yet another embodiment, R 1 is a linear hexadecyl.
[0116] In another embodiment, the dry powder composition comprises about 240 μg of a compound of formula (I) or a pharmaceutically acceptable salt thereof. 1 is hexadecyl. In yet another embodiment, R 1 is a linear hexadecyl.
[0117] In one embodiment, the dry powder composition comprises about 320 μg of a compound of formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. 1 is hexadecyl. In yet another embodiment, R 1 is a linear hexadecyl.
[0118] In another embodiment, the dry powder composition comprises about 400 μg of a compound of formula (I) or a pharmaceutically acceptable salt thereof.1 is hexadecyl. In yet another embodiment, R 1 is a linear hexadecyl.
[0119] In another embodiment, the dry powder composition comprises about 480 μg of a compound of formula (I) or a pharmaceutically acceptable salt thereof. 1 is hexadecyl. In yet another embodiment, R 1 is a linear hexadecyl.
[0120] In one embodiment, the dry powder composition comprises about 640 μg of a compound of formula (I) or a pharmaceutically acceptable salt thereof. 1 is hexadecyl. In yet another embodiment, R 1 is a linear hexadecyl.
[0121] In preferred embodiments of the dry powder compositions provided herein, the leucine is L-leucine.
[0122] In another aspect, the present disclosure provides dry powder compositions comprising a compound of Formula (I) or (II), or a pharmaceutically acceptable salt thereof, which provide a particular pharmacokinetic profile after once-daily administration. Advantageously, the pharmacokinetic profile is C , compared to the current treprostinil inhalation solution, Tyvaso®. max is low and has a long half-life.
[0123] In one embodiment, a dry powder composition exhibiting one of the pharmacokinetic profiles described herein is a composition described in U.S. Patent Application Publication No. 2020 / 0338005, the entirety of which is incorporated herein by reference for all purposes.
[0124] In another embodiment, a dry powder composition exhibiting one of the pharmacokinetic profiles described herein comprises (a) about 1 wt% to about 5 wt% of a compound of Formula (I) or (II) by total weight of the dry powder composition, (b) about 25 wt% to about 61 wt% of leucine, and the balance (c) a sugar selected from trehalose and mannitol, the total of (a), (b), and (c) being 100 wt%.
[0125] As discussed in Example 5, the pharmacokinetic (PK) profile measured for the compound of Formula (I) or (II), its stereoisomers, or a pharmaceutically acceptable salt thereof was linear over the dose range of 112.5 μg to 675 μg. Based on this data, one skilled in the art could determine the pharmacokinetic parameters for doses outside the range, or for doses within this range that were not specifically tested in Example 5. For example, to find the pharmacokinetic parameters at a dose, one may plot the Cmax and AUC associated with a particular dose (112.5 μg, 225 μg, 450 μg, and / or 675 μg). The scatter plot may be fitted with a straight line, y = mx + b, where m is the slope of the line and b is the y-intercept, and the value of the unknown pharmacokinetic parameter (y) may be calculated by plugging the dose for x. Furthermore, the dose range of 112.5 μg to 675 μg is within the R 1 is hexadecyl (i.e., the compound of formula (II)). 1 The equivalent dose of 112.5 μg of Formula II (where R is tetradecyl, pentadecyl, heptadecyl, or octadecyl) can be calculated using the molecular weight of the treprostinil prodrug of interest. For example, 1 is hexadecyl) is equivalent to the compound R 1 The dose of the compound of formula (I) where R is tetradecyl is 112.5 μg, 1 is tetradecyl, the molecular weight of the compound of formula (II) (614.95 μg / mol) can be calculated by multiplying the ratio of the molecular weight of the compound of formula (I) (586.9 μg / mol).
[0126] In embodiments, the dry powder compositions of the present disclosure are formulated for once-daily administration by inhalation to the lungs of a subject at a dose ranging from about 80 μg to about 675 μg of a compound of Formula (I) or (II), a stereoisomer, or a pharmaceutically acceptable salt thereof, and provide at least one of the following characteristics: (a) Treprosintil maximum plasma concentration (C) ranging from about 14 pg / mL to about 1430 pg / mL max ),or (b) Approximately 500pg * h / mL~approx. 10000pg * Area under the treprostinil plasma concentration curve (AUC) in the range of h / mL.
[0127] In further embodiments, the composition comprises about 80 μg, about 112.5 μg, about 160 μg, about 225 μg, about 240 μg, about 320 μg, about 400 μg, about 450 μg, about 480 μg, about 640 μg, or about 675 μg of a compound of formula (I). In further embodiments, the composition comprises about 80 μg, about 160 μg, about 240 μg, about 320 μg, about 400 μg, about 480 μg, or about 640 μg of a compound of formula (I). In further embodiments, R 1 is hexadecyl, e.g., linear hexadecyl. In one embodiment, the composition can be present in one dry powder capsule or multiple (two or more) dry powder capsules. When present in multiple capsules, one of the aforementioned doses of the compound of formula (I) is divided among the capsules.
[0128] In embodiments, the dry powder compositions of the present disclosure are formulated for once-daily administration by inhalation to the lungs of a subject (e.g., a patient) of a dose ranging from about 80 μg to about 640 μg of a compound of Formula (II), or a pharmaceutically acceptable salt thereof, and provide at least one of the following characteristics: (a) Treprosintil maximum plasma concentration (C) ranging from about 14 pg / mL to about 1430 pg / mL max ),or (b) Approximately 380pg * h / mL~approx. 10000pg *Treprostinil area under the plasma concentration curve (AUC) in the range of h / mL.
[0129] In further embodiments, the composition comprises about 80 μg, about 160 μg, about 240 μg, about 320 μg, about 400 μg, about 480 μg, or about 640 μg of the compound of Formula (II). In one embodiment, the composition can be present in one dry powder capsule or multiple (two or more) dry powder capsules. When present in multiple capsules, one of the aforementioned doses of the compound of Formula (II) is divided among the multiple capsules.
[0130] In one embodiment, the dry powder composition is formulated for once-daily administration by inhalation to the lungs of a subject (e.g., a patient) of a dose ranging from about 112.5 μg to about 675 μg of the compound of Formula (II), a stereoisomer, or a pharmaceutically acceptable salt thereof, and provides at least one of the following characteristics: (a) Treprosintil maximum plasma concentration (C) ranging from about 17 pg / mL to about 1370 pg / mL max ),or (b) Approximately 700pg * h / mL ~ approx. 7800pg * Area under the treprostinil plasma concentration curve (AUC) in the range of h / mL.
[0131] In further embodiments, the composition comprises about 80 μg, about 160 μg, about 240 μg, about 320 μg, about 400 μg, about 480 μg, or about 640 μg of the compound of Formula (II). In one embodiment, the composition can be present in one dry powder capsule or multiple (two or more) dry powder capsules. When present in multiple capsules, one of the aforementioned doses of the compound of Formula (II) is divided among the multiple capsules.
[0132] In embodiments, the dry powder composition comprises one of the pharmacokinetic profiles described herein and includes about 80 μg to about 675 μg of a compound of Formula (I), e.g., about 80 μg to about 640 μg, or about 112.5 μg to about 675 μg. In one embodiment, the dry powder composition having one of the pK profiles described herein comprises a dry powder composition having a pK profile of about 80 μg, about 100 μg, about 110 μg, about 112.5 μg, about 120 μg, about 130 μg, about 140 μg, about 150 μg, about 160 μg, about 170 μg, about 180 μg, about 190 μg, about 200 μg, about 210 μg, about 220 μg, about 225 μg, about 230 μg, about 240 μg, about 250 μg, about 260 μg, about 270 μg, about 280 μg, about 290 μg, about 300 μg, about 310 μg, about 320 μg, about 330 μg, about 340 μg, about 350 μg, about 360 μg, about 370 μg, and about 380 μg, including all values and ranges therein. 70μg, about 380μg, about 390μg, about 400μg, about 410μg, about 420μg, about 430μg, about 440μg, about 450μg, about 460μg, Approximately 470μg, approximately 480μg, approximately 490μg, approximately 500μg, approximately 510μg, approximately 520μg, approximately 530μg, approximately 540μg, approximately 550μg, approximately 560μg In a further embodiment, R 1 is hexadecyl, for example, linear hexadecyl.
[0133] In some embodiments, following once-daily administration of a dry powder composition comprising about 80 μg to about 675 μg (e.g., about 80 μg to about 640 μg, or about 112.5 μg to about 675 μg) of the compound of Formula (I), a stereoisomer thereof (or an equivalent dose of a pharmaceutically acceptable salt thereof (e.g., the compound of Formula (II))), the dry powder composition or method of use thereof provides a maximum plasma concentration of treprostinil (C) ranging from about 10 pg / mL to about 2000 pg / mL. max), including, for example, about 10 pg / mL, about 15 pg / mL, about 20 pg / mL, about 25 pg / mL, about 30 pg / mL, about 35 pg / mL, about 40 pg / mL, about 45 pg / mL, about 50 pg / mL, about 55 pg / mL, about 60 pg / mL, about 65 pg / mL, about 70 pg / mL, about 75 pg / mL, about 80 pg / mL, about 85 pg / mL, about 90 pg / mL, about 95 pg / mL, about 100 pg / mL, about 110 pg / mL, about 120 pg / mL, about 130 pg / mL, about 140 pg / mL, about 150 pg / mL, L, approximately 160pg / mL, approximately 170pg / mL, approximately 180pg / mL, approximately 190pg / mL, approximately 200pg / mL, approximately 210pg / mL, approximately 220pg / mL, approximately 230pg / mL, approximately 240pg / mL, approximately 250pg / mL, approximately 260pg / mL, approximately 270pg / mL, approximately 2 80pg / mL, approximately 290pg / mL, approximately 300pg / mL, approximately 310pg / mL, approximately 320pg / mL, approximately 330pg / mL, approximately 340pg / mL, approximately 350pg / mL, approximately 360pg / mL, approximately 370pg / mL, approximately 380pg / mL, approximately 390pg / mL, approximately 400pg / mL, approximately 410pg / mL, approximately 420pg / mL, approximately 430pg / mL, approximately 440pg / mL, approximately 450pg / mL, approximately 460pg / mL, approximately 470pg / mL, approximately 480pg / mL, approximately 490pg / mL, approximately 500pg / mL, approximately 510pg / mL, approximately 520pg / mL, Approximately 530pg / mL, approximately 540pg / mL, approximately 550pg / mL, approximately 560pg / mL, approximately 570pg / mL, approximately 580pg / mL, approximately 590pg / mL, approximately 600pg / mL, approximately 610pg / mL, approximately 620pg / mL, approximately 630pg / mL, approximately 640pg / mL, approximately 650 pg / mL, approximately 660pg / mL, approximately 670pg / mL, approximately 680pg / mL, approximately 690pg / mL, approximately 700pg / mL, approximately 750pg / mL, approximately 800pg / mL, approximately 850pg / mL, approximately 900pg / mL, approximately 950pg / mL, approximately 1000pg / mL, approximately 1050pg / mL, approximately 1100pg / mL, approximately 1150pg / mL, approximately 1200pg / mL, approximately 1250pg / mL, approximately 1300pg / mL, approximately 1350pg / mL, approximately 1400pg / mL, approximately 1450pg / mL, approximately 1500pg / mL, approximately 1550pg / mL, approximately 1600pg / mL,About 1650 pg / mL, about 1700 pg / mL, about 1750 pg / mL, about 1800 pg / mL, about 1850 pg / mL, about 1900 pg / mL, or about 2000 pg / mL.
[0134] In some embodiments, the disclosed dry capacity compositions or methods of use thereof comprise about 300 pg of a compound of Formula (I) followed by about 80 pg to about 675 pg (e.g., about 80 pg to about 640 pg, or about 112.5 pg to about 675 pg). * h / mL~approx. 11000pg * and about 1000 pg*h / mL, about 1100 pg*h / mL, about 1200 pg*h / mL, about 1300 pg*h / mL, including all values and ranges therein. *h / mL, approx. 1400pg*h / mL, approx. 1500pg*h / mL, approx. 1600pg*h / mL, approx. 1700pg*h / mL, approx. 1800pg*h / mL, approx. 1900pg*h / mL, approx. 2000pg *h / mL, approx. 2100pg*h / mL, approx. 2200pg*h / mL, approx. 2300pg*h / mL, approx. 2400pg*h / mL, approx. 2500pg*h / mL, approx. 2600pg*h / mL, approx. 2700ng * h / mL, approximately 2800ng * h / mL, approx. 2900pg*h / mL, approx. 3000pg*h / mL, approx. 3100pg*h / mL, approx. 3200pg*h / mL, approx. 3300pg*h / mL, approx. 3400pg*h / m L, approx. 3500pg*h / mL, approx. 3600pg*h / mL, approx. 3700pg*h / mL, approx. 3800pg*h / mL, approx. 3900pg*h / mL, approx. 4000pg*h / mL, approx. 4 100pg*h / mL, approx. 4200pg*h / mL, approx. 4300pg*h / mL, approx. 4400pg*h / mL, approx. 4500pg*h / mL, approx. 4600pg*h / mL, approx. 4700 pg*h / mL, approx. 4800pg*h / mL, approx. 4900pg*h / mL, approx. 5000pg*h / mL, approx. 5100pg*hr / mL, approx. 5200pg*hr / mL, approx. 5300pg *hr / mL, approx. 5400pg*hr / mL, approx. 5500pg*hr / mL, approx. 5600pg*hr / mL, approx. 5700pg*hr / mL, approx. 5800pg*hr / mL, approx. 5900pg*hr / mL, approximately 6000pg*hr / mL, approximately 6100pg*hr / mL, approximately 6200pg*hr / mL, approximately 6300pg*hr / mL, approximately 6400pg*hr / mL, approximately 6500pg*hr / m L, approximately 6600pg*hr / mL, approximately 6700pg*hr / mL, approximately 6800pg*hr / mL, approximately 6900pg*hr / mL, approximately 7000pg*hr / mL, approximately 7100pg*hr / mL, Approx. 7200pg*hr / mL, approx. 7300pg*hr / mL, approx. 7400pg*hr / mL, approx. 7500pg*hr / mL, approx. 7600pg*hr / mL, approx. 7700pg*hr / mL, approx. 7 800pg*hr / mL, approx. 7900pg*hr / mL, approx. 8000pg*hr / mL, approx. 8100pg*hr / mL, approx. 8200pg*hr / mL, approx. 8300pg*hr / mL, approx. 840 0pg*hr / mL, approx. 8500pg*hr / mL, approx. 8600pg*hr / mL, approx. 8700pg*hr / mL, approx. 8800pg*hr / mL, approx. 8900pg*hr / mL, approx. 9000p g*hr / mL, approx. 9100pg*hr / mL, approx. 9200pg*hr / mL, approx. 9300pg*hr / mL, approx. 9400pg*hr / mL, approx. 9500pg*hr / mL, approx. 9600pg* hr / mL, approx. 9700pg*hr / mL, approx. 9800pg*hr / mL, approx. 9900pg*hr / mL, approx. 10000pg*hr / mL, approx. 10100pg*hr / mL, approx. 10200pg * *hr / mL, about 10300pg*hr / mL, about 10400pg*hr / mL, about 10500pg*hr / mL, about 10600pg*hr / mL, about 10700pg*hr / mL, about 10800pg*hr / mL, about 10900pg*hr / mL, or about 11000pg*hr / mL.
[0135] In some embodiments, the disclosed dry powder compositions or methods achieve treprostinil plasma trough concentrations throughout the administration period of the dry powder composition. In some embodiments, the plasma trough levels are sufficient to provide a sustained therapeutic response throughout the administration period. In some embodiments, the dry powder composition contains about 80 μg to about 675 μg of a compound of Formula (I) or a stereoisomer thereof (e.g., R 1is hexadecyl, e.g., linear hexadecyl), and after once daily administration, has a concentration of at least about 1 pg / mL, about 2 pg / mL, about 3 pg / mL, about 4 pg / mL, about 5 pg / mL, about 10 pg / mL, about 15 pg / mL, about 20 pg / mL, about 25 pg / mL, about 30 pg / mL, about 35 pg / mL, about 40 pg / mL, about 45 pg / mL, about 50 pg / mL, about 55 pg / mL, about 60 pg / mL, about 65 pg / mL, about 70 pg / mL, inclusive of all values and ranges therein. The dry powder composition may provide, or the subject (e.g., patient) has, a treprostinil plasma trough concentration of about 75 pg / mL, about 80 pg / mL, about 85 pg / mL, about 90 pg / mL, about 95 pg / mL, about 100 pg / mL, about 100 pg / mL, about 110 pg / mL, about 120 pg / mL, about 130 pg / mL, about 140 pg / mL, about 150 pg / mL, about 160 pg / mL, about 170 pg / mL, about 180 pg / mL, about 190 pg / mL, or about 200 pg / mL. In some embodiments, the dry powder composition comprises about 80 μg to about 640 μg of the compound of Formula (II), and the treprostinil plasma trough concentration ranges from about 3 pg / mL to about 125 pg / mL, including all values and ranges therein, such as about 3 pg / mL, about 4 pg / mL, about 5 pg / mL, about 10 pg / mL, about 15 pg / mL, about 20 pg / mL, about 25 pg / mL, about 3 pg / mL, about 4 pg / mL, about 5 pg / mL, about 6 pg / mL, about 7 pg / mL, about 8 pg / mL, about 9 ...3 pg / mL, about 4 pg / mL, about 5 pg / mL, about 10 pg / mL, about 15 pg / mL, about 20 pg / mL, about 25 pg / mL, about 3 pg / mL, about 3 pg / mL, about 4 pg / mL, about 5 pg / mL, about 10 pg / mL, about 15 pg / mL, about 20 pg / mL, about 25 pg / mL, about 3 pg / mL, about 3 pg / mL, about 4 pg / mL, about 5 pg / mL, about 10 pg / mL, about 15 pg / mL, about 20 pg In some embodiments, the dry powder composition comprises about 80 μg to about 640 μg of the compound of Formula (II), and the treprostinil plasma trough concentration ranges from about 10 pg / mL to about 100 pg / mL.
[0136] In some embodiments, following once-daily administration of a dry powder composition comprising about 80 μg to about 675 μg of a compound of Formula (II) or a stereoisomer thereof (or an equivalent dose of a pharmaceutically acceptable salt thereof, or a compound of Formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof), the dry powder composition provides, or a subject (e.g., a patient) has, at least one of the following characteristics: (a) Maximum treprostinil plasma concentrations (C) within about 80% to about 125% of the range of about 17 pg / mL to about 1150 pg / mL max), for example, about 13 pg / mL, about 14 pg / mL, about 15 pg / mL, about 20 pg / mL, about 25 pg / mL, about 30 pg / mL, about 35 pg / mL, about 40 pg / mL, about 45 pg / mL, about 50 pg / mL, about 55 pg / mL, about 60 pg / mL, about 65 pg / mL, about 70 pg / mL, about 75 pg / mL, about 80 pg / mL, about 85 pg / mL, about 90 pg / mL, about 95 pg / mL, about 100 pg / mL, about 110 pg / mL, about 120 pg / mL, about 130 pg / mL, about 140 pg / mL, including all values and ranges therein. mL, approximately 150pg / mL, approximately 160pg / mL, approximately 170pg / mL, approximately 180pg / mL, approximately 190pg / mL, approximately 200pg / mL, approximately 210pg / mL, approximately 220pg / mL, approximately 230pg / mL, approximately 240pg / mL, approximately 250pg / mL, approximately 260pg / m L, about 270pg / mL, about 280pg / mL, about 290pg / mL, about 300pg / mL, about 310pg / mL, about 320pg / mL, about 330pg / mL, about 340pg / mL, about 350pg / mL, about 360pg / mL, about 370pg / mL, about 380pg / mL, Approximately 390pg / mL, approximately 400pg / mL, approximately 410pg / mL, approximately 420pg / mL, approximately 430pg / mL, approximately 440pg / mL, approximately 450pg / mL, approximately 460pg / mL, approximately 470pg / mL, approximately 480pg / mL, approximately 490pg / mL, approximately 500pg / mL, approximately 510pg / mL, approximately 520pg / mL, approximately 530pg / mL, approximately 540pg / mL, approximately 550pg / mL, approximately 560pg / mL, approximately 570pg / mL, approximately 580pg / mL, approximately 590pg / mL, approximately 600pg / mL, approximately 610pg / mL, approximately 620pg / mL, approximately 63 0 pg / mL, about 640 pg / mL, about 650 pg / mL, about 660 pg / mL, about 670 pg / mL, about 680 pg / mL, about 690 pg / mL, about 700 pg / mL, about 750 pg / mL, about 800 pg / mL, about 850 pg / mL, about 900 pg / mL, about 950 pg / mL, about 1000 pg / mL, about 1050 pg / mL, about 1100 pg / mL, about 1150 pg / mL, about 1200 pg / mL, about 1250 pg / mL, about 1300 pg / mL, about 1350 pg / mL, about 1400 pg / mL, or about 1430 pg / mL. (b) the area under the treprostinil plasma concentration curve (AUC) within about 80% to about 125% of the range of about 475 pg*h / mL to about 8000 pg*h / mL 0-inf ) is, for example, approximately 370 pg, including all values and ranges therein. * h / mL, approximately 400pg * h / mL, approximately 450pg * h / mL, approximately 500pg * h / mL, approximately 550pg * h / mL, approximately 600pg * h / mL, approximately 650pg * h / mL, approximately 700pg * h / mL, approximately 800pg * h / mL, approximately 900pg * h / mL, approximately 1000pg * h / mL, approximately 1100pg * h / mL, approximately 1200pg * h / mL, approximately 1300pg * h / mL, approximately 1400pg * h / mL, approximately 1500pg * h / mL, approximately 1600pg * h / mL, approximately 1700pg * h / mL, approximately 1800pg * h / mL, approximately 1900pg * h / mL, approximately 2000pg * h / mL, approximately 2100pg * h / mL, approximately 2200pg * h / mL, approximately 2300pg * h / mL, approximately 2400pg * h / mL, approximately 2500pg * h / mL, approximately 2600pg * h / mL, approximately 2700ng * h / mL, approximately 2800ng * h / mL, approximately 2900pg * h / mL, approximately 3000pg * h / mL, approximately 3100pg * h / mL, approximately 3200pg * h / mL, approximately 3300pg * h / mL, approximately 3400pg * h / mL, approximately 3500pg * h / mL, approximately 3600pg* h / mL, about 3700 pg * h / mL, about 3800 pg * h / mL, about 3900 pg * h / mL, about 4000 pg * h / mL, about 4100 pg * h / mL, about 4200 pg * h / mL, about 4300 pg * h / mL, about 4400 pg * h / mL, about 4500 pg * h / mL, about 4600 pg * h / mL, about 4700 pg * h / mL, about 4800 pg * h / mL, about 4900 pg * h / mL, about 5000 pg * h / mL, about 5100 pg * h / mL, about 5200 pg * h / mL, about 5300 pg * h / mL, about 5400 pg * h / mL, about 5500 pg * h / mL, about 5600 pg * h / mL, about 5700 pg * h / mL, about 5800 pg * h / mL, about 5900 pg * h / mL, about 6000 pg * h / mL, about 6100 pg * h / mL, about 6200 pg * h / mL, about 6300 pg * h / mL, about 6400 pg * h / mL, about 6500 pg * h / mL, about 6600 pg * h / mL, about 6700 pg * h / mL, about 6800 pg*h / mL, about 6900 pg * h / mL, about 7000 pg * h / mL, about 7100 pg * h / mL, about 7200 pg*h / mL, about 7300 pg * h / mL, about 7400 pg * h / mL, about 7500 pg * h / mL, about 7600 pg*h / mL, about 7700 pg *h / mL, approximately 7800pg * h / mL, approximately 7900pg * h / mL, approx. 8000pg*h / mL, approx. 8100pg * h / mL, approximately 8200pg * h / mL, approximately 8300pg * h / mL, approx. 8400pg*h / mL, approx. 8500pg * h / mL, approximately 8600pg * h / mL, approximately 8700pg * h / mL, approx. 8800pg*h / mL, approx. 8900pg * h / mL, approximately 9000pg * h / mL, approximately 9100pg * h / mL, approx. 9200pg*h / mL, approx. 9300pg * h / mL, approximately 9400pg * h / mL, approximately 9500pg * h / mL, approx. 9600pg*h / mL, approx. 9700pg * h / mL, approximately 9800pg * h / mL, approximately 9900pg * h / mL, or approximately 10,000 pg * h / mL.
[0137] In some embodiments, the dry powder composition comprises about 80 μg of the compound of Formula (II) administered once daily and provides treprostinil C in the range of about 14 pg / mL to about 155 pg / mL. maxFor example, about 14 pg / mL, about 15 pg / mL, about 20 pg / mL, about 25 pg / mL, about 30 pg / mL, about 35 pg / mL, about 40 pg / mL, about 45 pg / mL, about 50 pg / mL, about 55 pg / mL, about 60 pg / mL, about 65 pg / mL, about 70 pg / mL, about 75 pg / mL, about 80 pg / mL, including all values and ranges therein. In some embodiments, about 80 μg of a compound of Formula (II), or a stereoisomer thereof (or an equivalent dose of a pharmaceutically acceptable salt thereof, or a compound of Formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof) is administered once daily to achieve about 80% to 125% of the treprostinil C in the range of about 17 pg / mL to about 125 pg / mL. max In some embodiments, about 80 μg of the compound of Formula (II), or a stereoisomer thereof (or an equivalent dose of a pharmaceutically acceptable salt thereof, or the compound of Formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof) is administered once daily to provide about 80% to 125% of the treprostinil C in the range of about 35 pg / mL to about 105 pg / mL. max to provide.
[0138] In some embodiments, the dry powder composition comprises about 112.5 μg of the compound of Formula (II) or a stereoisomer thereof (or an equivalent dose of a pharmaceutically acceptable salt thereof, or the compound of Formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof), and has a treprostinil C ranging from about 80% to about 125% of about 78.4 (72.9) pg / mL. max (CV%) is provided.
[0139] In some embodiments, the dry powder composition comprises about 160 μg of the compound of Formula (II), administered once daily, and treprostinil C in the range of about 30 pg / mL to about 335 pg / mL. maxFor example, about 30 pg / mL, about 35 pg / mL, about 40 pg / mL, about 45 pg / mL, about 50 pg / mL, about 55 pg / mL, about 60 pg / mL, about 65 pg / mL, about 70 pg / mL, about 75 pg / mL, about 80 pg / mL, about 85 pg / mL, about 90 pg / mL, about 95 pg / mL, about 100 pg / mL, about 105 pg / mL, including all values and ranges therein. pg / mL, approx. 110 pg / mL, approx. 115 pg / mL, approx. 120 pg / mL, approx. 125 pg / mL, approx. 130 pg / mL, approx. 135 pg / mL, approx. 140 pg / mL, approx. 145 pg / m L, about 150pg / mL, about 155pg / mL, about 160pg / mL, about 165pg / mL, about 170pg / mL, about 175pg / mL, about 180pg / mL, about 1850pg / mL, about 190pg / mL, approx. 195pg / mL, approx. 200pg / mL, approx. 205pg / mL, approx. 210pg / mL, approx. 215pg / mL, approx. 220pg / mL, approx. 225pg / mL, approx. 230 pg / mL, approx. 235pg / mL, approx. 240pg / mL, approx. 245pg / mL, approx. 250pg / mL, approx. 255pg / mL, approx. 260pg / mL, approx. 265pg / mL, approx. 270pg / m L, about 275 pg / mL, about 280 pg / mL, about 285 pg / mL, about 290 pg / mL, about 295 pg / mL, about 300 pg / mL, about 305 pg / mL, about 310 pg / mL, about 315 pg / mL, about 320 pg / mL, about 325 pg / mL, about 330 pg / mL, about 335 pg / mL, about 340 pg / mL, about 345 pg / mL, or about 350 pg / mL. In some embodiments, about 160 μg of the compound of Formula (II), a stereoisomer thereof (or an equivalent dose of a pharmaceutically acceptable salt thereof, or the compound of Formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof) is administered once daily to achieve about 80% to 125% of the treprostinil C in the range of about 35 pg / mL to about 270 pg / mL. max In some embodiments, about 160 μg of the compound of Formula (II), or a stereoisomer thereof (or an equivalent dose of a pharmaceutically acceptable salt thereof, or the compound of Formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof) is administered once daily to provide about 80% to 125% of the treprostinil C in the range of about 76 pg / mL to about 230 pg / mL. maxto provide.
[0140] In some embodiments, the dry powder composition comprises about 225 μg of the compound of Formula (II), administered once daily, and provides a treprostinil C in the range of about 80% to about 125% of about 287 (46.6) pg / mL. max In some embodiments, the dry powder composition comprises about 225 μg of the compound of Formula (II) or a stereoisomer thereof (or an equivalent dose of a pharmaceutically acceptable salt thereof, or the compound of Formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof), and has a steady-state treprostinil C in the range of about 80% to about 125% of about 193 (32.9) pg / mL. max In some embodiments, the dry powder composition comprises about 225 μg of the compound of Formula (II), administered once daily, and provides a steady-state treprostinil C in the range of about 80% to about 125% of about 228 (46.4) pg / mL. max (CV%) is provided.
[0141] In some embodiments, the dry powder composition comprises about 240 μg of the compound of Formula (II) administered once daily and provides treprostinil C in the range of about 45 pg / mL to about 520 pg / mL. maxFor example, about 45 pg / mL, about 50 pg / mL, about 60 pg / mL, about 70 pg / mL, about 80 pg / mL, about 90 pg / mL, about 100 pg / mL, about 110 pg / mL, about 120 pg / mL, about 130 pg / mL, about 140 pg / mL, about 150 pg / mL, about 160 pg / mL, about 170 pg / mL, about 180 pg / mL, about 190 pg / mL, about 200 pg / mL, about 210 pg / mL, about 220 pg / mL, about 230 pg / mL, about 240 pg / mL, about 250 pg / mL, about 260 pg / mL, about 270 pg / mL, including all values and ranges therein. mL, about 280 pg / mL, about 290 pg / mL, about 300 pg / mL, about 310 pg / mL, about 320 pg / mL, about 330 pg / mL, about 340 pg / mL, about 350 pg / mL, about 360 pg / mL, about 370 pg / mL, about 380 pg / mL, about 390 pg / mL, about 400 pg / mL, about 410 pg / mL, about 420 pg / mL, about 430 pg / mL, about 440 pg / mL, about 450 pg / mL, about 460 pg / mL, about 470 pg / mL, about 480 pg / mL, about 490 pg / mL, about 500 pg / mL, about 510 pg / mL, or about 520 pg / mL. In some embodiments, about 240 μg of the compound of Formula (II), or a stereoisomer thereof (or an equivalent dose of a pharmaceutically acceptable salt thereof, or the compound of Formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof) is administered once daily to achieve about 80% to 125% of the treprostinil C in the range of about 55 pg / mL to about 415 pg / mL. max In some embodiments, about 240 μg of the compound of Formula (II), or a stereoisomer thereof (or an equivalent dose of a pharmaceutically acceptable salt thereof, or the compound of Formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof) is administered once daily to provide about 80% to 125% of the treprostinil C in the range of about 115 pg / mL to about 355 pg / mL. max to provide.
[0142] In some embodiments, the dry powder composition comprises about 320 μg of the compound of Formula (II) administered once daily and provides treprostinil C in the range of about 60 pg / mL to about 700 pg / mL. maxFor example, about 60 pg / mL, about 70 pg / mL, about 80 pg / mL, about 90 pg / mL, about 100 pg / mL, about 110 pg / mL, about 120 pg / mL, about 130 pg / mL, about 135 pg / mL, about 140 pg / mL, about 140 pg / mL, about 150 pg / mL, about 160 pg / mL, about 170 pg / mL, about 180 pg / mL, about 190pg / mL, approx. 200pg / mL, approx. 210pg / mL, approx. 220pg / mL, approx. 230pg / mL, approx. 240pg / mL, approx. 250pg / mL, approx. 260pg / mL, approx. 270pg / m L, approx. 280pg / mL, approx. 290pg / mL, approx. 300pg / mL, approx. 310pg / mL, approx. 320pg / mL, approx. 330pg / mL, approx. 340pg / mL, approx. 350pg / mL, approx. 360pg / mL, approximately 370pg / mL, approximately 380pg / mL, approximately 390pg / mL, approximately 400pg / mL, approximately 410pg / mL, approximately 420pg / mL, approximately 430pg / mL, approximately 440pg / mL, approximately 45 0pg / mL, approx. 460pg / mL, approx. 470pg / mL, approx. 480pg / mL, approx. 490pg / mL, approx. 500pg / mL, approx. 510pg / mL, approx. 520pg / mL, approx. 530pg / mL, approx. In some embodiments, about 320 μg of the compound of Formula (II) is administered once daily to achieve a treprostinil C of about 80% to 125% of the range of about 80 pg / mL to about 560 pg / mL. max In some embodiments, about 320 μg of the compound of Formula (II) is administered once daily to provide about 80% to 125% of the treprostinil C range of about 160 pg / mL to about 480 pg / mL. max to provide.
[0143] In some embodiments, the dry powder composition comprises about 400 μg of the compound of Formula (II) administered once daily and provides treprostinil C in the range of about 80 pg / mL to about 885 pg / mL. maxFor example, about 80 pg / mL, about 90 pg / mL, about 100 pg / mL, about 110 pg / mL, about 120 pg / mL, about 130 pg / mL, about 135 pg / mL, about 140 pg / mL, about 140 pg / mL, about 150 pg / mL, about 160 pg / mL, about 170 pg / mL, about 180 pg / mL, about 190 pg / mL, about 200 pg / mL, about 210 pg / mL, about 220 pg / mL, about 230 pg / mL, about 240 pg / mL, Approx. 250pg / mL, approx. 260pg / mL, approx. 270pg / mL, approx. 280pg / mL, approx. 290pg / mL, approx. 300pg / mL, approx. 310pg / mL, approx. 320pg / mL, approx. 330pg / mL, approx. 340pg / mL, approx. 350pg / mL, approximately 360pg / mL, approximately 370pg / mL, approximately 380pg / mL, approximately 390pg / mL, approximately 400pg / mL, approximately 410pg / mL, approximately 420pg / mL, approximately 430pg / mL, approximately 440pg / mL, approximately 450pg / mL, approximately 460p g / mL, approximately 470 pg / mL, approximately 480 pg / mL, approximately 490 pg / mL, approximately 500 pg / mL, approximately 510 pg / mL, approximately 520 pg / mL, approximately 530 pg / mL, approximately 540 pg / mL, approximately 550 pg / mL, approximately 560 pg / mL, approximately 5 70pg / mL, approximately 580pg / mL, approximately 590pg / mL, approximately 600pg / mL, approximately 610pg / mL, approximately 620pg / mL, approximately 630pg / mL, approximately 640pg / mL, approximately 650pg / mL, approximately 660pg / mL, approximately 670pg / mL, about 680 pg / mL, about 690 pg / mL, about 700 pg / mL, about 710 pg / mL, about 720 pg / mL, about 730 pg / mL, about 740 pg / mL, about 750 pg / mL, about 760 pg / mL, about 770 pg / mL, about 780 pg / mL, about 790 pg / mL, about 800 pg / mL, about 810 pg / mL, about 820 pg / mL, about 830 pg / mL, about 840 pg / mL, about 850 pg / mL, about 860 pg / mL, about 870 pg / mL, or about 880 pg / mL. In some embodiments, about 400 μg of the compound of Formula (II) is administered once daily to achieve about 80% to 125% of the treprostinil C range of about 100 pg / mL to about 705 pg / mL. maxIn some embodiments, about 400 μg of the compound of formula (II) is administered once daily to provide about 80% to 125% of the treprostinil C in the range of about 200 pg / mL to about 605 pg / mL. max to provide.
[0144] In some embodiments, the dry powder composition comprises about 450 μg of the compound of formula (II) or a stereoisomer thereof (or an equivalent dose of a pharmaceutically acceptable salt thereof, or the compound of formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof), and has a treprostinil C in the range of about 80% to about 125% of about 387 (38.6) pg / mL. max to provide.
[0145] In some embodiments, the dry powder composition comprises about 480 μg of the compound of Formula (II), administered once daily, and provides treprostinil C in the range of about 95 pg / mL to about 1065 pg / mL. maxand about 95 pg / mL, about 100 pg / mL, about 110 pg / mL, about 120 pg / mL, about 130 pg / mL, about 135 pg / mL, about 140 pg / mL, about 140 pg / mL, about 150 pg / mL, about 160 pg / mL, about 170 pg / mL, about 180 pg / mL, about 190 pg / mL, about 200 pg / mL, about 210 pg / mL, about 220 pg / mL, about 230 pg / mL, about 240 pg / mL, about 250 pg / mL, about 260 pg / mL, about 270 pg / mL, about 280 pg / mL, about 290 pg / mL, including all values and ranges therein. pg / mL, approximately 300pg / mL, approximately 310pg / mL, approximately 320pg / mL, approximately 330pg / mL, approximately 340pg / mL, approximately 350pg / mL, approximately 360pg / mL, approximately 370pg / mL, approximately 380pg / mL, approximately 390pg / mL, approximately 400pg / mL, approximately 410pg / mL , about 420pg / mL, about 430pg / mL, about 440pg / mL, about 450pg / mL, about 460pg / mL, about 470pg / mL, about 480pg / mL, about 490pg / mL, about 500pg / mL, about 510pg / mL, about 520pg / mL, about 530pg / mL, about 540 pg / mL, approximately 550 pg / mL, approximately 560 pg / mL, approximately 570 pg / mL, approximately 580 pg / mL, approximately 590 pg / mL, approximately 600 pg / mL, approximately 610 pg / mL, approximately 620 pg / mL, approximately 630 pg / mL, approximately 640 pg / mL, approximately 650 pg / mL, approximately 660 pg / mL , about 670pg / mL, about 680pg / mL, about 690pg / mL, about 700pg / mL, about 710pg / mL, about 720pg / mL, about 730pg / mL, about 740pg / mL, about 750pg / mL, about 760pg / mL, about 770pg / mL, about 780pg / mL, about 790 pg / mL, approximately 800pg / mL, approximately 810pg / mL, approximately 820pg / mL, approximately 830pg / mL, approximately 840pg / mL, approximately 850pg / mL, approximately 860pg / mL, approximately 870pg / mL, approximately 880pg / mL, approximately 890pg / mL, approximately 900pg / mL, approximately 910pg / mL , about 920pg / mL, about 930pg / mL, about 940pg / mL, about 950pg / mL, about 960pg / mL, about 970pg / mL, about 980pg / mL, about 1000pg / mL, about 1010pg / mL, about 1020pg / mL, about 1030pg / mL, about 1040pg / mL,In some embodiments, about 480 μg of the compound of Formula (II) is administered once daily to achieve about 80% to 125% of the treprostinil C of about 120 pg / mL to about 855 pg / mL. max In some embodiments, about 480 μg of the compound of formula (II) is administered once daily to provide about 80% to 125% of the treprostinil C in the range of about 240 pg / mL to about 730 pg / mL. max to provide.
[0146] In some embodiments, the dry powder composition comprises about 640 μg of the compound of Formula (II) administered once daily and provides treprostinil C in the range of about 130 pg / mL to about 1430 pg / mL. maxand about 130 pg / mL, about 135 pg / mL, about 140 pg / mL, about 140 pg / mL, about 150 pg / mL, about 160 pg / mL, about 170 pg / mL, about 180 pg / mL, about 190 pg / mL, about 200 pg / mL, about 210 pg / mL, about 220 pg / mL, about 230 pg / mL, about 240 pg / mL, about 250 pg / mL, about 260 pg / mL, about 270 pg / mL, about 280 pg / mL, about 290 pg / mL, about 300 pg / mL, about 310 pg / mL, about 320 pg / mL, about 330pg / mL, approximately 340pg / mL, approximately 350pg / mL, approximately 360pg / mL, approximately 370pg / mL, approximately 380pg / mL, approximately 390pg / mL, approximately 400pg / mL, approximately 410pg / mL, approximately 420pg / mL, approximately 430pg / mL, approximately 440pg / mL, approximately 450p g / mL, approximately 460 pg / mL, approximately 470 pg / mL, approximately 480 pg / mL, approximately 490 pg / mL, approximately 500 pg / mL, approximately 510 pg / mL, approximately 520 pg / mL, approximately 530 pg / mL, approximately 540 pg / mL, approximately 550 pg / mL, approximately 560 pg / mL, approximately 570 pg / mL, Approximately 580pg / mL, approximately 590pg / mL, approximately 600pg / mL, approximately 610pg / mL, approximately 620pg / mL, approximately 630pg / mL, approximately 640pg / mL, approximately 650pg / mL, approximately 660pg / mL, approximately 670pg / mL, approximately 680pg / mL, approximately 690pg / mL, approximately 700 pg / mL, approximately 710 pg / mL, approximately 720 pg / mL, approximately 730 pg / mL, approximately 740 pg / mL, approximately 750 pg / mL, approximately 760 pg / mL, approximately 770 pg / mL, approximately 780 pg / mL, approximately 790 pg / mL, approximately 800 pg / mL, approximately 810 pg / mL, approximately 820 pg / mL , about 830pg / mL, about 840pg / mL, about 850pg / mL, about 860pg / mL, about 870pg / mL, about 880pg / mL, about 890pg / mL, about 900pg / mL, about 910pg / mL, about 920pg / mL, about 930pg / mL, about 940pg / mL, about 95 0pg / mL, approximately 960pg / mL, approximately 970pg / mL, approximately 980pg / mL, approximately 1000pg / mL, approximately 1010pg / mL, approximately 1020pg / mL, approximately 1030pg / mL, approximately 1040pg / mL, approximately 1050pg / mL, approximately 1060pg / mL, approximately 1070pg / mL,Approx. 1080pg / mL, approx. 1090pg / mL, approx. 1100pg / mL, approx. 1110pg / mL, approx. 1120pg / mL, approx. 1130pg / mL, approx. 1140pg / mL, approx. 1150pg / mL, approx. 1160pg / mL, approx. 1170pg / mL, approximately 1180pg / mL, approximately 1190pg / mL, approximately 1200pg / mL, approximately 1210pg / mL, approximately 1220pg / mL, approximately 1230pg / mL, approximately 1240pg / mL, approximately 1250pg / mL, approximately 12 In some embodiments, about 640 μg of the compound of Formula (II) is administered once daily to achieve about 80% to 125% of the treprostinil C in the range of about 160 pg / mL to about 1140 pg / mL. max In some embodiments, about 640 μg of the compound of formula (II) is administered once daily to provide a treprostinil C in the range of about 80% to 125% of about 325 pg / mL to about 980 pg / mL. max to provide.
[0147] In some embodiments, the dry powder composition comprises about 675 μg of the compound of formula (II) and has a treprostinil C ranging from about 80% to about 125% of about 717 (52.8) pg / mL. max to provide.
[0148] In some embodiments, the dry powder composition comprises about 80 μg of the compound of Formula (II) and, upon administration, provides a treprostinil AUC in the range of about 375 pg*h / mL to about 1800 pg*h / mL. 0-inf 375pg, including all values and ranges therein. * h / mL, 400 pg * h / mL, 500 pg * h / mL, 600 pg * h / mL, approximately 700pg* h / mL, approximately 800pg * h / mL, approximately 900pg * h / mL, approximately 1000pg * h / mL, approximately 1100pg * h / mL, approximately 1200pg * h / mL, approximately 1300pg * h / mL, approximately 1400pg * h / mL, approximately 1500pg * h / mL, approximately 1600pg * h / mL, approximately 1700pg * h / mL, or approximately 1800 pg * In some embodiments, about 80 μg of the compound of Formula (II) is administered once daily, and about 475 pg * h / mL~approx. 1430pg * Treprostinil AUC in the range of approximately 80% to 125% of h / mL 0-inf In some embodiments, the dry powder composition comprises about 80 μg of the compound of Formula (II), and upon administration, provides about 660 μg * h / mL~approx. 1240pg * Approximately 80% to 125% of the treprostinil AUC in h / mL 0-inf to provide.
[0149] In some embodiments, the dry powder composition comprises about 112.5 μg of the compound of Formula (II), * Treprostinil AUC in the range of approximately 80% to approximately 125% of h / mL 0-inf to provide.
[0150] In some embodiments, the dry powder composition comprises about 160 μg of the compound of Formula (II) and, upon administration, about 630 μg * Treprostinil AUC ranges from h / mL to approximately 3000 pg*h / mL 0-inf , including all values and ranges therein, e.g., 630pg * h / mL, approximately 700pg * h / mL, approximately 800pg * h / mL, approximately 900pg * h / mL, approximately 1000pg *h / mL, approx. 1100pg*h / mL, approx. 1200pg * h / mL, approximately 1300pg * h / mL, approximately 1400pg * h / mL, approx. 1500pg*h / mL, approx. 1600pg * h / mL, approximately 1700pg * h / mL, approximately 1800pg * h / mL, approx. 1900pg*h / mL, approx. 2000pg * h / mL, approximately 2100pg * h / mL, approximately 2200pg * h / mL, approx. 2300pg*h / mL, approx. 2400pg * h / mL, approximately 2500pg * h / mL, approximately 2600pg * h / mL, approx. 2700pg*h / mL, approx. 2800pg * h / mL, approximately 2900pg * h / mL, or approximately 3000 pg * In some embodiments, the dry powder composition comprises about 160 μg of the compound of Formula (II) and, upon administration, about 785 μg * h / mL ~ approx. 2370pg * Treprostinil AUC from approximately 80% to 125% of the h / mL range 0-inf In some embodiments, the dry powder composition comprises about 160 μg of the compound of Formula (II) and, upon administration, about 1100 pg * h / mL ~ approx. 2050pg * Treprostinil AUC in the range of approximately 80% to 125% of h / mL 0-inf to provide.
[0151] In some embodiments, the dry powder composition comprises about 225 μg of the compound of Formula (II) and, upon administration, about 2130 (30.0) mg * AUC in the range of approximately 80% to approximately 125% of h / mL 0-inf In some embodiments, the dry powder composition comprises about 225 μg of the compound of formula (II) and about 1680 (28.7) mg * Steady-state treprostinil AUC0- in the range of approximately 80% to approximately 125% of h / mL 24In some embodiments, the dry powder composition comprises about 225 μg of the compound of formula (II) or a stereoisomer thereof (or an equivalent dose of a pharmaceutically acceptable salt thereof, or the compound of formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof), providing a CV% of about 1790 (39.6) ng * Steady-state treprostinil AUC0- in the range of approximately 80% to approximately 125% of h / mL 24 (CV%) is provided.
[0152] In some embodiments, the dry powder composition comprises about 450 μg of the compound of Formula (II) and, upon administration, about 4040 (27.4) pg * Treprostinil AUC in the range of approximately 80% to approximately 125% of h / mL 0-inf to provide.
[0153] In some embodiments, the dry powder composition comprises about 240 μg of the compound of Formula (II) and, upon administration, about 880 μg * h / mL ~ approx. 4130pg * Treprostinil AUC in the range of h / mL 0-inf provides, for example, approximately 800 pg, including all values and ranges therein. * h / mL, approximately 900pg * h / mL, approximately 950pg * h / mL, approximately 1000pg * h / mL, approximately 1050pg * h / mL, approximately 1100pg * h / mL, approximately 1150pg * h / mL, approximately 1200pg * h / mL, approximately 1250pg * h / mL, approximately 1300pg * h / mL, approximately 1350pg * h / mL, approximately 1400pg * h / mL, approximately 1450pg * h / mL, approximately 1500pg * h / mL, approximately 1550pg * h / mL, approximately 1600pg * h / mL, approximately 1650pg * h / mL, approximately 1700pg *h / mL, about 1750 pg * h / mL, about 1800 pg * h / mL, about 1850 pg * h / mL, about 1950 pg * h / mL, about 2000 pg * h / mL, about 2050 pg * h / mL, about 2100 pg * h / mL, about 2150 pg * h / mL, about 2200 pg * h / mL, about 2250 pg * h / mL, about 2300 pg * h / mL, about 2350 pg * h / mL, about 2400 pg * h / mL, about 2450 pg * h / mL, about 2500 pg * h / mL, about 2550 pg * h / mL, about 2600 pg * h / mL, about 2650 pg * h / mL, about 2700 pg * h / mL, about 2750 pg * h / mL, about 2800 pg * h / mL, about 2850 pg * h / mL, about 2950 pg * h / mL, about 3000 pg * h / mL, about 3050 pg * h / mL, about 3100 pg * h / mL, about 3150 pg * h / mL, about 3200 pg * h / mL, about 3250 pg * h / mL, about 3300 pg * h / mL, about 3350 pg * h / mL, about 3400 pg * h / mL, about 3450 pg * h / mL, about 3500 pg * h / mL, about 3550 pg * h / mL, about 3600 pg * h / mL, about 3650 pg * h / mL, about 3700 pg * h / mL, about 3750 pg * h / mL, about 3800 pg *h / mL, approximately 3850pg * h / mL, approximately 3950pg * h / mL, approximately 4000pg * h / mL, approximately 4050pg * h / mL, approximately 4100pg * h / mL, approximately 4130pg * In some embodiments, the dry powder composition comprises about 240 μg of the compound of Formula (II) and, upon administration, about 1100 pg * h / mL ~ approx. 3305pg * Treprostinil AUC in the range of approximately 80% to 125% of h / mL 0-inf In some embodiments, the dry powder composition comprises about 240 μg of the compound of Formula (II) and, upon administration, provides about 1540 μg * h / mL ~ approx. 2865pg * Treprostinil AUC in the range of approximately 80% to 125% of h / mL 0-inf to provide.
[0154] In some embodiments, the dry powder composition comprises about 320 μg of the compound of Formula (II) and, upon administration, provides a treprostinil AUC in the range of about 1130 pg*h / mL to about 5310 pg*h / mL. 0-infand about 1130 pg*h / mL, about 1200 pg*h / mL, about 1300 pg*h / mL, about 1400 pg*h / mL, about 1450 pg*h / mL, about 1500 pg*h / mL, about 1550 pg*h / mL, about 1600 pg*h / mL, about 1700 pg*h / mL, about 1800 pg*h / mL, about 190 0pg*h / mL, approx. 2000pg*h / mL, approx. 2100pg*h / mL, approx. 2200pg*h / mL, approx. 2300pg*h / mL, approx. 2400pg*h / mL, approx. 2500p g*h / mL, approximately 2600pg*h / mL, approximately 2700pg*h / mL, approximately 2800pg*h / mL, approximately 2900pg*h / mL, approximately 3000pg*h / mL, approximately 3100pg*h / mL, approx. 3200pg*h / mL, approx. 3300pg*h / mL, approx. 3400pg*h / mL, approx. 3500pg*h / mL, approx. 3600pg*h / mL, approx. 3700pg*h / m L, approx. 3800pg*h / mL, approx. 3900pg*h / mL, approx. 4000pg*h / mL, approx. 4100pg*h / mL, approx. 4200pg*h / mL, approx. 4300pg*h / mL, approx. In some embodiments, the dry powder composition comprises about 320 μg of the compound of Formula (II) and, upon administration, has a treprostinil AUC of about 4400 pg*h / mL, about 4500 pg*h / mL, about 4600 pg*h / mL, about 4700 pg*h / mL, about 4800 pg*h / mL, about 4900 pg*h / mL, about 5000 pg*h / mL, about 5100 pg*h / mL, about 5200 pg*h / mL, about 5300 pg*h / mL, about 5300 pg*h / mL, or about 5310 pg*h / mL. 0-inf In some embodiments, about 320 μg of the compound of Formula (II), or a stereoisomer thereof (or an equivalent dose of a pharmaceutically acceptable salt thereof, or the compound of Formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof) is administered once daily to provide about 1975 μg * h / mL ~ approx. 3680 pg * Treprostinil AUC in the range of approximately 80% to 125% of h / mL 0-inf to provide.
[0155] In some embodiments, the dry powder composition comprises about 400 μg of the compound of Formula (II) and, upon administration, provides a treprostinil AUC in the range of about 1380 pg*h / mL to about 6480 pg*h / mL. 0-inf and about 1380 pg*h / mL, about 1400 pg*h / mL, about 1450 pg*h / mL, about 1500 pg*h / mL, about 1550 pg*h / mL, about 1600 pg*h / mL, about 1700 pg*h / mL, about 1800 pg*h / mL, about 1900 pg*h / mL, about 2000 pg*h / mL, about 2100 pg*h / mL, about 2200 pg*h / mL, about 230 0pg*h / mL, approx. 2400pg*h / mL, approx. 2500pg*h / mL, approx. 2600pg*h / mL, approx. 2700pg*h / mL, approx. 2800pg*h / mL, approx. 2900pg*h / mL, approx. 3000p g*h / mL, approximately 3100pg*h / mL, approximately 3200pg*h / mL, approximately 3300pg*h / mL, approximately 3400pg*h / mL, approximately 3500pg*h / mL, approximately 3600pg*h / mL, approximately 3700pg*h / mL, approx. 3800pg*h / mL, approx. 3900pg*h / mL, approx. 4000pg*h / mL, approx. 4100pg*h / mL, approx. 4200pg*h / mL, approx. 4300pg*h / mL, approx. 4400pg*h / m L, approx. 4500pg*h / mL, approx. 4600pg*h / mL, approx. 4700pg*h / mL, approx. 4800pg*h / mL, approx. 4900pg*h / mL, approx. 5000pg*h / mL, approx. 5100pg*h / mL, approx. In some embodiments, the dry powder composition comprises about 400 μg of the compound of Formula (II) and, upon administration, has a treprostinil AUC of about 5200 pg*h / mL, about 5300 pg*h / mL, about 5400 pg*h / mL, about 5500 pg*h / mL, about 5600 pg*h / mL, about 5700 pg*h / mL, about 5800 pg*h / mL, about 5900 pg*h / mL, about 6000 pg*h / mL, about 6100 pg*h / mL, about 6200 pg*h / mL, about 6300 pg*h / mL, about 6400 pg*h / mL, or about 6480 pg*h / mL. 0-infIn some embodiments, the dry powder composition comprises about 400 μg of the compound of Formula (II) and, upon administration, provides a treprostinil AUC of about 80% to 125%, in the range of about 2415 pg*h / mL to about 4490 pg*h / mL. 0-inf to provide.
[0156] In some embodiments, the dry powder composition comprises about 480 μg of the compound of Formula (II) and, upon administration, provides a treprostinil AUC in the range of about 1630 pg*h / mL to about 7650 pg*h / mL. 0-inf provides, for example, approximately 1630pg, including all values and ranges therein. * h / mL, approximately 1700pg * h / mL, approximately 1800pg * h / mL, approximately 1900pg * h / mL, approximately 2000pg * h / mL, approximately 2100pg * h / mL, approximately 2200pg * h / mL, approximately 2300pg * h / mL, approximately 2400pg * h / mL, approximately 2500pg * h / mL, approximately 2600pg * h / mL, approximately 2700pg * h / mL, approximately 2800pg * h / mL, approximately 2900pg * h / mL, approximately 3000pg * h / mL, approximately 3100pg * h / mL, approximately 3200pg * h / mL, approximately 3300pg * h / mL, approximately 3400pg * h / mL, approximately 3500pg * h / mL, approximately 3600pg * h / mL, approximately 3700pg * h / mL, approximately 3800pg * h / mL, approximately 3900pg * h / mL, approximately 4000pg * h / mL, approximately 4100pg * h / mL, approximately 4200pg * h / mL, approximately 4300pg * h / mL, approximately 4400pg* h / mL, approximately 4500pg * h / mL, approximately 4600pg * h / mL, approximately 4700pg * h / mL, approximately 4800pg * h / mL, approximately 4900pg * h / mL, approximately 5000pg * h / mL, approximately 5100pg * h / mL, approximately 5200pg * h / mL, approximately 5300pg * h / mL, approximately 5400pg * h / mL, approximately 5500pg * h / mL, approximately 5600pg * h / mL, approximately 5700pg * h / mL, approximately 5800pg * h / mL, approximately 5900pg * h / mL, approximately 6000pg * h / mL, approximately 6100pg * h / mL, approximately 6200pg * h / mL, approximately 6300pg * h / mL, approximately 6400pg * h / mL, approximately 6500pg * h / mL, approximately 6600pg * h / mL, approximately 6700pg * h / mL, approximately 6800pg * h / mL, approximately 6900pg * h / mL, approximately 7000pg * h / mL, approximately 7100pg * h / mL, approximately 7200pg * h / mL, approximately 7300pg * h / mL, approximately 7400pg * h / mL, approximately 7500pg * h / mL, or approximately 7650 pg * In some embodiments, the dry powder composition comprises about 480 μg of the compound of Formula (II) and, upon administration, about 2040 pg * h / mL ~ approx. 6120pg * Treprostinil AUC in the range of approximately 80% to 125% of h / mL 0-infIn some embodiments, the dry powder composition comprises about 480 μg of the compound of Formula (II) and, upon administration, provides about 2855 μg * h / mL ~ approx. 5310pg * Treprostinil AUC in the range of approximately 80% to 125% of h / mL 0-inf to provide.
[0157] In some embodiments, the dry powder composition comprises about 640 μg of the compound of Formula (II) and, upon administration, about 2130 μg * Treprostinil AUC ranges from h / mL to approximately 10,000 pg*h / mL 0-inf provides, for example, approximately 2130 pg, including all values and ranges therein. * h / mL, approximately 2200pg * h / mL, approximately 2300pg * h / mL, approximately 2400pg * h / mL, approximately 2500pg * h / mL, approximately 2600pg * h / mL, approximately 2700pg * h / mL, approximately 2800pg * h / mL, approximately 2900pg * h / mL, approximately 3000pg * h / mL, approximately 3100pg * h / mL, approximately 3200pg * h / mL, approximately 3300pg * h / mL, approximately 3400pg * h / mL, approximately 3500pg * h / mL, approximately 3600pg * h / mL, approximately 3700pg * h / mL, approximately 3800pg * h / mL, approximately 3900pg * h / mL, approximately 4000pg * h / mL, approximately 4100pg * h / mL, approximately 4200pg * h / mL, approximately 4300pg * h / mL, approximately 4400pg * h / mL, approximately 4500pg * h / mL, approximately 4600pg * h / mL, approximately 4700pg *h / mL, about 4800 pg * h / mL, about 4900 pg * h / mL, about 5000 pg * h / mL, about 5100 pg * h / mL, about 5200 pg * h / mL, about 5300 pg * h / mL, about 5400 pg * h / mL, about 5500 pg * h / mL, about 5600 pg * h / mL, about 5700 pg * h / mL, about 5800 pg * h / mL, about 5900 pg * h / mL, about 6000 pg * h / mL, about 6100 pg * h / mL, about 6200 pg * h / mL, about 6300 pg * h / mL, about 6400 pg * h / mL, about 6500 pg * h / mL, about 6600 pg * h / mL, about 6700 pg * h / mL, about 6800 pg * h / mL, about 6900 pg * h / mL, about 7000 pg * h / mL, about 7100 pg * h / mL, about 7200 pg * h / mL, about 7300 pg * h / mL, about 7400 pg * h / mL, about 7500 pg * h / mL, about 7600 pg * h / mL, about 7700 pg * h / mL, about 7800 pg * h / mL, about 8000 pg * h / mL, about 8100 pg * h / mL, about 8200 pg * h / mL, about 8300 pg * h / mL, about 8400 pg * h / mL, about 8500 pg * h / mL, about 8600 pg * h / mL, about 8700 pg * h / mL, about 8800 pg *h / mL, approximately 8900pg * h / mL, approximately 9000pg * h / mL, approximately 9100pg * h / mL, approximately 9200pg * h / mL, approximately 9300pg * h / mL, approximately 9350pg * h / mL, approximately 9400pg * h / mL, approximately 9450pg * h / mLL, approximately 9500pg * h / mL, approximately 9600pg * h / mL, approximately 9700pg * h / mL, approximately 9800pg * h / mL, approximately 9900pg * h / mL, or approximately 10,000 pg * In some embodiments, the dry powder composition comprises about 640 μg of the compound of Formula (II) and, upon administration, about 2650 pg * h / mL~about 8000pg * Treprostinil AUC in the range of approximately 80% to 125% of h / mL 0-inf In some embodiments, the dry powder composition comprises about 640 μg of the compound of Formula (II) and, upon administration, provides from about 3730 to about 6935 μg * Treprostinil AUC in the range of approximately 80% to 125% of h / mL 0-inf to provide.
[0158] In some embodiments, the dry powder composition comprises about 675 μg of the compound of Formula (II) or a stereoisomer thereof (or an equivalent dose of a pharmaceutically acceptable salt thereof, or the compound of Formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof), and about 5480 (13.8) pg * Treprostinil AUC in the range of approximately 80% to approximately 125% of h / mL 0-24 In a further embodiment, the compound is a compound of formula (II):
[0159] In some embodiments, the dry powder composition comprises about 80 μg to about 675 μg of a compound of Formula (II), and the dry powder composition provides a treprostinil plasma trough concentration in the range of about 3 pg / mL to about 150 mg / mL, or following once-daily administration, a subject (e.g., a patient) has a treprostinil plasma trough concentration in the range of about 3 pg / mL to about 150 mg / mL, for example, about 4 pg / mL, about 5 pg / mL, about 10 pg / mL, about 15 pg / mL, about 20 pg / mL, about 25 pg / mL, about 30 pg / mL, about 35 pg / mL, about 40 pg / mL, about 45 pg / mL, about 50 pg / mL, about 55 pg / mL, about 60 pg / mL, about 65 pg / mL, about 70 pg / mL, and about 75 pg / mL, inclusive of all values and ranges therein. , about 80 pg / mL, about 85 pg / mL, about 90 pg / mL, about 95 pg / mL, about 100 pg / mL, about 100 pg / mL, about 105 pg / mL, about 110 pg / mL, about 115 pg / mL, about 120 pg / mL, about 125 pg / mL, about 130 pg / mL, about 135 pg / mL, about 140 pg / mL, about 145 pg / mL, or about 150 pg / mL.
[0160] In some embodiments, the dry powder composition comprises about 80 μg of a compound of Formula (II), and the dry powder composition provides a treprostinil plasma trough concentration ranging from about 3 pg / mL to about 25 mg / mL, or following once-daily administration, the subject (e.g., patient) has a treprostinil plasma trough concentration ranging from about 3 pg / mL to about 25 mg / mL, e.g., about 3 pg / mL, about 4 pg / mL, about 5 pg / mL, about 10 pg / mL, about 15 pg / mL, about 20 pg / mL, or about 25 pg / mL, including all values and ranges therein. In further embodiments, the treprostinil plasma trough concentration ranges from about 6 pg / mL to about 18 mg / mL.
[0161] In some embodiments, the dry powder composition comprises about 112.5 μg of the compound of Formula (II), and the dry powder composition provides a treprostinil plasma trough concentration in the range of about 4 pg / mL to about 30 mg / mL, or following once-daily administration, the subject (e.g., patient) has a treprostinil plasma trough concentration in the range of about 4 pg / mL to about 30 mg / mL, for example, about 4 pg / mL, about 5 pg / mL, about 10 pg / mL, about 15 pg / mL, about 20 pg / mL, about 25 pg / mL, and about 30 pg / mL, including all values and ranges therein.
[0162] In some embodiments, the dry powder composition comprises about 160 μg of a compound of Formula (II), and the dry powder composition provides a treprostinil plasma trough concentration ranging from about 5 pg / mL to about 35 mg / mL, or following once-daily administration, the subject (e.g., patient) has a treprostinil plasma trough concentration ranging from about 5 pg / mL to about 35 mg / mL, for example, about 5 pg / mL, about 10 pg / mL, about 15 pg / mL, about 20 pg / mL, about 25 pg / mL, about 30 pg / mL, and about 35 pg / mL, including all values and ranges therein. In further embodiments, the treprostinil plasma trough concentration ranges from about 10 pg / mL to about 30 mg / mL, or from 15 pg / mL to about 25 pg / mL.
[0163] In some embodiments, the dry powder composition comprises about 225 μg of the compound of Formula (II), and the dry powder composition provides a treprostinil plasma trough concentration in the range of about 15 pg / mL to about 45 mg / mL, or following once-daily administration, the subject (e.g., patient) has a treprostinil plasma trough concentration in the range of about 15 pg / mL to about 45 mg / mL, for example, about 15 pg / mL, about 20 pg / mL, about 25 pg / mL, about 30 pg / mL, about 35 pg / mL, about 40 pg / mL, and about 45 pg / mL, including all values and ranges therein.
[0164] In some embodiments, the dry powder composition comprises about 240 μg of a compound of Formula (II), and the dry powder composition provides a treprostinil plasma trough concentration ranging from about 7 pg / mL to about 50 mg / mL, or following once-daily administration, a subject (e.g., a patient) has a treprostinil plasma trough concentration ranging from about 7 pg / mL to about 50 mg / mL. For example, about 7 pg / mL, about 10 pg / mL, about 15 pg / mL, about 20 pg / mL, about 25 pg / mL, about 30 pg / mL, about 35 pg / mL, about 40 pg / mL, about 45 pg / mL, or about 50 pg / mL, including all values and ranges therein. In some embodiments, the treprostinil plasma trough concentration ranges from about 15 pg / mL to about 50 mg / mL, or from 20 pg / mL to about 45 pg / mL.
[0165] In some embodiments, the dry powder composition comprises about 320 μg of the compound of Formula (II), and the dry powder composition provides a treprostinil plasma trough concentration in the range of about 9 pg / mL to about 65 mg / mL, or following once-daily administration, the subject (e.g., patient) has a treprostinil plasma trough concentration in the range of about 9 pg / mL to about 65 mg / mL, e.g., about 9 pg / mL, about 10 pg / mL, about 15 pg / mL, about 20 pg / mL, about 25 pg / mL, about 30 pg / mL, about 35 pg / mL, about 40 pg / mL, about 45 pg / mL, about 50 pg / mL, about 55 pg / mL, about 60 pg / mL, or about 65 pg / mL, including all values and ranges therein. In some embodiments, treprostinil plasma trough concentrations range from about 15 pg / mL to about 50 mg / mL, or from 20 pg / mL to about 45 pg / mL.
[0166] In some embodiments, the dry powder composition comprises about 400 μg of a compound of Formula (II), and the dry powder composition provides a treprostinil plasma trough concentration in the range of about 10 pg / mL to about 80 mg / mL, or following once-daily administration, the subject (e.g., patient) has a treprostinil plasma trough concentration in the range of about 10 pg / mL to about 80 mg / mL, e.g., about 10 pg / mL, about 15 pg / mL, about 20 pg / mL, about 25 pg / mL, about 30 pg / mL, about 35 pg / mL, about 40 pg / mL, about 45 pg / mL, about 50 pg / mL, about 55 pg / mL, about 60 pg / mL, about 65 pg / mL, about 70 pg / mL, about 75 pg / mL, and about 80 pg / mL, including all values and ranges therein. In some embodiments, treprostinil plasma trough concentrations range from about 35 pg / mL to about 70 mg / mL, or from 40 pg / mL to about 65 pg / mL.
[0167] In some embodiments, the dry powder composition comprises about 480 μg of the compound of Formula (II), wherein the dry powder composition provides a treprostinil plasma trough concentration in the range of about 13 pg / mL to about 95 mg / mL, or following once-daily administration, the subject (e.g., patient) has a treprostinil plasma trough concentration in the range of about 13 pg / mL to about 95 mg / mL. For example, about 13 pg / mL, about 15 pg / mL, about 20 pg / mL, about 25 pg / mL, about 30 pg / mL, about 35 pg / mL, about 40 pg / mL, about 45 pg / mL, about 50 pg / mL, about 55 pg / mL, about 60 pg / mL, about 65 pg / mL, about 70 pg / mL, about 75 pg / mL, about 80 pg / mL, about 85 pg / mL, about 90 pg / mL, and about 95 pg / mL, including all values and ranges therein. In some embodiments, the treprostinil plasma trough concentration ranges from about 25 pg / mL to about 75 mg / mL, or from 30 pg / mL to about 70 pg / mL.
[0168] In some embodiments, the dry powder composition comprises about 640 μg of the compound of Formula (II), wherein the dry powder composition provides a treprostinil plasma trough concentration in the range of about 15 pg / mL to about 125 mg / mL, or following once-daily administration, the subject (e.g., patient) has a treprostinil plasma trough concentration in the range of about 15 pg / mL to about 125 mg / mL. For example, about 15 pg / mL, about 20 pg / mL, about 25 pg / mL, about 30 pg / mL, about 35 pg / mL, about 40 pg / mL, about 45 pg / mL, about 50 pg / mL, about 55 pg / mL, about 60 pg / mL, about 65 pg / mL, about 70 pg / mL, about 75 pg / mL, about 80 pg / mL, about 85 pg / mL, about 90 pg / mL, about 95 pg / mL, about 100 pg / mL, about 105 pg / mL, about 110 pg / mL, about 115 pg / mL, about 120 pg / mL, about 125 pg / mL, including all values and ranges therein. In some embodiments, treprostinil plasma trough concentrations range from about 35 pg / mL to about 100 mg / mL, or from 50 pg / mL to about 90 pg / mL.
[0169] In some embodiments, the dry powder composition comprises about 450 μg of a compound of Formula (II), and the dry powder composition provides a treprostinil plasma trough concentration in the range of about 30 pg / mL to about 75 mg / mL, or following once-daily administration, a subject (e.g., a patient) has a treprostinil plasma trough concentration in the range of about 30 pg / mL to about 75 mg / mL, e.g., about 30 pg / mL, about 35 pg / mL, about 40 pg / mL, about 45 pg / mL, about 50 pg / mL, about 55 pg / mL, about 60 pg / mL, about 65 pg / mL, about 70 pg / mL, and about 75 pg / mL, including all values and ranges therein.
[0170] In some embodiments, the dry powder composition comprises about 675 μg of the compound of Formula (II), and the dry powder composition provides a treprostinil plasma trough concentration in the range of about 50 pg / mL to about 100 mg / mL, or following once-daily administration, the subject (e.g., patient) has a treprostinil plasma trough concentration in the range of about 50 pg / mL to about 100 mg / mL, for example, about 50 pg / mL, about 55 pg / mL, about 60 pg / mL, about 65 pg / mL, about 70 pg / mL, about 75 pg / mL, about 80 pg / mL, about 85 pg / mL, about 90 pg / mL, about 95 pg / mL, about 100 pg / mL, and about 100 pg / mL, including all values and ranges therein.
[0171] Aerosolized Composition In some embodiments, the dry powder compositions described herein are aerosolized via a DPI to provide an aerosolized composition. The aerosolized composition is administered to a patient in need of treatment for PH. In another embodiment, the aerosolized composition is administered to a patient in need of treatment for pulmonary fibrosis (e.g., PH-ILD, where the ILD is pulmonary fibrosis). The aerosolized composition can be characterized by certain parameters known to those skilled in the art, such as mass median aerodynamic diameter (MMAD) and fine particle fraction (FPF).
[0172] The mass median aerodynamic diameter (MMAD) is the aerodynamic diameter at which 50% of the mass in a given aerosol is associated with particles smaller than the median aerodynamic diameter (MAD) and 50% of the mass is associated with particles larger than the MAD. MMAD can be determined by impactor measurements, such as an Andersen Cascade Impactor (ACT) or Next Generation Impactor (NGI). In some embodiments, the aerosolized dry powder composition contains particles with an MMAD of about 1 μm to about 10 μm, about 1 μm to about 7 μm, about 1 μm to about 5 μm, or about 1 μm to about 4 μm, or about 1.5 μm to about 3.5 μm, or about 2 μm to about 3 μm, as measured by NGI. In one embodiment, a dry powder composition exhibiting one of the MMAD profiles provided above contains mannitol. In another embodiment, a dry powder composition exhibiting the MMAD profile provided above contains trehalose.
[0173] "Fine particle fraction" or "FPF" refers to the proportion of an aerosol having a particle size less than 5 μm in diameter as measured by cascade impaction. FPF is typically expressed as a percentage. FPF has been demonstrated to correlate with the fraction of powder deposited in a subject's lungs (e.g., a patient). In some embodiments, a dry powder composition is in the form of an aerosol containing particles with an FPF of at least 20%, at least 30%, at least 40%, at least 50%, about 30% to about 60%, about 35% to about 55%, or about 40% to about 50%, as measured by NGI. In one embodiment, an aerosolized dry powder composition contains particles with an FPF of about 40% to about 70%, about 30% to about 60%, or about 50% to about 60%, as measured by NGI. In one embodiment, a dry powder composition exhibiting one of the FPF profiles provided above comprises mannitol. In another embodiment, the dry powder composition exhibiting the FPF profile provided above comprises trehalose.
[0174] The dry powder composition of the present disclosure may be produced from a liquid composition using freeze-drying or spray-drying techniques. When freeze-drying is used, the freeze-dried composition can be pulverized to obtain a finely divided dry powder containing particles within the desired size range described above. When spray-drying is used, the process is carried out under conditions that result in a finely divided dry powder containing particles within the desired size range described above. Examples of methods for preparing dry powder forms of pharmaceutical compositions are disclosed in WO96 / 32149, WO97 / 41833, WO98 / 29096, and U.S. Patent Nos. 5,976,574, 5,985,248, and 6,001,336, the disclosures of each of which are incorporated herein by reference in their entirety. Exemplary spray-drying methods are described in U.S. Patent Application Publication No. 2020 / 0338005, and U.S. Patent Nos. 6,848,197 and 8,197,845, the disclosures of each of which are incorporated herein by reference in their entirety.
[0175] In some embodiments, the dry powder composition of the present disclosure is prepared by the following process: A stock solution of a compound of Formula (I) or (II), its stereoisomer, or its pharmaceutically acceptable salt is prepared using an organic solvent such as alcohol (e.g., 1-propanol). An aqueous stock solution of a sugar (e.g., mannitol or trehalose) and leucine is also prepared. The required amount of the above stock solution is then added to a mixture of water and organic solvent to form a spray-drying feed solution. In the spray-drying feed solution, the volume ratio of water to organic solvent can be from about 3:2 to about 1:1.
[0176] Spray drying begins by heating the drying gas by starting the drying gas flow and setting the desired inlet temperature, for example, about 120°C to about 180°C, or about 135°C to about 150°C. After the spray dryer outlet temperature reaches an appropriate temperature, for example, about 55°C to about 65°C, the liquid skid inlet is set so that the blank solution is sprayed into the spray dryer with the aid of nitrogen, allowing the system to cool and stabilize. Product filter pulsing is initiated, and the product filter purge flow rate is set, for example, to 10 to 20 scfh. After the system stabilizes, the liquid skid inlet is switched to the feed solution adjusted above, and the process continues until the feed solution is depleted. At this point, the liquid skid inlet is switched to the blank solution, allowing spraying for about 5 to about 20 minutes. At this point, powder collects at the bottom of the product filter. After spraying the blank solution for about 5 to about 20 minutes, the system is shut down by turning off the liquid line, atomizing gas, drying gas heater, drying gas inlet, and finally the exhaust.
[0177] The dry powder composition of the present disclosure is delivered to the lungs of a subject (e.g., a patient) via inhalation using a dry powder inhaler (DPI). In one embodiment, the dry powder inhaler is a single-dose dry powder inhaler. A DPI, which is a propellant-free device, uses the subject's (e.g., patient's) inhalation to deliver the dry powder to the subject's (e.g., patient's) lungs. The unit dose of the dry powder composition used in a DPI device is often a dry powder blister disk in a hard capsule. Exemplary DPI devices suitable for delivering the dry powder composition of the present disclosure include the devices described in the following paragraphs and the DPIs described in U.S. Patent Nos. 6,766,799, 7,278,425, and 8,496,002, the disclosures of each of which are incorporated herein by reference in their entirety.
[0178] The AIR® inhaler (Alkermes) contains a small breath-activated system that delivers a porous powder from a capsule. The porous particles have an aerodynamic diameter of 1-5 μm. See International Patent Application Publication Nos. WO 99 / 66903 and WO 00 / 10541, the disclosures of each of which are incorporated herein by reference in their entirety.
[0179] The Aerolizer™ (Novartis) is a single-dose dry powder inhaler. In this device, the dry powder medication is stored in a capsule and released by puncturing the capsule wall with a Teflon-coated steel pin. See U.S. Patents 6,488,027 and 3,991,761, the disclosures of each of which are incorporated herein by reference in their entirety.
[0180] Bang Olufsen offers a breath-actuated inhaler that uses a blister strip with up to sixty doses. Dose is only available during inhalation via a novel trigger mechanism. The device is equipped with a dose counter and can be disposed of after all doses have been used. See EP1522325, the disclosure of which is incorporated herein by reference in its entirety.
[0181] Clickhaler® (Innovata PLC) is a large reservoir breath-activated multi-dose device. See U.S. Patent No. 5,437,270, the disclosure of which is incorporated herein by reference in its entirety.
[0182] DirectHaler™ (Direct-Haler A / S) is a single-dose, pre-metered, pre-filled, disposable DPI device made from polypropylene. See U.S. Patent No. 5,797,392, the disclosure of which is incorporated herein by reference in its entirety.
[0183] Diskus™ (GlaxoSmithKline) is a small, disposable DPI device that holds up to 60 doses in a double foil blister strip and provides moisture protection. See GB2242134, the disclosure of which is incorporated herein by reference in its entirety.
[0184] Eclipse™ (Aventis) is a breath-activated, reusable capsule device capable of delivering up to 20 mg of dry powder composition. When the subject (e.g., patient) inhales from the capsule, the powder is drawn into a vortex chamber where a rotating ball assists in breaking down the powder. See U.S. Patent No. 6,230,707 and WO 9503846, the disclosures of each of which are incorporated herein by reference in their entirety.
[0185] The Flexhaler® is a plastic, breath-activated dry powder inhaler that can be used in conjunction with the dry powder compositions provided herein.
[0186] FlowCaps® (Hovione) is a capsule-based, refillable, reusable passive dry powder inhaler that holds up to 14 capsules. The inhaler itself is moisture-resistant. See U.S. Patent No. 5,673,686, the disclosure of which is incorporated herein by reference in its entirety.
[0187] Gyrohaler® (Vectura) is a passive disposable DPI containing a strip of blisters. See GB2407042, the disclosure of which is incorporated herein by reference in its entirety.
[0188] The HandiHaler® (Boehringer Ingelheim GmbH) is a single-dose DPI device. It can deliver up to 30 mg of dry powder composition in a capsule. See International Patent Application Publication No. W04 / 024156, the disclosure of which is incorporated herein by reference in its entirety.
[0189] MicroDose DPI (Microdose Technologies) is a small electronic DPI device. It uses a piezoelectric vibrator (ultrasonic frequencies) to break up drug powder in aluminum blisters (single or multi-dose). See U.S. Patent No. 6,026,809, the disclosure of which is incorporated herein by reference in its entirety.
[0190] The Nektar Dry Powder Inhaler® (Nektar) is a palm-sized, easy-to-use device that offers convenient dosing and flow-independent lung deposition from a standard capsule.
[0191] The Nektar Pulmonary Inhaler® (Nektar) efficiently removes powder from the packaging, breaks down particles, and creates an aerosol cloud suitable for deep lung delivery. This allows the aerosolized particles to be transported from the device to the deep lung during a subject's (e.g., patient's) breathing, reducing losses in the throat and upper airways. Compressed gas is used to aerosolize the powder. See AU4090599 and U.S. Patent No. 5,740,794, the disclosures of each of which are incorporated herein by reference in their entirety.
[0192] NEXT DPI™ is a device that features multiple dose capability, moisture resistance, and dose counting. The device can be used regardless of orientation (upside down) and dose only when adequate respiratory flow is achieved. See EP1196146, U.S. Patent No. 6,528,096, WO0178693, and WO0053158, the disclosures of each of which are incorporated herein by reference in their entirety.
[0193] Neohaler® is a capsule-based plastic breath-activated dry powder inhaler.
[0194] The Oriel™ DPI is an active DPI that utilizes a piezoelectric membrane and nonlinear vibrations to aerosolize powder formulations. See International Patent Application Publication No. WO1 / 68169, the disclosure of which is incorporated herein by reference in its entirety.
[0195] In one embodiment, the DPI is a capsule-based DPI. In a further embodiment, the capsule-based DPI is manufactured by Plastiape. In yet another embodiment, the capsule-based DPI is the RS01 single-dose dry powder inhaler developed by Plastiape, which features a compact size and a simple and effective perforation system and is suitable for both gelatin and HMPC capsules.
[0196] Pressair™ is a plastic, breath-activated, dry powder inhaler.
[0197] The Pulvinal® Inhaler (Chesi) is a breath-actuated, multi-dose (100-dose) dry powder inhaler. The dry powder is stored in a reservoir that is transparent and clearly marked to indicate when the 100th dose has been delivered. See U.S. Patent No. 5,351,683, the disclosure of which is incorporated herein by reference in its entirety.
[0198] Rotohaler® (GlaxoSmithKline) is a single-use device that utilizes a capsule. See U.S. Patent Nos. 5,673,686 and 5,881,721, the disclosures of each of which are incorporated herein by reference in their entirety.
[0199] Rexam DPI (Rexam Pharma) is a single-dose, reusable device designed for use with capsules. See U.S. Patent No. 5,651,359 and EP 0707862, the disclosures of each of which are incorporated herein by reference in their entirety.
[0200] The S2 (Innovata PLC) is a reusable or disposable, single-dose DPI for delivering highly concentrated dry powder compositions. Its dispersion mechanism requires minimal effort to achieve excellent drug delivery to the subject's (e.g., patient's) lungs. The S2 is easy to use and has a passive engine, so no batteries or power source are required. See AU3320101, the disclosure of which is incorporated herein by reference in its entirety.
[0201] The SkyeHaler® DPI (SkyePharma) is a multi-dose device containing up to 300 individual doses in a single-use or replaceable cartridge. The device is breath-actuated and does not require coordination between breath and actuation. See U.S. Patent No. 6,182,655 and WO 97 / 20589, the disclosures of each of which are incorporated herein by reference in their entirety.
[0202] The Taifun® DPI (LAB International) is a multi-dose (up to 200) DPI device. It is breath-actuated and flow rate independent. The device contains a unique moisture-balanced drug reservoir coupled to a volumetric dose-measuring system for consistent dosing. See U.S. Patent No. 6,132,394, the disclosure of which is incorporated herein by reference in its entirety.
[0203] TurboHaler® (AstraZeneca) is described in U.S. Patent No. 5,983,893, the disclosure of which is incorporated herein by reference in its entirety. This DPI device is an inspiratory flow-driven, multi-dose dry powder inhaler with a multi-dose reservoir that provides up to 200 doses of dry powder composition and a dose range from a few micrograms to 0.5 mg.
[0204] The Twisthaler® (Schering-Plough) is a multi-dose device with dose counting capability, capable of 14 to 200 actuations. The dry powder composition is packaged in a cartridge containing a desiccant. See U.S. Patent No. 5,829,434, the disclosure of which is incorporated herein by reference in its entirety.
[0205] Ultrahaler® (Aventis) combines accurate dose measurement with excellent dispersibility. It is an easy-to-use, separate, pocket-sized device with a dose counter, dose intake indicator, and lockout mechanism. The device can deliver up to 20 mg of dry powder composition. Ultrahaler® is described in U.S. Pat. No. 5,678,538 and WO2004026380, the disclosures of each of which are incorporated herein by reference in their entirety.
[0206] Xcelovair™ (Meridica / Pfizer) holds 60 pre-measured, sealed doses ranging from 5 to 20 mg. The device provides moisture protection under accelerated conditions of 40°C / 75% RH. The dispersion system maximizes the fine particle fraction, delivering up to 50% fine particle mass.
[0207] In another aspect, a system is provided that includes (i) one of the dry powder compositions described herein and (ii) a dry powder inhaler (DPI) for administering the dry powder composition. The DPI includes (a) a reservoir containing a dry powder composition disclosed herein, and (b) a means for introducing the dry powder composition into a subject's lungs via inhalation. In one embodiment, the reservoir contains the dry powder composition of the present invention in a capsule or blister pack. The capsule shell material may be gelatin, cellulose derivatives, starch, starch derivatives, chitosan, or synthetic plastics. The DPI may be a single-dose or multi-dose inhaler. Furthermore, the DPI may be pre-metered or device-metered. In one embodiment, the dry powder inhaler is a single-dose dry powder inhaler.
[0208] In one embodiment, the system is used to treat pulmonary hypertension (e.g., Group 1 or Group 3 PH), portopulmonary hypertension, or pulmonary fibrosis, as described in more detail below. The system includes a dry powder composition disclosed herein, i.e., a dry powder composition comprising a compound of Formula (I) or (II), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a DPI. In one embodiment, the dry powder composition comprises a compound of Formula (I) or (II), or a pharmaceutically acceptable salt thereof. In another embodiment, the dry powder composition comprises a compound of Formula (I) or (II). The dry powder inhaler may be as described above and may be a single-dose or multi-dose inhaler, and / or may be pre-metered or device-metered. In one embodiment, the dry powder inhaler is a single-dose dry powder inhaler.
[0209] The term "treating" includes (1) preventing or delaying the onset of clinical symptoms of a condition, disorder, or condition in a patient who may be afflicted with or affected by the condition, disorder, or condition, but who has not yet experienced or exhibited clinical or subclinical symptoms of the condition, disorder, or condition; (2) inhibiting the condition, disorder, or condition (e.g., halting, reducing, or delaying the onset of the disease, or in the case of maintenance treatment, halting, reducing, or delaying the recurrence of at least one clinical or subclinical symptom thereof); and / or (3) alleviating the condition (e.g., causing the alleviation of the condition, disorder, or condition, or at least one of its clinical or subclinical symptoms). In one embodiment, "treating" refers to inhibiting the condition, disorder, or condition (e.g., halting, reducing, or delaying the onset of the disease, or in the case of maintenance treatment, of at least one clinical or subclinical symptom thereof). In another embodiment, "treating" refers to alleviating the condition (e.g., by causing regression of the condition, disorder, or condition, or at least one of its clinical or subclinical symptoms). The benefit to a treated patient is either statistically significant as compared with the condition or condition of the same patient before treatment, or as compared with the condition or condition of an untreated control patient, or the benefit is at least perceptible to the patient or to a physician.
[0210] "Effective amount" means the amount of the dry powder composition of the present disclosure sufficient to produce the desired therapeutic response. An "effective amount" is the amount of a compound of Formula (I) or (II) administered in a single administration session.
[0211] In one aspect of the present invention, a method of treating pulmonary hypertension (PH) in a patient in need thereof is provided. The method comprises administering an effective amount of one of the dry powder compositions disclosed herein to the patient's lungs via a dry powder inhaler (DPI) once daily for an administration period. The dry powder composition comprises a compound of Formula (I) or (II), or a pharmaceutically acceptable salt thereof. The administration comprises (i) aerosolizing the dry powder composition via the DPI to provide an aerosolized dry powder composition, and (ii) administering the aerosolized dry powder composition to the patient's lungs via inhalation by the DPI.
[0212] The World Health Organization (WHO) has classified PH into five groups. Group 1 PH includes pulmonary arterial hypertension (PAH), idiopathic pulmonary arterial hypertension (IPAH), familial pulmonary arterial hypertension (FPAH), and pulmonary arterial hypertension associated with other diseases (APAH). For example, pulmonary arterial hypertension associated with collagen vascular disease (e.g., scleroderma), congenital shunts between the systemic and pulmonary circulation, portal hypertension, and / or HIV infection is included in Group 1 PH. Group 2 PH includes pulmonary hypertension associated with left heart disease, e.g., atrial or ventricular disease, or valvular disease (e.g., mitral stenosis). WHO Group 3 pulmonary hypertension is characterized as pulmonary hypertension associated with lung disease, e.g., chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), and / or hypoxemia. Group 4 pulmonary hypertension is pulmonary hypertension due to chronic thrombotic and / or embolic disease. Group 4 PH is also called chronic thromboembolic pulmonary hypertension. Patients with Group 4 PH experience blockage or narrowing of blood vessels due to blood clots. Group 5 PH is a "miscellaneous" category and includes PH caused by blood disorders (e.g., polycythemia vera, essential thrombocythemia), systemic disorders (e.g., sarcoidosis, vasculitis), and / or metabolic disorders (e.g., thyroid disease, glycogen storage disease).
[0213] The methods provided herein can be used to treat patients with Group 1, Group 2, Group 3, Group 4, or Group 5 PH, as characterized by the WHO.
[0214] In one embodiment of this method, the pulmonary hypertension being treated is chronic thromboembolic pulmonary hypertension.
[0215] In a preferred embodiment, the pulmonary hypertension is Class 1 PH as characterized by the WHO. In a further embodiment, the method provided herein is a method for treating pulmonary arterial hypertension (PAH). In a further embodiment, the PAH is Class I PAH, Class II PAH, Class III PAH, or Class IV PAH as characterized by the New York Heart Association (NYHA).
[0216] In one embodiment, the PAH is Class I PAH characterized by NYHA.
[0217] In another embodiment, the PAH is Class II PAH characterized by NYHA.
[0218] In yet another embodiment, the PAH is Class III PAH characterized by NYHA.
[0219] In yet another embodiment, the PAH is Class IV PAH characterized by NYHA.
[0220] In one embodiment, the pulmonary hypertension (PH) is portopulmonary hypertension (PPH). PPH is defined by the coexistence of portal and pulmonary hypertension. The diagnosis of portopulmonary hypertension is based on hemodynamic criteria: (1) portal hypertension and / or liver disease (clinical diagnosis - ascites / varices / splenomegaly), (2) resting mean pulmonary artery pressure >25 mmHg, (3) pulmonary vascular resistance >240 dynes / cm 5 (4) pulmonary artery occlusion pressure <15 mmHg or transpulmonary gradient >12 mmHg. PPH is a serious complication of liver disease, present in 0.25–4% of patients with cirrhosis. PPH coexists in an estimated 4–6% of patients referred for liver transplantation.
[0221] In a preferred embodiment, the pulmonary hypertension is PH group 3 as characterized by the WHO. In a further embodiment, the method provided herein is a method of treating PH associated with interstitial lung disease (PH-ILD).
[0222] In the methods of treating PH-ILD provided herein, the ILD can include one or more pulmonary conditions. In one embodiment, the one or more pulmonary conditions include idiopathic pulmonary fibrosis (IPF), idiopathic interstitial pneumonia (COP), desquamative interstitial pneumonia, nonspecific interstitial pneumonia, hypersensitivity pneumonitis, acute interstitial pneumonia, interstitial pneumonia (e.g., idiopathic interstitial pneumonia), connective tissue disease, sarcoidosis, or asbestosis. In one embodiment, the ILD is connective tissue disease-associated interstitial lung disease (CTD-ILD). In another embodiment, the ILD is sarcoidosis. In yet another embodiment, the ILD is IPF. In yet another embodiment, the ILD is idiopathic interstitial pneumonia (IIP).
[0223] In one embodiment of the treatment of PH-ILD provided herein, the ILD includes pulmonary fibrosis, e.g., idiopathic pulmonary fibrosis (IPF). Pulmonary fibrosis is a respiratory disease in which scarring occurs in lung tissue, causing severe breathing problems. Scarring, i.e., the accumulation of excess fibrous connective tissue, leads to thickening of the lung walls and a decrease in oxygen supply in the blood. As a result, patients with pulmonary fibrosis suffer from permanent shortness of breath. While a specific cause of the disease is diagnosed in some patients, in others, the presumed cause cannot be identified, resulting in a condition called IPF.
[0224] The length of the administration period in any given case may depend on the nature and severity of the PH to be treated, and how well the patient tolerates and responds to treatment.The treatment method provided herein is provided as a long-term therapy, and therefore, the patient continues to receive treatment as long as the treatment is safe and effective.Therefore, in one embodiment, the administration period continues until the patient dies.In another embodiment, the administration period is the length of time that the treatment is effective.
[0225] In one embodiment, if a patient experiences side effects from treatment, the patient is provided with a reduced dose during the administration period. Similarly, if a lower dose is adequately tolerated, the patient may be titrated to a higher dose. In one embodiment, dose escalation occurs only after the patient has tolerated the lower dose for two or more days, for example, two, three, four, five, six, or seven days.
[0226] In some embodiments, the administration period is about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, about 6 years, about 7 years, about 8 years, about 9 years, about 10 years, about 15 years, about 20 years, or about 30 years.
[0227] In another embodiment, the administration period of the methods provided herein is at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 1 year, at least about 2 years, at least about 3 years, at least about 4 years, at least about 5 years, at least about 6 years, at least about 7 years, at least about 8 years, at least about 9 years, or at least about 10 years, or at least about 20 years. In another embodiment, the administration period is from about 30 days to about 2 years. In another embodiment, the administration period is from about 6 months to about 3 years, or from 6 months to about 4 years, or from about 6 months to about 5 years, or from about 6 months to about 6 years, or from about 6 months to about 7 years, or from about 6 months to about 8 years, or from about 1 year to about 10 years, or from about 2 years to about 10 years, or from about 6 months to about 20 years, or from about 5 years to about 20 years, or from about 10 years to about 30 years.
[0228] In one embodiment, the administration period is at least about 1 year.
[0229] In one embodiment, the administration period is at least about 5 years.
[0230] In one embodiment, the administration period is about 1 year to about 15 years. In another embodiment, the administration period is about 5 years to about 15 years. In yet another embodiment, the administration period is about 10 years to about 20 years. In yet another embodiment, the administration period is about 1 year to about 20 years.
[0231] In one embodiment of the disclosed method, the patient is administered the dry powder composition once daily in a single administration session during the administration period. In another embodiment, the patient is administered the dry powder composition twice daily, i.e., in two separate administration sessions. In one embodiment, administration is accompanied by food. In one embodiment, each administration session comprises one to five inhalations (puffs) from the DPI, e.g., one inhalation (one puff), two inhalations (two puffs), three inhalations (three puffs), four inhalations (four puffs), or five inhalations (five puffs). As used herein, "administration session" refers to one to five inhalations (puffs) from the DPI required to administer about 80 μg to about 700 μg of a compound of Formula (I) or (II), its stereoisomer, or a pharmaceutically acceptable salt thereof. The DPI, in one embodiment, is small and transportable by the patient. In one embodiment, the DPI is a single-dose DPI.
[0232] To achieve a particular dose, in one embodiment, multiple DPI capsules containing the composition can be employed. For example, for a 640 μg dose, two 320 μg DPI capsules can be used. Each capsule can be administered, for example, via one or two inhalations.
[0233] An effective amount of a compound of Formula (I) or (II), its stereoisomer, or a pharmaceutically acceptable salt thereof can include a fixed dose of a compound of Formula (I) or (II), its stereoisomer, or its pharmaceutically acceptable salt. The fixed dose, in one embodiment, is present in one or more DPI capsules. The fixed dose, in one embodiment, is a dose that is titrated (either increased or decreased) from a previous dose. In another embodiment, the fixed dose is the same or substantially the same as a previous dose. In one embodiment, the effective amount is the amount of a compound of Formula (I) or (II), its stereoisomer, or its pharmaceutically acceptable salt administered during each administration session. In some embodiments, the "administered" amount refers to the amount of a compound of Formula (I) or (II), its stereoisomer, or its pharmaceutically acceptable salt administered in a capsule or multiple capsules in a DPI administered in a single administration session. In some embodiments, the fixed dose is in the range of about 80 μg to about 700 μg of a compound of Formula (I) or (II), its stereoisomer, or a pharmaceutically acceptable salt thereof, e.g., about 80 μg, about 112.5 μg, about 160 μg, about 225 μg, about 240 μg, about 320 μg, about 400 μg, about 450 μg, about 480 μg, about 640 μg, or about 675 μg of a compound of Formula (II), its stereoisomer, or a pharmaceutically acceptable salt thereof. For example, if the dry powder composition is administered once daily in a single administration session, the effective amount can be considered to be the amount of a compound of Formula (I) or (II), its stereoisomer, or a pharmaceutically acceptable salt thereof in the capsule or capsules administered during the single administration session. For example, in one embodiment, one or more capsules may be formulated in a dry powder composition, wherein the one or more capsules have a total dose of about 80 μg, about 112.5 μg, about 160 μg, about 225 μg, about 240 μg, about 320 μg, about 400 μg, about 450 μg, about 480 μg, about 640 μg, or 675 μg of a compound of Formula (I) or (II), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, each of the foregoing doses may be an effective amount, and may also be referred to as an amount administered once daily in a single administration session during the administration period.By way of further example, in one embodiment, a capsule contains a dry powder composition comprising about 320 μg of the compound of Formula (II), its stereoisomer, or a pharmaceutically acceptable salt thereof; for purposes of this disclosure, the administered amount is 640 μg, even if more than one puff from two capsules is required to administer 640 μg. Similarly, in this example, the administered amount is 640 μg even if a residual amount of the compound of Formula (II), its stereoisomer, or a pharmaceutically acceptable salt thereof remains in the DPI (e.g., about 5%, 10%, 20%, 30%, 40%, or 50% remains in the DPI).
[0234] The dose "administered" in a single administration session also encompasses situations in which the DPI is refilled or recharged one or more times (e.g., by changing capsules) to achieve the desired effective dose. In such situations, "administration" refers to the total dose in the capsules administered in the administration session. For example, to administer a dose of 240 μg of the compound of formula (II), its stereoisomer, or its pharmaceutically acceptable salt, one 80 μg capsule and one 160 μg capsule may be used. The DPI may be refilled with the first 80 μg capsule, and after emptying the cartridge with one or more puffs, the 160 μg capsule may be loaded into the DPI and emptied with one or more puffs. Both capsules are used in the same administration session, and the administered dose is therefore 240 μg.
[0235] In another embodiment, the effective amount includes increasing doses during the administration period. In a further embodiment, the effective amount is based on dose escalation, based on the patient's maximum tolerated dose. In one embodiment, the patient is initially administered 80 μg. If this dose is well tolerated, the dose is gradually increased until the patient's maximum tolerated dose is reached. During the titration period, the patient remains on the same dose for a minimum cumulative number of days, such as at least 2, 3, or 4 days, before increasing to the next higher dose. See, for example, FIG. 21 for an embodiment of dose titration. If the dose is not tolerated, the dose may be reduced to the previous dose level.
[0236] During the titration period, each patient's dose can be gradually increased to the patient's maximum tolerated dose. As an example, in one embodiment, a patient begins the method of the present invention with a single 80 μg DPI capsule once daily. If this dose is well tolerated, the dose is gradually increased until the patient's maximum tolerated dose is reached. During the titration period, the patient remains on the investigational drug for a minimum cumulative number of days (e.g., 2 days at 80 μg, 160 μg, or 240 μg, 3 days at 320 μg, or 4 days at 400 μg or 480 μg) before starting the next higher dose. Titration of the investigational drug may occur more slowly, but not sooner, than in the above example. Figure 21 provides an exemplary embodiment of dose titration for a patient in need of treatment. If the dose is not tolerated, the dose may be reduced to the previous dose level.
[0237] In some embodiments, patients treated with the disclosed methods exhibit one or more of the following therapeutic responses during the administration period compared to before the administration period: (1) a decrease in pulmonary vascular resistance index (PVRI), (2) a decrease in mean pulmonary artery pressure, (3) an increase in hypoxemia score, (4) a decrease in oxygenation index, (5) an improvement in right heart function, and (6) an improvement in exercise capacity (e.g., as measured by the six-minute walk test).
[0238] The 6MWT is a validated method for measuring exercise capacity and assessing pulmonary function and is performed in accordance with the American Thoracic Society (ATS) guidelines. See American Thoracic Society. ATS Statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111-17, the entire contents of which are incorporated herein by reference for all purposes. In one embodiment, the 6MWT is performed at approximately the same time on the day before the administration period and on the day during the administration period. In a further embodiment, the 6MWT is performed using the same device. In yet another embodiment, the 6MWT is performed by the same person.
[0239] In one embodiment, the patient's walking distance in the 6MWT is increased by at least about 5 meters, at least about 10 meters, at least about 20 meters, at least about 30 meters, at least about 40 meters, or at least about 50 meters during the administration period compared to before the administration period. In another embodiment, the patient's walking distance in the 6MWT is increased by about 5 meters to about 60 meters, about 5 meters to about 50 meters, about 10 meters to about 50 meters, about 15 meters to about 50 meters, or about 20 meters to about 40 meters during the administration period compared to before the administration period. In yet another embodiment, the patient's walking distance in the 6MWT is increased by at least about 30 meters during the administration period compared to before the administration period.
[0240] In one embodiment, the patient's walking distance in the 6MWT increases by about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, or about 90% during the administration period compared to before the administration period. In another embodiment, the patient's walking distance in the 6MWT is increased by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, or at least about 50% during the administration period compared to before the administration period. In another embodiment, the patient's walking distance in the 6MWT is increased by about 5% to about 50%, about 5% to about 40%, about 5% to about 30%, about 5% to about 20%, about 10% to about 50%, about 15% to about 50%, about 20% to about 50%, or about 25% to about 50% during the administration period compared to before the administration period.
[0241] In one embodiment for treating PH, the treatment includes improving the patient's quality of life during the administration period compared to the patient's quality of life before the administration period. Quality of life, in one embodiment, is measured by the Cambridge Pulmonary Hypertension Outcome Assessment (CAMPHOR) questionnaire. See McCabe et al. (2013). Chest. 2013;144(2):522-30, which is incorporated herein by reference in its entirety and for all purposes. The CAMPHOR questionnaire is a health-related quality of life (QOL) measure specific to pulmonary hypertension and consists of three sections assessing a total of 65 items (25 symptom items, 15 activity items, and 25 QOL items). CAMPHOR scores are negatively weighted, so the higher the score, the worse the QOL and the greater the functional limitations. Both symptom and QOL items are scored out of 25 points, and the activity item is scored out of 30 points with three possible responses (scores 0-2). Each CAMPHOR assessment takes an average of 10 minutes. In one embodiment for treating PH, treatment comprises reducing the patient's CAMPHOR questionnaire score during the administration period compared to the CAMPHOR questionnaire score before the administration period, which reduction, in one embodiment, is 1 to about 10, 1 to about 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 1 to 2.
[0242] In one embodiment of the method of treating PH, the method includes increasing the saturation of the patient's peripheral capillary oxygen supply (SpO2) at rest as assessed by pulse oximetry during the administration period compared to the patient's SpO2 at rest before the administration period.
[0243] Oxygen saturation indicates the amount of hemoglobin in the blood that is bound to oxygen, typically given as the ratio of oxyhemoglobin to total hemoglobin. SpO2 indicates oxygen saturation in the peripheral capillaries. Exemplary methods for measuring SpO2 include, but are not limited to, pulse oximetry using a pulse oximeter. In one embodiment of the methods of treating PH provided herein, the method comprises increasing the patient's resting SpO2 by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 11%, at least about 12%, at least about 13%, at least about 14%, at least about 15%, at least about 16%, at least about 17%, at least about 18%, at least about 19%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, or at least about 90% during the administration period compared to before the administration period. In another embodiment, the method of treating PH comprises increasing the patient's resting SpO2 by about 5% to about 50%, about 5% to about 40%, about 5% to about 30%, about 5% to about 20%, about 10% to about 50%, about 15% to about 50%, about 20% to about 50%, or about 25% to about 50% during the administration period compared to before the administration period.
[0244] In one embodiment, the methods of treating PH provided herein include improving the patient's pulmonary function during the administration period compared to the patient's pulmonary function before the administration period. In one embodiment, the improved pulmonary function is measured by spirometry.
[0245] The improvement in the patient's pulmonary function, in one embodiment, includes, during the administration period, increasing the patient's forced vital capacity (FVC), increasing the patient's percent predicted forced vital capacity (ppFVC), increasing the patient's forced inspiratory volume in one second (FEV1), increasing the patient's percent predicted forced inspiratory volume in one second (ppFEV1), and increasing the patient's FVC (FEF), compared to their respective values prior to the administration period. (25~75%) ), increasing the patient's total lung capacity (TLC), or increasing the patient's diffusing capacity for carbon monoxide (DLCO).
[0246] For example, FVC, ppFVC, FEV 1、 ppFEV1, FEF (25~75%) Assessment of pulmonary function via pulmonary stimuli, TLC, or DLCO measurements, in one embodiment, involves comparing the patient's pulmonary function prior to the administration period, e.g., immediately before treatment, to an average of measurements taken at a time during the administration period or during the administration period.
[0247] As described herein, in one embodiment, a method of treating PH includes improving a patient's pulmonary function during a dosing period, as measured by spirometry, compared to the respective values measured before the dosing period. Spirometry is a physiological test that measures how much air an individual inhales or exhales. The primary signal measured in spirometry can be volume or flow rate. In the methods described herein, spirometry (e.g., FEV 1、 FVC, FEF (25~75%)Pulmonary function tests (PFTs) by spirometry (and TLC) are performed according to the American Thoracic Society (ATS) / European Respiratory Society (ERS) standards, for example, as set forth by Miller et al. (See Miller et al., "Standardization of Spirometry," Eur. Respir. J. 26:319-38 (2005), which is incorporated herein by reference in its entirety.) DLCO can be measured using the technique described in Modi P, Cascella M, "Diffusing Capacity Of The Lungs For Carbon Monoxide," [Updated 2021 Mar 24]. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing, 2021 Jan-. Available from: www.ncbi.nlm.nih.gov / books / NBK556149 / ; Graham et al., “2017 ERS / ATS standards for single-breath carbon monoxide uptake in the lung,” European Respiratory Journal 49:1600016 (2017); each of which is incorporated by reference in its entirety for all purposes.
[0248] In one embodiment, the spirometer is capable of accumulating volume for 15 seconds or more, e.g., 20 seconds or more, 25 seconds or more, 30 seconds or more, 35 seconds or more. In one embodiment, the spirometer is capable of accumulating volume between 0 and 14 L·s with an accuracy of at least ±3% of the reading or ±0.050 L, whichever is greater. -1 At a flow rate of 14 L·s, a volume of 8 L or more (BTPS) can be measured. -1 The total resistance to airflow through the spirometer at 1.5 cmH2O L -1 ·s -1 (0.15 kPa?L -1 ·s -1). In one embodiment, the total resistance of the spirometer is measured, including any tubing, valves, pre-filters, etc. that may be inserted between the patient and the spirometer. For devices that exhibit resistance changes due to water vapor condensation, in one embodiment, the spirometer accuracy requirements are met under BTPS (body temperature, ambient pressure, water vapor saturation) conditions with up to eight consecutive FVC maneuvers over a 10-minute period without receiving a breath from the device.
[0249] With respect to the forced expiratory maneuvers described herein, in one embodiment, the range and accuracy recommendations set forth in Table 6 of Miller et al. are met (see Miller et al., "Standardization of Spirometry," Eur. Respir. J. 26:319-38 (2005)), the entire text of which is incorporated herein by reference for all purposes).
[0250] In one embodiment, the improvement in pulmonary function comprises an improvement in the patient's forced vital capacity (FVC), i.e., an improvement in the maximum volume of air exhaled from maximal inspiration during the administration period compared to the FVC before administration. FVC is expressed in liters at body temperature and ambient pressure saturated with water vapor (BTPS). In another embodiment, the improvement in pulmonary function is an improvement in percent predicted forced vital capacity (ppFVC).
[0251] "Forced vital capacity" (FVC) refers to the volume of gas exhaled during forced expiration, beginning at full inspiration and ending at full expiration, and is one measure of therapeutic efficacy. FVC may be expressed as a percentage of predicted FVC (i.e., ppFVC) obtained from a normal population based on the patient's age, height, sex, and sometimes weight and race. In one embodiment of a method of treating PH, improving the patient's pulmonary function comprises increasing the patient's FVC or ppFVC during the administration period compared to the patient's corresponding FVC or ppFVC prior to the administration period. The increase in FVC or ppFVC, in one embodiment, is at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, or at least about 50%. In another embodiment, the increase in FVC or ppFVC is about 1% to about 20%, about 1% to about 15%, about 1% to about 10%, about 1% to about 5%, about 5% to about 50%, about 5% to about 40%, about 5% to about 30%, about 5% to about 20%, about 10% to about 50%, about 15% to about 50%, about 20% to about 50%, or about 25% to about 50%. In one embodiment, the increase in FVC or ppFVC is an increase in pre-bronchodilator FVC or ppFVC. In another embodiment, the increase in FVC or ppFVC is an increase in post-bronchodilator FVC or ppFVC.
[0252] In one embodiment, the patient's ppFVC is 80% or less prior to the administration period. In a further embodiment, the patient's ppFVC is 70% or less prior to the administration period. In a further embodiment, the patient's ppFVC is 60% or less prior to the administration period. In a further embodiment, the patient's ppFVC is 50% or less prior to the administration period. In another embodiment, the patient's ppFVC is 30% to 80%, 40% to 70%, or 50% to 60% prior to the administration period.
[0253] The FVC maneuver can be performed according to procedures known to those skilled in the art. Briefly, the three distinct phases to the FVC maneuver are (1) maximal inspiration, (2) an exhalation "burst," and (3) continuation of full exhalation to the end of the test (EOT). The maneuver can be performed via either a closed-circuit or open-circuit technique. In either case, the patient takes a rapid, complete breath at total lung capacity (TLC), with a pause of less than one second. The patient then maximally exhales until no more air can be exhaled while maintaining an upright position. Exhalation begins with a "burst" of air from the lungs, followed by encouragement to exhale completely. Intensive patient coaching continues for at least three maneuvers.
[0254] FEV1 is the volume of gas exhaled in a specified time (usually 1 second, i.e., FEV1) from the start of a forced vital capacity maneuver. (See Quanjer et al. (1993). Eur. Respir. J. 6, Suppl. 16, pp. 5-40, which is incorporated herein by reference in its entirety for all purposes.) FEV1 may also be expressed as a percentage of a predicted FEV1 (i.e., ppFEV1) obtained from a normal population based on the patient's sex, height, and age, and sometimes race and weight.
[0255] In one embodiment, improving the patient's pulmonary function comprises increasing the patient's FEV1 or ppFEV1 during the administration period compared to the patient's corresponding FEV1 or ppFEV1 prior to the administration period. The increase in FEV1 or ppFEV1, in one embodiment, is an increase of about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, and about 90%. In another embodiment, the increase in FEV1 or ppFEV1 is about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, or about 50%. In another embodiment, the increase in FEV1 or ppFEV1 includes an increase of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, or at least about 50%. In another embodiment, the increase in FEV1 or ppFEV1 is about 5% to about 50%, about 5% to about 40%, about 5% to about 30%, about 5% to about 20%, about 10% to about 50%, about 15% to about 50%, about 20% to about 50%, or about 25% to about 50%.
[0256] In one embodiment, the increase in FEV1 or ppFEV1 is an increase in FEV1 or ppFEV1 before administration of a bronchodilator. In another embodiment, the increase in FEV1 or ppFEV1 is an increase in FEV1 or ppFEV1 after administration of a bronchodilator.
[0257] In one embodiment, the patient's ppFEV1 is 80% or less before the administration period. In a further embodiment, the patient's ppFEV1 is 70% or less before the administration period. In a further embodiment, the patient's ppFEV1 is 60% or less before the administration period. In a further embodiment, the patient's ppFEV1 is 50% or less before the administration period. In another embodiment, the patient's ppFEV1 is 30% to 80%, 40% to 70%, or 50% to 60% before the administration period.
[0258] In another embodiment, improving the patient's pulmonary function comprises increasing the patient's FEV1 during the administration period compared to the patient's FEV1 before the administration period by about 25 mL to about 500 mL, about 25 mL to about 400 mL, about 25 mL to about 300 mL, about 25 mL to about 250 mL, about 25 mL to about 200 mL, or about 50 mL to about 200 mL, compared to the patient's FEV1 before the administration period. In one embodiment, the increase in FEV1 is an increase in FEV1 before administration of the bronchodilator. In another embodiment, the increase in FEV1 is an increase in FEV1 after administration of the bronchodilator.
[0259] In one embodiment, improving the patient's pulmonary function is measured by measuring the patient's FEF before the administration period. (25~75%) Compared with the mean forced expiratory flow (FEF) between 25% and 75% of the patient's FVC during the treatment period, (25~75%) This involves increasing the maximum mid-expiratory flow (FEF) (also known as peak mid-expiratory flow). (25~75%) Measurement depends on the availability of FVC measurement and the level of expiratory effort. FEF (25~75%) The index is the maximum sum of FEV1 and FVC, obtained by exhalation.
[0260] In one embodiment, the FEF of the patient during the administration period (25~75%) In another embodiment, the increase in the FEF of the patient during the administration period includes an increase of at least about 1%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, or at least about 50%. (25~75%)The increase in FEF includes an increase of about 5% to about 50%, about 5% to about 40%, about 5% to about 30%, about 5% to about 20%, about 10% to about 50%, about 15% to about 50%, about 20% to about 50%, or about 25% to about 50%. (25~75%) The increase in pre-bronchodilator FEF (25~75%) In another embodiment, the FEF (25~75%) The increase in FEF after bronchodilator administration (25~75%) is an increase.
[0261] Total lung capacity (TLC) is the sum of vital capacity, which represents the total volume of air that can be accommodated in the lungs, and residual volume. Total lung capacity (TLC) is divided into four volumes: tidal volume (V T ) is the volume inhaled or exhaled in normal quiet breathing. Inspiratory reserve volume (IRV) is the maximum volume that can be inhaled after normal quiet inhalation. Expiratory reserve volume (ERV) is the maximum volume that can be exhaled after normal quiet exhalation. Residual volume (RV) is the volume remaining in the lungs after a maximal exhalation. Vital capacity (VC) is the maximum volume that can be exhaled after a maximal inhalation: VC = IRV + V T +ERV. In one embodiment, improving the patient's pulmonary function comprises increasing the patient's total lung capacity (TLC) during the administration period compared to the patient's TLC before the administration period. In one embodiment, the increase is at least about 1%, at least about 2%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, or at least about 50%. In another embodiment, the increase is between about 1% and about 50%, between about 5% and about 50%, between about 5% and about 40%, between about 5% and about 30%, between about 5% and about 20%, between about 10% and about 50%, between about 15% and about 50%, between about 20% and about 50%, or between about 25% and about 50%.
[0262] The diffusing capacity of the lungs for carbon monoxide (DLCO), also known as the transport component, is a measure of the lungs' ability to transfer inhaled air into the bloodstream. Carbon monoxide (CO) has a high affinity for hemoglobin and follows the same pathway as oxygen to ultimately bind to hemoglobin. Inhaled CO is used in this test because of its high affinity for hemoglobin (200–250 times that of oxygen). Because anemia can decrease DLCO, DLCO may need to be adjusted for hemoglobin levels. DLCO may also need to be adjusted for several other factors, such as carboxyhemoglobin and FiO. See Modi P, Cascella M, “Diffusing Capacity of the Lungs for Carbon Monoxide,” [Updated 2021 Mar 24]. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2021 Jan, incorporated herein by reference in its entirety for all purposes. In one embodiment, improving the patient's pulmonary function comprises increasing the patient's DLCO during the administration period compared to the patient's DLCO before the administration period. In one embodiment, the DLCO is adjusted for hemoglobin levels, i.e., improving the patient's pulmonary function comprises increasing the patient's DLCO adjusted for hemoglobin during the administration period compared to the patient's DLCO adjusted for hemoglobin before the administration period. In another embodiment, improving the patient's pulmonary function comprises increasing the patient's predicted DLCO percentage (DLCO%) during the administration period compared to the patient's predicted DLCO percentage before the administration period. Predicted normal DLCO values may be calculated according to the equation established by Crapo et al., Am Rev Respir Dis. 123(2):185-9 (1981) or Miller et al., Am Rev Respir Dis. 127(3):270-7 (1983), each of which is incorporated by reference in its entirety for all purposes. In a further embodiment, the patient's predicted DLCO% is adjusted for hemoglobin.
[0263] In one embodiment, improving pulmonary function comprises increasing the patient's DLCO or % predicted DLCO by at least about 1%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, or at least about 50%. In another embodiment, improving pulmonary function comprises increasing the patient's DLCO or % predicted DLCO by about 5% to about 50%, about 5% to about 40%, about 5% to about 30%, about 5% to about 20%, about 10% to about 50%, about 15% to about 50%, about 20% to about 50%, or about 25% to about 50%. In a further embodiment, the patient's DLCO or % predicted DLCO is adjusted for hemoglobin.
[0264] In one embodiment, the patient's predicted DLCO% is 80% or less, 70% or less, 60% or less, or 50% or less prior to the administration period. In a further embodiment, the patient's predicted DLCO% is adjusted for hemoglobin. In another embodiment, the patient's predicted DLCO% is 30% to 80%, 40% to 70%, or 50% to 60% prior to the administration period. In a further embodiment, the patient's predicted DLCO% is adjusted for hemoglobin.
[0265] In one embodiment of the methods of treating PH provided herein, the method comprises prolonging the time to clinical deterioration, compared to untreated PH patients or compared to PH patients not treated with a compound of Formula (I) or (II), where clinical deterioration is selected from the group consisting of death, hospitalization due to respiratory signs (e.g., dyspnea and / or worsening pulmonary function as indicated by a decrease in FVC, DLOC, and / or SpO), a 10% or greater decline in percent-predicted FVC (ppFVC) on two consecutive occasions separated by 4-14 weeks compared to the patient's ppFVC prior to the treatment period, lung transplant, and a 15% or greater decline in 6-minute walk test (6MWT) distance walked on two consecutive occasions separated by at least 24 hours compared to the patient's 6MWT distance walked prior to the treatment period.
[0266] In one embodiment, the time to clinical deterioration is increased by about 1 day, about 3 days, about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, or about 6 weeks. In another embodiment, the time to clinical deterioration is increased by at least about 1 day, at least about 3 days, at least about 1 week, at least about 2 weeks, at least about 3 weeks, at least about 4 weeks, at least about 5 weeks, or at least about 6 weeks. In another embodiment, the time to clinical deterioration is increased by about 20 to about 100 days, about 30 to about 100 days, about 20 to about 75 days, about 20 to about 50 days, or about 20 to about 40 days. In another embodiment, the time to clinical deterioration is increased by at least 1 month, e.g., about 1 month to about 6 months, about 1 month to about 4 months, or about 1 month to about 3 months.
[0267] In one embodiment, the method of treating PH provided herein includes increasing a patient's lobar volume and / or airway volume, as assessed by computed tomography (CT), during an administration period compared to the patient's lobar volume and / or airway volume before the administration period. CT may be performed via chest CT scanning during a respiratory cycle to generate CT images at functional residual capacity (FRC) and / or total lung capacity (TLC). In one embodiment, the lobar volume is the volume of the lobar structures of the patient's respiratory system at TLC or FRC, and the airway volume is the volume of the airway structures of the patient's respiratory system at TLC or FRC.
[0268] In one embodiment, the increase in lobar volume and / or airway volume in the patient comprises an increase of at least about 1%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, or at least about 50%. In another embodiment, the increase in lobar volume and / or airway volume in the patient is between about 5% and about 50%, between about 5% and about 40%, between about 5% and about 30%, between about 5% and about 20%, between about 10% and about 50%, between about 15% and about 50%, between about 20% and about 50%, or between about 25% and about 50%.
[0269] Additional Embodiments
[0270] Embodiment 1 (a) about 0.1 wt % to about 5 wt % of formula (I); [ka] In the formula, R 1 is tetradecyl, pentadecyl, hexadecyl, heptadecyl, or octadecyl, or an enantiomer, diastereomer, or pharmaceutically acceptable salt thereof; (b) about 10 wt% to about 50 wt% leucine; the remainder (c) being a sugar selected from the group consisting of trehalose and mannitol; A dry powder composition, the total of (a), (b), and (c) being 100 wt%.
[0271] Embodiment 2 2. The dry powder composition of embodiment 1, wherein (a) is a compound of formula (I) or a pharmaceutically acceptable salt thereof.
[0272] Embodiment 3 3. The dry powder composition of embodiment 1 or 2, wherein (a) is a compound of formula (I).
[0273] Embodiment 4 R 1 4. The dry powder composition of any one of embodiments 1-3, wherein is tetradecyl.
[0274] Embodiment 5 R 1 5. The dry powder composition of embodiment 4, wherein
[0275] Embodiment 6 R 1 4. The dry powder composition of any one of embodiments 1-3, wherein is pentadecyl.
[0276] Embodiment 7 R 17. The dry powder composition of embodiment 6, wherein
[0277] Embodiment 8 R 1 4. The dry powder composition of any one of embodiments 1-3, wherein is heptadecyl.
[0278] Embodiment 9 R 1 9. The dry powder composition of embodiment 8, wherein
[0279] Embodiment 10 R 1 4. The dry powder composition of any one of embodiments 1-3, wherein is octadecyl.
[0280] Embodiment 11 R 1 11. The dry powder composition of embodiment 10, wherein is linear octadecyl.
[0281] Embodiment 12 R 1 4. The dry powder composition of any one of embodiments 1-3, wherein is hexadecyl.
[0282] Embodiment 13 R 1 13. The dry powder composition of embodiment 12, wherein is linear hexadecyl.
[0283] Embodiment 14 14. The dry powder composition of any one of embodiments 1-13, wherein the compound of formula (I), or an enantiomer, diastereomer, or pharmaceutically acceptable salt thereof, is present in about 0.1 wt% to about 4.5 wt% of the total weight of the dry powder composition.
[0284] Embodiment 15 15. The dry powder composition of embodiment 14, wherein the compound of formula (I), or a pharmaceutically acceptable salt thereof, is present in about 0.1 wt% to about 4.5 wt% of the total weight of the dry powder composition.
[0285] Embodiment 16 16. The dry powder composition of embodiment 14 or 15, wherein the compound of formula (I) is present in about 0.1 wt% to about 4.5 wt% of the total weight of the dry powder composition.
[0286] Embodiment 17 14. The dry powder composition of any one of embodiments 1-13, wherein the compound of formula (I), or an enantiomer, diastereomer, or pharmaceutically acceptable salt thereof, is present in about 0.1 wt% to about 4 wt% of the total weight of the dry powder composition.
[0287] Embodiment 18 18. The dry powder composition of embodiment 17, wherein the compound of formula (I), or a pharmaceutically acceptable salt thereof, is present in about 0.1 wt% to about 4 wt% of the total weight of the dry powder composition.
[0288] Embodiment 19 19. The dry powder composition of embodiment 17 or 18, wherein the compound of formula (I) is present in about 0.1 wt% to about 4 wt% of the total weight of the dry powder composition.
[0289] Embodiment 20 14. The dry powder composition of any one of embodiments 1-13, wherein the compound of formula (I), or an enantiomer, diastereomer, or pharmaceutically acceptable salt thereof, is present in about 0.1 wt% to about 3.5 wt% of the total weight of the dry powder composition.
[0290] Embodiment 21 21. The dry powder composition of embodiment 20, wherein the compound of formula (I), or a pharmaceutically acceptable salt thereof, is present in about 0.1 wt% to about 3.5 wt% of the total weight of the dry powder composition.
[0291] Embodiment 22 22. The dry powder composition of embodiment 20 or 21, wherein the compound of formula (I) is present in about 0.1 wt% to about 3.5 wt% of the total weight of the dry powder composition.
[0292] Embodiment 23 14. The dry powder composition of any one of embodiments 1-13, wherein the compound of formula (I), or an enantiomer, diastereomer, or pharmaceutically acceptable salt thereof, is present in about 0.1 wt% to about 3 wt% of the total weight of the dry powder composition.
[0293] Embodiment 24 24. The dry powder composition of embodiment 23, wherein the compound of formula (I), or a pharmaceutically acceptable salt thereof, is present in about 0.1 wt% to about 3 wt% of the total weight of the dry powder composition.
[0294] Embodiment 25 25. The dry powder composition of embodiment 23 or 24, wherein the compound of formula (I) is present in about 0.1 wt% to about 3 wt% of the total weight of the dry powder composition.
[0295] Embodiment 26 14. The dry powder composition of any one of embodiments 1-13, wherein the compound of formula (I), or an enantiomer, diastereomer, or pharmaceutically acceptable salt thereof, is present in about 0.5 wt% to about 3.5 wt%, or about 0.8 wt% to about 3.3 wt% of the total weight of the dry powder composition.
[0296] Embodiment 27 27. The dry powder composition of embodiment 26, wherein the compound of formula (I), or a pharmaceutically acceptable salt thereof, is present in about 0.5 wt% to about 3.5 wt%, or about 0.8 wt% to about 3.3 wt% of the total weight of the dry powder composition.
[0297] Embodiment 28 28. The dry powder composition of embodiment 26 or 27, wherein the compound of formula (I) is present in about 0.5 wt% to about 3.5 wt%, or about 0.8 wt% to about 3.3 wt% of the total weight of the dry powder composition.
[0298] Embodiment 29 14. The dry powder composition of any one of embodiments 1-13, wherein the compound of formula (I), or an enantiomer, diastereomer, or pharmaceutically acceptable salt thereof, is present in about 1 wt% to about 2 wt% of the total weight of the dry powder composition.
[0299] Embodiment 30 30. The dry powder composition of embodiment 29, wherein the compound of formula (I), or a pharmaceutically acceptable salt thereof, is present in about 1 wt% to about 2 wt% of the total weight of the dry powder composition.
[0300] Embodiment 31 31. The dry powder composition of embodiment 29 or 30, wherein the compound of formula (I) is present in about 1 wt% to about 2 wt% of the total weight of the dry powder composition.
[0301] Embodiment 32 14. The dry powder composition of any one of embodiments 1-13, wherein the compound of formula (I), or an enantiomer, diastereomer, or pharmaceutically acceptable salt thereof, is present in about 1.2 wt% to about 1.8 wt% of the total weight of the dry powder composition.
[0302] Embodiment 33 33. The dry powder composition of embodiment 32, wherein the compound of formula (I), or a pharmaceutically acceptable salt thereof, is present in about 1.2 wt% to about 1.8 wt% of the total weight of the dry powder composition.
[0303] Embodiment 34 34. The dry powder composition of embodiment 32 or 33, wherein the compound of formula (I) is present in about 1.2 wt% to about 1.8 wt% of the total weight of the dry powder composition.
[0304] Embodiment 35 14. The dry powder composition of any one of embodiments 1-13, wherein the compound of formula (I), or an enantiomer, diastereomer, or pharmaceutically acceptable salt thereof, is present in about 1 wt% to about 1.5 wt% of the total weight of the dry powder composition.
[0305] Embodiment 36 36. The dry powder composition of embodiment 35, wherein the compound of formula (I), or a pharmaceutically acceptable salt thereof, is present in about 1 wt% to about 1.5 wt% of the total weight of the dry powder composition.
[0306] Embodiment 37 37. The dry powder composition of embodiment 35 or 36, wherein the compound of formula (I) is present in about 1 wt% to about 1.5 wt% of the total weight of the dry powder composition.
[0307] Embodiment 38 14. The dry powder composition of any one of embodiments 1-13, wherein the compound of formula (I), or an enantiomer, diastereomer, or pharmaceutically acceptable salt thereof, is present in about 1.4 wt% to about 1.6 wt% of the total weight of the dry powder composition.
[0308] Embodiment 39 39. The dry powder composition of embodiment 38, wherein the compound of formula (I), or a pharmaceutically acceptable salt thereof, is present in about 1.4 wt% to about 1.6 wt% of the total weight of the dry powder composition.
[0309] Embodiment 40. The dry powder composition of embodiment 38 or 39, wherein the compound of Formula (I) is present in about 1.4 wt% to about 1.6 wt% of the total weight of the dry powder composition.
[0310] Embodiment 41 14. The dry powder composition of any one of embodiments 1-13, wherein the compound of formula (I), or an enantiomer, diastereomer, or pharmaceutically acceptable salt thereof, is present in about 1 wt% of the total weight of the dry powder composition.
[0311] Embodiment 42 42. The dry powder composition of embodiment 41, wherein the compound of formula (I), or a pharmaceutically acceptable salt thereof, is present in about 1 wt% of the total weight of the dry powder composition.
[0312] Embodiment 43 43. The dry powder composition of embodiment 41 or 42, wherein the compound of formula (I) is present in about 1 wt% of the total weight of the dry powder composition.
[0313] EMBODIMENT 44 14. The dry powder composition of any one of embodiments 1-13, wherein the compound of formula (I), or an enantiomer, diastereomer, or pharmaceutically acceptable salt thereof, is present in about 1.5 wt% of the total weight of the dry powder composition.
[0314] Embodiment 45 45. The dry powder composition of embodiment 44, wherein the compound of formula (I), or a pharmaceutically acceptable salt thereof, is present in about 1.5 wt% of the total weight of the dry powder composition.
[0315] Embodiment 46 46. The dry powder composition of embodiment 44 or 45, wherein the compound of formula (I) is present in about 1.5 wt% of the total weight of the dry powder composition.
[0316] Embodiment 47 14. The dry powder composition of any one of embodiments 1-13, wherein the compound of formula (I), or an enantiomer, diastereomer, or pharmaceutically acceptable salt thereof, is present in about 0.5 wt% to about 1.5 wt% of the total weight of the dry powder composition.
[0317] Embodiment 48 48. The dry powder composition of embodiment 47, wherein the compound of formula (I), or a pharmaceutically acceptable salt thereof, is present in about 0.5 wt% to about 1.5 wt% of the total weight of the dry powder composition.
[0318] Embodiment 49 49. The dry powder composition of embodiment 47 or 48, wherein the compound of formula (I) is present in about 0.5 wt% to about 1.5 wt% of the total weight of the dry powder composition.
[0319] Embodiment 50 14. The dry powder composition of any one of embodiments 1-13, wherein the compound of formula (I), or an enantiomer, diastereomer, or pharmaceutically acceptable salt thereof, is present in about 0.7 wt% to about 1.3 wt% of the total weight of the dry powder composition.
[0320] Embodiment 51 51. The dry powder composition of embodiment 50, wherein the compound of formula (I), or a pharmaceutically acceptable salt thereof, is present in about 0.7 wt% to about 1.3 wt% of the total weight of the dry powder composition.
[0321] Embodiment 52 52. The dry powder composition of embodiment 50 or 51, wherein the compound of formula (I) is present in about 0.7 wt% to about 1.3 wt% of the total weight of the dry powder composition.
[0322] Embodiment 53 14. The dry powder composition of any one of embodiments 1-13, wherein the compound of formula (I), or an enantiomer, diastereomer, or pharmaceutically acceptable salt thereof, is present in about 0.8 wt% to about 1.2 wt% of the total weight of the dry powder composition.
[0323] EMBODIMENT 54 54. The dry powder composition of embodiment 53, wherein the compound of formula (I), or a pharmaceutically acceptable salt thereof, is present in about 0.8 wt% to about 1.2 wt% of the total weight of the dry powder composition.
[0324] Embodiment 55 55. The dry powder composition of embodiment 53 or 54, wherein the compound of formula (I) is present in about 0.8 wt% to about 1.2 wt% of the total weight of the dry powder composition.
[0325] Embodiment 56 14. The dry powder composition of any one of embodiments 1-13, wherein the compound of formula (I), or an enantiomer, diastereomer, or pharmaceutically acceptable salt thereof, is present in about 0.9 wt% to about 1.1 wt% of the total weight of the dry powder composition.
[0326] Embodiment 57 57. The dry powder composition of claim 56, wherein the compound of formula (I), or a pharmaceutically acceptable salt thereof, is present in about 0.9 wt% to about 1.1 wt% of the total weight of the dry powder composition.
[0327] Embodiment 58 58. The dry powder composition of embodiment 56 or 57, wherein the compound of formula (I) is present in about 0.9 wt% to about 1.1 wt% of the total weight of the dry powder composition.
[0328] Embodiment 59 14. The dry powder composition of any one of embodiments 1-13, wherein the compound of formula (I), or an enantiomer, diastereomer, or pharmaceutically acceptable salt thereof, is present in about 1.5 wt% to about 3.5 wt% of the total weight of the dry powder composition.
[0329] Embodiment 60 60. The dry powder composition of embodiment 59, wherein the compound of formula (I), or a pharmaceutically acceptable salt thereof, is present in about 1.5 wt% to about 3.5 wt% of the total weight of the dry powder composition.
[0330] Embodiment 61 61. The dry powder composition of embodiment 59 or 60, wherein the compound of formula (I) is present in about 1.5 wt% to about 3.5 wt% of the total weight of the dry powder composition.
[0331] Embodiment 62 14. The dry powder composition of any one of embodiments 1-13, wherein the compound of formula (I), or an enantiomer, diastereomer, or pharmaceutically acceptable salt thereof, is present in about 2.5 wt% to about 3.5 wt% of the total weight of the dry powder composition.
[0332] Embodiment 63 63. The dry powder composition of embodiment 62, wherein the compound of formula (I), or a pharmaceutically acceptable salt thereof, is present in about 2.5 wt% to about 3.5 wt% by total weight of the dry powder composition.
[0333] EMBODIMENT 64 64. The dry powder composition of embodiment 62 or 63, wherein the compound of formula (I) is present in about 2.5 wt% to about 3.5 wt% of the total weight of the dry powder composition.
[0334] Embodiment 65 14. The dry powder composition of any one of embodiments 1-13, wherein the compound of formula (I), or an enantiomer, diastereomer, or pharmaceutically acceptable salt thereof, is present in about 2.7 wt% to about 3.3 wt% of the total weight of the dry powder composition.
[0335] Embodiment 66 66. The dry powder composition of embodiment 65, wherein the compound of formula (I), or a pharmaceutically acceptable salt thereof, is present in about 2.7 wt% to about 3.3 wt% of the total weight of the dry powder composition.
[0336] Embodiment 67 67. The dry powder composition of embodiment 65 or 66, wherein the compound of formula (I) is present in about 2.7 wt% to about 3.3 wt% of the total weight of the dry powder composition.
[0337] Embodiment 68 14. The dry powder composition of any one of embodiments 1-13, wherein the compound of formula (I), or an enantiomer, diastereomer, or pharmaceutically acceptable salt thereof, is present in about 2.8 wt% to about 3.2 wt% of the total weight of the dry powder composition.
[0338] Embodiment 69 69. The dry powder composition of embodiment 68, wherein the compound of formula (I), or a pharmaceutically acceptable salt thereof, is present in about 2.8 wt% to about 3.2 wt% of the total weight of the dry powder composition.
[0339] Embodiment 70 70. The dry powder composition of embodiment 68 or 69, wherein the compound of formula (I) is present in about 2.8 wt% to about 3.2 wt% of the total weight of the dry powder composition.
[0340] Embodiment 71 14. The dry powder composition of any one of embodiments 1-13, wherein the compound of formula (I), or an enantiomer, diastereomer, or pharmaceutically acceptable salt thereof, is present in about 2.9 wt% to about 3.1 wt% of the total weight of the dry powder composition.
[0341] Embodiment 72 72. The dry powder composition of embodiment 71, wherein the compound of formula (I), or a pharmaceutically acceptable salt thereof, is present in about 2.9 wt% to about 3.1 wt% of the total weight of the dry powder composition.
[0342] Embodiment 73 73. The dry powder composition of embodiment 71 or 72, wherein the compound of formula (I) is present in about 2.9 wt% to about 3.1 wt% of the total weight of the dry powder composition.
[0343] EMBODIMENT 74 14. The dry powder composition of any one of embodiments 1-13, wherein the compound of formula (I), or an enantiomer, diastereomer, or pharmaceutically acceptable salt thereof, is present in about 3 wt% of the total weight of the dry powder composition.
[0344] Embodiment 75 75. The dry powder composition of embodiment 74, wherein the compound of formula (I), or a pharmaceutically acceptable salt thereof, is present in about 3 wt% of the total weight of the dry powder composition.
[0345] Embodiment 76 76. The dry powder composition of embodiment 74 or 75, wherein the compound of formula (I) is present in about 3 wt% of the total weight of the dry powder composition.
[0346] Embodiment 77 77. The dry powder composition of any one of embodiments 1-76, wherein the leucine is present at about 12 wt% to about 42 wt% of the total weight of the dry powder composition.
[0347] Embodiment 78 78. The dry powder composition of embodiment 77, wherein the leucine is present in about 15 wt% to about 40 wt% of the total weight of the dry powder composition.
[0348] Embodiment 79 79. The dry powder composition of embodiment 78, wherein the leucine is present in about 18 wt% to about 33 wt% of the total weight of the dry powder composition.
[0349] Embodiment 80 80. The dry powder composition of embodiment 79, wherein the leucine is present in about 20 wt% to about 33 wt% of the total weight of the dry powder composition.
[0350] Embodiment 81 81. The dry powder composition of embodiment 80, wherein the leucine is present in about 25 wt% to about 33 wt% of the total weight of the dry powder composition.
[0351] Embodiment 82 82. The dry powder composition of embodiment 81, wherein the leucine is present at about 27 wt% to about 33 wt% of the total weight of the dry powder composition.
[0352] Embodiment 83 83. The dry powder composition of embodiment 82, wherein the leucine is present in about 27 wt% to about 31 wt% of the total weight of the dry powder composition.
[0353] Embodiment 84 84. The dry powder composition of embodiment 83, wherein the leucine is present in about 27 wt% to about 30 wt% of the total weight of the dry powder composition.
[0354] Embodiment 85 85. The dry powder composition of embodiment 84, wherein the leucine is present at about 28 wt% to about 30 wt% of the total weight of the dry powder composition.
[0355] Embodiment 86 81. The dry powder composition of embodiment 80, wherein the leucine is present at about 20 wt% of the total weight of the dry powder composition.
[0356] Embodiment 87 81. The dry powder composition of embodiment 80, wherein the leucine is present at about 30 wt% of the total weight of the dry powder composition.
[0357] Embodiment 88 88. The dry powder composition of any one of embodiments 1-87, wherein the sugar is trehalose.
[0358] Embodiment 89 88. The dry powder composition of any one of embodiments 1-87, wherein the sugar is mannitol.
[0359] Embodiment 90 14. The dry powder composition of any one of embodiments 1-13, comprising: (a) about 1.5 wt. % of a compound of formula (I), or an enantiomer, diastereomer, or pharmaceutically acceptable salt thereof; (b) about 29.3 wt. % of leucine; and the remainder (c) mannitol.
[0360] Embodiment 91 91. The dry powder composition of embodiment 90, comprising: (a) about 1.5 wt% of a compound of formula (I), or a pharmaceutically acceptable salt thereof; (b) about 29.3 wt% of leucine; and the remainder (c) mannitol.
[0361] Embodiment 92 92. The dry powder composition of embodiment 90 or 91, comprising: (a) about 1.5 wt% of the compound of formula (I); (b) about 29.3 wt% of leucine; and the remainder (c) mannitol.
[0362] Embodiment 93 14. The dry powder composition of any one of embodiments 1-13, comprising: (a) about 1 wt. % of a compound of formula (I), or an enantiomer, diastereomer, or pharmaceutically acceptable salt thereof; (b) about 29.3 wt. % of leucine; and the remainder (c) mannitol.
[0363] Embodiment 94 94. The dry powder composition of embodiment 93, comprising: (a) about 1 wt. % of a compound of formula (I), or a pharmaceutically acceptable salt thereof; (b) about 29.3 wt. % of leucine; and the remainder (c) mannitol.
[0364] Embodiment 95 95. The dry powder composition of embodiment 93 or 94, comprising: (a) about 1 wt% of the compound of formula (I); (b) about 29.3 wt% of leucine; and the remainder (c) mannitol. [Example]
[0365] The present invention will be further illustrated by reference to the following examples, however, it should be noted that these examples, like the above-described embodiments, are illustrative and should not be construed as limiting the scope of the invention in any way.
[0366] The following examples relate to two different treprostinil palmityl inhalation powder (TPIP) formulations (TPIP-A and TPIP-B). The compositions of TPIP-A and TPIP-B, expressed as weight ratios, the target weight percentages calculated based on the weight ratios, and the actual weight percentages of the components from a typical batch of each formulation are summarized in Tables D and E, respectively. [Table 4] [Table 5]
[0367] Example 1: Preparation, Characterization, and Encapsulation of an Inhalable Treprostinil Palmityl Dry Powder Formulation This example describes the preparation of TPIP-B by spray drying and encapsulation. This example also describes the characterization of TPIP-B in parallel with TPIP-A for moisture content, residual solvent, particle morphology using scanning electron microscopy (SEM), particle size distribution, and thermal properties. 1. Spray drying production of TPIP-B
[0368] Spray-dried TPIP-B was produced using a BLD-200 spray dryer with a drying gas flow rate of 200 kg / h. Specifically, the spray solution was prepared according to the composition shown in Table 1. [Table 6]
[0369] The composition of the final spray-dried TPIP-B is shown in Table 2. [Table 7]
[0370] The manufacturing process for spray-dried TPIP-B is summarized in Table 3. [Table 8]
[0371] 2. Analytical characterization and stability testing of TPIP-B TPIP-B and TPIP-A were manufactured, packaged in high-density polyethylene bottles, sealed in low-density polyethylene bags with desiccant, then sealed in foil bags and stored at 2-8°C. Initial analytical characterization and stability testing were then performed. Initial analytical characterization included moisture content, residual solvents, particle morphology using SEM, particle size distribution, and thermal properties. The analytical characterization methodology described above is described in U.S. Patent Application No. 16 / 860,428, the disclosure of which is incorporated herein by reference in its entirety. The physical stability of the two spray-dried powder formulations was evaluated using SEM based on changes in thermal properties, moisture content, particle size distribution, and particle morphology from the initial time point at storage conditions of 25°C / 60% RH and 40°C / 75% RH for 1, 3, and 6 months.
[0372] Table 4 summarizes the results of the initial characterization of TPIP-B and TPIP-A, showing that TPIP-B and TPIP-A have similar measured properties. [Table 9]
[0373] Tables 5A, 5B, and 5C show the results of the stability study at 1, 3, and 6 months, respectively. The results show that TPIP-B and TPIP-A had similar stability profiles. [Table 10] [Table 11] [Table 12]
[0374] 3. Powder encapsulation Approximately 7.5 mg of spray-dried TPIP-B was filled into size #3 hydroxypropylmethylcellulose (HPMC) DPI-grade capsules using an Xcelodose 600S. Three sets of capsules were prepared, packaged in high-density polyethylene bottles, sealed in low-density polyethylene bags with desiccant, then sealed in foil bags and stored at 2-8°C. The fine particle dose (FPD) and MMAD were then determined by NGI of the dry powder formulation from the stored capsules. The FPD and MMAD results are shown in Table 6. Additionally, the amount of treprostinil palmitate per capsule was determined to be 114.3 mcg. [Table 13]
[0375] Example 2: Pharmacokinetic evaluation of TPIP-B and TPIP-A in Sprague-Dawley rats material and method A. species Male Sprague-Dawley rats weighing 300-350 g were used in these PK studies. The exact weights of the rats were recorded on the day of the experiment. B. Test System Identification and Randomization 1. Animals arrived at the site at least 3 days before the planned experiment. 2. Upon arrival, animals were identified according to CCAC guidelines. 3. All animal care and vivarium maintenance was recorded and documented at the study facility. 4. The study director randomly assigned animals prior to the experiment and recorded each animal's ID number. C. Drug Administration and Dose Selection 170 mg of TPIP-B or TPIP-A was loaded into a Vilnius Aerosol Generator (VAG), which was connected to a 12-port rodent nasal-only inhalation system (CH Technologies, Westwood, NJ, USA) located at the base of the tower. Airflow through the nasal-only chamber was set at 7 L / min. Material from the VAG was delivered at an output voltage of 1.0 volts, and the aerosol was turned off when all material was aerosolized, which took approximately 40 min. The actual duration of aerosolization was recorded for each exposure. A glass fiber filter was placed over one of the exposure ports and connected to a vacuum source with a vacuum flow of 0.5 L / min for 5 min (starting 5 min after the start of aerosolization and ending 10 min later). A Mercer-style cascade impactor was placed over one of the exposure ports and connected to a vacuum source with a vacuum flow of 0.5 L / min for 5 min. After administration of the test substance (i.e., TPIP-B or TPIP-A), the animals were euthanized for collection of various biological samples (bronchoalveolar lavage fluid, lung, spleen, liver, kidney, heart, stomach, and plasma) depending on the time point (Tables 7 and 8). The tower, nasal restraint tube, and all connecting tubes were washed with an aqueous solution of 0.5% sodium dodecyl sulfate (SDS), tap water, and distilled water between experiments. Powder in the VAG cup was removed, and all parts of the VAG system were blown clean with air. D. Sample Analysis Filters collected from a nasal-only inhalation tower and powder collected with a Mercer-style cascade impactor were analyzed. Treprostinil palmitate (TP) and treprostinil (TRE) concentrations in lung, liver, heart, kidney, spleen, stomach, BALC, and BALF, and plasma were analyzed by LC-MS / MS. TP and TRE values reported as below the level of quantitation (BLQ) were assigned a value of zero, respectively. E. Study Design and Experimental Procedures 1. Study Design Thirty-six (36) rats were exposed to TPIP-A and 36 (36) rats were exposed to TPIP-B. Rats were placed in the chamber once daily for three consecutive days, habituating to the nose-cone chamber for increasing periods of time (starting at 5 min, increasing to 15 min, and ending at 20 min). On the day of dosing, the first cohort of nine rats was placed in a nose-cone restraint chamber connected to a 12-port nasal-only inhalation chamber. The test substance was delivered via a VAG at an airflow of 7 L / min, and the actual dose duration was recorded. A glass fiber filter was placed over one of the exposure ports and connected to a vacuum source with a vacuum flow of 0.5 L / min for 5 min (starting 5 min after the start of aerosolization and ending 10 min later). A Mercer-style cascade impactor was placed over one of the exposure ports and connected to a vacuum source with a vacuum flow of 0.5 L / min for 5 min. After sampling, the impactor was disassembled, and the aerosol was collected at each stage with 4 mL (4 × 1 mL) of 75% IPA. Collection using a Mercer cascade impactor was performed on cohorts 2 and 4. This experiment was performed twice, with each cohort containing nine rats. The following day, cohorts 3 and 4 were exposed to the test article. At the end of compound exposure, blood and tissue samples were obtained according to the schedule outlined in Table 7. IPD necropsy times were recorded. For each time point, rats undergoing the final time point were anesthetized with 2% isoflurane inhalation with pure oxygen. Rats were weighed. Approximately 3.0 mL of blood samples were obtained by cardiac puncture. K2-EDTA tubes were centrifuged at 3,000 rpm for 10 minutes at 4°C. Approximately 0.5 mL of plasma was aliquoted into triplicate 1 mL tubes labeled with study number, animal identification, dose group, and time point. Plasma samples were snap-frozen and stored frozen (-80°C) prior to drug concentration analysis. Animals were exsanguinated by cutting the abdominal aorta. For BAL fluid collection in cohorts 3 and 4, the trachea was isolated and a 14G InSyte catheter was inserted toward the lungs, just above the thoracic inlet, ensuring it was positioned above the carina. A syringe containing 2 mL of sterile PBS was flushed into the lungs. The chest was gently massaged four times by applying internal pressure to the rib cage, after which the BAL fluid was transferred back into the syringe. The wash was repeated with another 2 mL of sterile PBS and transferred to the same Eppendorf tube.The BALF fluid was centrifuged, and the supernatant was removed and stored at -80°C. The last drop of BALF (to remove as much as possible) was discarded. The cell pellet was saved, flash-frozen, and stored at -80°C. The lungs, spleen, kidneys, heart, and liver lobes were collected and cleaned to remove excess tissue, and the stomach was dissected open and emptied of solids. All organs were weighed, placed in 5.0 mL Eppendorf tubes, flash-frozen, and stored at -80°C for subsequent analysis of lung drug concentrations. [Table 14] F. Delivered Drug Dose Calculation Based on Filter Data The total dose and lung-delivered dose were calculated from the equations described in Alexander DJ et al. in Association of Inhalation Toxicologists (AIT) Working Party Recommendation for Standard Delivered Dose Calculation and Expression in Non-Clinical Aerosol Inhalation Toxicology Studies with Pharmaceuticals Inhal. Tox. 20:p1179-1189, 2008, which are derived from the TP concentration in the nasal-only inhalation tower (filter result), respiratory minute volume, exposure time, deposition rate, and body weight.
number
[0376] result [Table 16] [Table 17] [Table 18] [Table 19] [Table 20] [Table 21] [Table 22] [Table 23] [Table 24] [Table 25] [Table 26]
[0377] This study evaluated the plasma, tissue, and BAL (fluid and cellular) pharmacokinetics of two different formulations, TPIP-A and TPIP-B. TPIP-A and TPIP-B exposure was well tolerated at each dose and did not result in any deaths. The total delivered inhaled doses of TPIP-B and TPIP-A were 100.5 and 85.5 μg / kg body weight, respectively (Table 9). C in Cohorts 1-2 exposed to TPIP-B and TPIP-A. max The corresponding lung TPeq concentrations at 0.5 h were an average of 2768 and 2264 ng / g lung tissue, respectively (Table 10). Because BAL extractions were performed in cohorts 3–4 (Table 10), the lung TPeq levels in cohorts 3–4 exposed to TPIP-B and TPIP-A were 1217 and 1084 ng / g, respectively, which were lower than those in comparison cohorts 1–2.
[0378] Over a 24-hour period, the peak lung concentrations (Cmax) of TP, TRE, and TPeq occurred at 0.5 hours after exposure to TPIP-B and TPIP-A in cohorts 1 and 2 (Table 11). Furthermore, there was a monoexponential decrease in lung drug concentrations during this 24-hour period (Table 9 and Figures 1-3). The lung profiles of TPeq in cohorts 3 and 4 with TPIP-B were slightly different, as Cmax occurred at 3 hours after exposure, and TRE Cmax also appeared at 3 hours after exposure to TPIP-A (Table 11). This difference can be explained by the BAL performed in these rats. In general, TPIP-B and TPIP-A have similar pharmacokinetic profiles.
[0379] Plasma concentrations of TRE after inhalation of TPIP-A and TPIP-B were highest at 0.5 h after exposure and declined monoexponentially over 24 h (Table 12). Plasma TP concentrations were very low at 0.5 h (Table 13).
[0380] The pharmacokinetic profiles of TPIP-A and TPIP-B were also assessed by bronchoalveolar lavage (BAL). TP, TRE, and TPeq concentrations were analyzed in cells and fluid collected from BAL after cell removal. Maximum concentrations were found in cells and fluid at 0.5 hours for both formulations, except for cohorts 3 and 4, which were exposed to TPIP, and TRE Cmax was observed at 3 hours post-dose (Tables 15 and 17, and Figures 5–10).
[0381] In summary, the PK profiles of inhaled TPIP-A and TPIP-B showed similar drug profiles, with the highest concentrations of TPeq in the lung and TRE in plasma observed by 30 minutes, and a monoexponential decline in drug levels over 24 hours. Some exceptions were observed for Cohorts 1-2 and 3-4 exposed to TPIP-B. Plasma TRE concentrations increased slightly by 6 hours in Cohorts 1-2, and lung TPeq increased slightly by 3 hours in Cohorts 3-4.
[0382] Example 3: Efficacy of different doses of TPIP-B in hypoxic-challenged telemetered rats material and method A. species Male Sprague-Dawley rats weighing 300-500 g at the time of implantation with a dual pressure telemetry implant device (TRM-54-PP) were used at the start of the study. The exact weight of the rats was recorded on the day of the experiment. B. Test System Identification and Randomization 1. Animals arrived at the site at least 3 days before the planned experiment. 2. Upon arrival, animals were identified according to CCAC guidelines. 3. All animal care and vivarium maintenance was recorded and documented at the study facility. 4. The study director randomly assigned animals prior to the experiment and recorded each animal's ID number. C. Drug Administration and Dose Selection TPIP-B was administered using a Vilnius aerosol generator (VAG). The VAG was connected to a 12-port rodent nasal-only inhalation system (CH Technologies, Westwood, NJ, USA) at the base of the tower. Airflow from the top of the nasal-only inhalation chamber, connected to the bottom, was introduced into the VAG at a flow rate of 7 L / min. TPIP-B was placed in the VAG chamber at doses of 25 mg, 50 mg, 90 mg, and 170 mg for aerosolization of the material at VAG voltages of 0.125, 0.25, 0.5, and 1.0 volts (V), respectively. The aerosol was turned off when all material had aerosolized and exited the VAG chamber or when no visible drug was present at the nasal-only inhalation outlet port. The time for complete aerosolization of the material was measured. The nasal inhalation tower, tubing, and other materials used in the dry powder process were cleaned by sequentially flushing with a 0.5% aqueous solution of sodium dodecyl sulfate (SDS), tap water, and distilled water. After use, any remaining powder inside the aerosol generator was removed using blown air in a fume hood equipped with a HEPA filter. After thorough cleaning of the tower and VAG, the next experiment was performed. D. Sample Analysis Filters collected from the nasal-only inhalation tower were used for analysis of C16TR by high-performance liquid chromatography (HPLC) and charged aerosol detector (CAD). Lung and plasma samples were also analyzed for C16TR and TRE concentrations in lung and plasma using LC-MS / MS. C16TR and TRE values reported as below the level of quantification (BLQ) were assigned a value of zero, respectively. E. Acquisition System A networked personal computer running Microsoft Windows Office 2016 was used for data acquisition. Data on systemic arterial blood pressure (SAP) and RVPP were acquired at a frequency of 500 Hz / s using a Powerlab acquisition system (AD Instruments) and Labchart software. All recordings were stored on a server for further analysis. Data were recorded every minute, and results were presented during the normoxia-hypoxia-normoxia period. To avoid misinterpretation of data due to animal movement or probe position relative to the ventricular wall, three to four consecutive representative pulses of both RVPP and SAP were manually selected. Normal right ventricular pressure has a nearly square, spike-free waveform. A good signal was obtained within the last minute of each of the three steps (normoxia-hypoxia-normoxia) for a 10-minute duration. Each of these values was retranscribed into an Excel file containing data for each individual rat at each time point before drug exposure (baseline data) and at different time points after drug exposure. F. Study Design and Experimental Procedures 1. Study Design Seven (7) telemetered male Sprague-Dawley rats were used in these studies. For each dose, three (3) telemetered rats were used for efficacy evaluation, and seven (7) PK rats were used for PK determination. In each experiment, a filter was connected to the remaining port of the nasal-only inhalation chamber to sample the inhaled drug content. The hypoxic challenge for the telemetered rats, as well as the blood and tissue collection for the PK rats, are shown in Tables 19 and 20. For PK rats, blood samples were collected from the jugular vein, blood was collected by cardiac puncture at the terminal time point, and lungs were harvested, cleared of surrounding tissue, and weighed. Plasma and lungs were stored at -80°C and filtered at 4°C. All telemetered rats were acclimated to the hypoxic exposure chamber, and the rats dedicated to the inhalation study (both telemetered and PK rats) were acclimated to the nasal-only inhalation tower once daily for three consecutive days, for an increasing duration (starting at 5 minutes and ending at 20 minutes at the end of the acclimation period). [Table 27] [Table 28] 2. Normoxia / Hypoxia Challenge of Telemeter-implanted Rats Each rat, housed individually in an 8 x 16 x 8 inch cage, was placed on top of a telemetry receiver (Smart Pad). A custom-made lid was placed on top of the cage, equipped with a port for air inlet, another exhaust port for air outlet, and an oxygen probe (Vernier, Beaverton, OR, USA), to continuously measure the oxygen concentration within the cage. A separate mixing chamber was pre-filled with a hypoxic (10% O2 / 90% N2) gas mixture obtained by combining 100% N2 and ambient air so that the oxygen level stabilized at 10% O2. The hypoxic gas mixture was delivered at a flow rate of approximately 35 L / min to four individual chambers housing the telemeter-implanted rats. The rats were exposed to room air, and cardiovascular data were collected for 10 min. The three-way stopcock was then switched to direct the hypoxic gas from the mixing chamber to the cage housing the rat. The hypoxic air then flowed through the inlet port, replacing the normoxic air in the rat cage. Equilibration took approximately 2 minutes until the rats were fully exposed to the 10% O2 / 90% N2 gas mixture. 。 Cardiovascular parameters were continuously recorded during the 10-minute hypoxic gas exposure. At the end of this 10-minute hypoxic challenge, the inflow of hypoxic air from the mixing box was stopped, the sealed lid was opened, and the rats were returned to normoxic gas breathing. Cardiovascular parameters were continuously recorded during the 10-minute normoxic recovery period following the hypoxic exposure. After collecting normoxic / hypoxic / normoxic exposure data, the rats were returned to their vivarium. All rats were provided with food and water ad libitum after drug and hypoxic exposure. 3. TPIP-B inhalation Three telemetered rats and seven PK rats were exposed to inhaled TPIP-B at voltages of 0.125, 0.25, 0.5, and 1.0 V using a nose cone chamber connected to a 12-port nasal-only inhalation chamber (CH Technologies). Airflow was circulated through the nasal-only chamber using an inlet airflow of 7 L / min. A glass fiber filter was connected to one of the exposure ports during the test. Airflow sampling was performed using a vacuum source established at 0.5 L / min for 5 min, beginning 5 min after the onset of aerosolization and ending 10 min later. Air circulation through the nasal-only inhalation tower entered at the bottom and exited through a port at the top of the tower. G. Method 1. A total of seven (7) male Sprague-Dawley rats previously implanted with dual pressure telemetry implants were used in these three studies. Three telemeter-implanted rats were used in these experiments at 0.125, 0.25, 0.5 V, and 1 V. Additionally, a cohort of seven rats was used for PK determination in each study. A filter was connected to the remaining port in each study. 2. Twenty-four hours before exposing the telemetered rats to the test substance, the rats were exposed to a normoxic / hypoxic / normoxic challenge with cardiopulmonary responses of RVPP and SAP measured continuously during this procedure. This procedure was repeated three times, performed at 1, 6, and 12 hours per day, and the average response from these three determinations was used to represent the baseline, pre-drug response to hypoxia. 3. After baseline hypoxic responses were obtained, exposure to the test article was performed. Rats were exposed to TPIP-B until no powder remained in the VAG cup. Cardiovascular responses to normoxia / hypoxia / return to normoxia challenge were performed as scheduled in Table 21. Blood and lung samples were collected from PK-only rats at the time points indicated in Table 20. 4. The filter was analyzed. 5. For blood sampling, 0.5 mL of blood was collected from the jugular vein of conscious rats and deposited into a 0.5 mL K2-EDTA tube, which was centrifuged at 900 g for 10 minutes at 4°C. 6. Plasma was aliquoted into 1 mL tubes, flash frozen, and stored at approximately −80°C prior to analysis. 7. Rats undergoing the final time point were anesthetized with 2% isoflurane inhaled with pure oxygen, and approximately 3.0 mL of blood samples were obtained by cardiac puncture. The K2-EDTA tubes were centrifuged at 900 x g for 10 minutes at 4°C. 8. Prior to drug concentration analysis, plasma was separated into three 1 mL tubes and stored at approximately -80°C. 9. The left and right lungs were collected, weighed, snap frozen and stored at -80°C for subsequent analysis of pulmonary drug concentrations.
[0383] result [Table 29] [Table 30] [Table 31] [Table 32] [Table 33] [Table 34] [Table 35] [Table 36]
[0384] This study evaluated the efficacy of different doses of DSPE-PEG-free TPIP (TPIP-B). Experiments were performed in conditioned rats using telemetry probes implanted in the right ventricle and descending aorta to measure increases in RVPP and changes in SAP induced by exposure to acute hypoxia. TPIP-B exposure was well tolerated and did not result in any mortality.
[0385] All doses of TPIP-B inhibited the ΔRVPP response to hypoxia over 24 hours. At the highest dose, 138 μg / kg, statistically significant (p<0.05) inhibition was observed over 24 hours except for 12 hours, with a 40% to 70% inhibitory effect. A slightly lower dose of TPIP-B, 57 μg / kg, increased activity over time, reaching a maximum effect (71% inhibition) at 24 hours. The lowest doses, 23 and 6 μg / kg, showed similar drug effects, with maximum activity at 1 hour (approximately 65% inhibition) declining to 57% and 40%, respectively, at 24 hours.
[0386] With increasing doses of TPIP-B, there was a dose-dependent increase in lung treprostinil palmitate equivalent (C16TReq) concentrations and plasma TRE concentrations. Lung C16TReq concentrations were high at 0.5 hours and decreased by 94-97% over 24 hours with each dose of TPIP-B. Plasma TRE concentrations were highest at 0.5 hours with all doses of TPIP-B, declined monoexponentially over 12 hours, and decreased by 89-92% over 24 hours.
[0387] In summary, efficacy studies in telemetered rats following hypoxic challenge demonstrated that the highest dose of TPIP-B, 138 μg / kg, produced a statistically significant inhibition of the increase in RVPP induced by hypoxic challenge over a 24-hour period. Lower doses of TPIP-B were less effective and, although active over a 24-hour period, were not significant at all time points.
[0388] Example 4: Evaluation of TPIP-B on cough and ventilation in guinea pigs In this example, TPIP-B was evaluated for its effects on coughing, changes in ventilation, and changes in Penh (Penh), a dimensionless index of changes in breathing patterns commonly seen during bronchoconstriction, in conscious male guinea pigs (see Chong BTY et al. (1998). Measurement of bronchoconstriction using whole-body plethysmograph: comparison of freely moving versus restrained guinea pigs. J. Pharmacol. Toxicol. Methods 39, 163-168 and Lomask M (2006). Further exploration of the Penh parameter. Exp. and Toxicol. Pathol. 57, 13-20). A. method 1. Experiments were conducted on male Hartley guinea pigs (230–430 g). After 3 days of acclimation to the experimental environment, the guinea pigs were placed in a whole-body plethysmograph for measurements of ventilation (tidal volume, respiratory rate, and minute ventilation), Penh, and cough using established techniques. Cough was measured from plethysmograph recordings showing a large inspiration followed by a large expiration and confirmed by manual observation, video recording, and cough sounds. Ventilation, Penh, and cough data were measured during a 15-minute baseline period before exposure to the dry powder aerosol. 2. Administration of the test substance in this study was accomplished by aerosolizing a specific amount of dry powder at a specific voltage output and microdust range using a Vilnius Aerosol Generator (VAG) (CH Technologies, Westwood, NJ), followed by a 120-minute observation period after the aerosolized compound was administered. Approximately 110 mg of TPIP-B placebo was administered at 1 volt, 2500 mg / m until the powder was completely consumed. 3The microdust range settings were aerosolized at 25 g / m (Table 29). TPIP-B was then administered under similar conditions using approximately 110 mg or 200 mg. To reduce exposure time, the 200 mg dose was also administered at 25 g / m. 3 To standardize the duration of exposure to the test substance, excess TPIP-B ranging from approximately 200 mg to 450 mg was administered at 25 g / m² at increasing VAG outputs of 0.15, 0.3, and 0.5 volts for 15 minutes. 3 Finally, to compare TPIP-A and TPIP-B, approximately 250 mg to 400 mg of TPIP-A was aerosolized at 25 g / m at settings of 0.15 and 0.5 volts. 3 The microdust range was delivered for 15 minutes (Table 29). 3. Air for aerosol delivery for all experiments was supplied by an air compressor with a total inflow of 5.5 L / min of humidified air (30% RH). 4.5 L / min of air was combined with 1 L / min of humidified air to disperse the aerosol, facilitate aerosol delivery to the plethysmograph, and minimize electrostatic adhesion problems. Ventilation, penh, and cough were measured before, during, and after exposure to the test substance. A vacuum suction of 8 L / min was established at the bottom of the plethysmograph, so that air and aerosol entered the top of the system and exited the bottom. A separate vacuum source of 0.5 L / min was also connected to a glass fiber filter assembly attached to a port in the plethysmograph to sample aerosol concentrations in TPIP-B placebo (containing 70 wt% mannitol and 30 wt% leucine), TPIP-B, and TPIP-A aerosols. Except for the TPIP-B placebo, filter samples of TP-B and TPIP-A were analyzed for TP(C16TR) analyte content using HPLC and CAD to determine TP aerosol concentrations. Filter sampling was maintained for the entire duration of the study, i.e., 135 min, while the filter exposure time or drug delivery time (the entire period from drug delivery to depletion at the beginning of the study, then adjusted to a 15-min drug delivery time for additional studies) was used to calculate TP aerosol concentrations in the plethysmograph. 4. The total inhaled TP delivered drug dose in the nose of guinea pigs was calculated using the following equation when the deposition factor (DF) was 100%:
number
[0389] Exposures to TPIP-B placebo, TPIP-B, and TPIP-A were well tolerated and did not result in any deaths. In the first series of experiments in which test substances were aerosolized until all material had disappeared, aerosolization of 100–115 mg of TPIP-B placebo for 32–45 min did not induce coughing in all four guinea pigs tested. Aerosolization of 89–105 mg of TPIP-B for 23–32 min (mean inhalation total delivered dose = 5.7 μg / kg body weight) did not induce coughing in two guinea pigs tested, and a TPIP-B study increasing the aerosolized drug dose to 184–201 mg (mean inhalation total delivered dose = 69.1 μg / kg body weight, exposure times ranging from 62–74 min) did induce coughing in one of three guinea pigs. However, aerosolization of 197 mg of TPIP-B (mean inhaled total delivered dose=69.2 μg / kg body weight) for 19 minutes did not produce coughing in one guinea pig tested.
[0390] In a second series of studies in which excess test substance was aerosolized for a fixed period of 15 minutes, aerosolization of 102-111 mg of TPIP-B (mean inhalation total delivered dose = 17.7 μg / kg body weight) elicited coughing in one of five guinea pigs tested, while a TPIP-B study in which the amount of drug aerosolized was increased to 115-139 mg (mean inhalation total delivered dose = 43.2 μg / kg body weight) did not elicit coughing in two guinea pigs tested. However, a TPIP-B study in which the amount of drug aerosolized was further increased to 211-457 mg (mean inhalation total delivered dose = 153.2 μg / kg body weight) elicited coughing in three of four guinea pigs (Table 29).
[0391] In summary, the results of this study indicate that coughing was observed at a threshold inhaled dose of 17.7 μg / kg for TPIP-B. For comparison, aerosolization of 90–98 mg of TPIP-A for 15 min (mean inhaled total delivered dose = 8.3 μg / kg body weight) did not produce coughing in two guinea pigs tested, and an increase in the amount of aerosolized drug to 322 mg (mean inhaled total delivered dose = 185.4 μg / kg body weight) also did not produce coughing in one guinea pig tested. However, based on the results of previous studies, coughing was observed at a threshold inhaled dose of 12.8 μg / kg for TPIP.
[0392] Administration of TPIP-B produced a 1- to 2-fold increase in Penh compared to values produced by exposure to a TPIP-B placebo. Based on previous experience with bronchoconstrictors such as capsaicin or citric acid, with values typically observed in the 1,000% or greater range during challenge, the Penh parameter values suggested that TPIP-B is not likely to cause bronchoconstriction and that inhaled doses of TPIP-B do not result in consistent changes in ventilation.
[0393] Lung TPeq concentrations increased as a function of inhaled drug dose (Table 29). [Table 37]
[0394] This study investigated the effects of TPIP-B on coughing and ventilation in guinea pigs, a species that exhibits coughing after exposure to inhaled TRE administered by nebulization. The results of this study showed that coughing occurred with TPIP-B at a threshold delivered dose of 17.7 μg TP / kg body weight (equivalent to 11.2 μg TRE / kg body weight), approximately nine times higher than the threshold dose of 1.2 μg TRE / kg body weight that induces coughing in guinea pigs. The cough threshold for TPIP-B is similar to that of TPIP-A at 12.8 μg TP / kg body weight (equivalent to 8.1 μg TRE / kg body weight).
[0395] The TRE dose is derived from the formula: TRE (equivalent) dose = TP dose x 390.52 / 614.94, (614.94 and 390.52 are the molecular weights of TP and TRE, respectively).
[0396] After exposure to TPIP-B at the cough threshold inhaled dose, the first bout of coughing occurred at 34 minutes, which was later than the timing of coughing with nebulized TRE, which occurred within the first 10 minutes of exposure. The cough response was representative of that observed with treprostinil exposure and occurred in distinct bouts of coughing (as seen in the TPIP-A study) rather than as individual coughs.
[0397] In summary, coughing occurred at a delivered dose of 17.7 μg TP / kg body weight (equivalent to 11.2 μg TRE / kg body weight) of TPIP-B, which was 9-fold higher than the delivered dose of nebulized TRE that elicited coughing in guinea pigs. There were no significant changes in cough and ventilatory responses between TPIP-B and TPIP-A.
[0398] Example 5: Evaluation of the safety, tolerability, and PK profile of single and multiple daily doses of TPIP-B in healthy adults design To evaluate the PK profile of TPIP-B in healthy adults, TPIP-B was formulated as a dry powder composition and administered via inhalation in single or multiple dose studies, as shown in Figure 19. The following single doses were tested: 112.5 μg, 225 μg, 450 μg, and 675 μg. Multiple dose groups were configured as follows: 225 μg, and 112.5 μg were administered on days 1-4, followed by an escalation where the dose increased to 225 μg on day 5.
[0399] All doses were administered using a 112.5 μg single-acting capsule. Blood samples for PK evaluation in the single-dose groups were collected within 15 minutes before dosing and at 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24 (Day 2), 36 (Day 2), 48 (Day 3), and 72 (Day 4) hours after administration of TPIP-A or placebo. PK assessments in the multiple-dose groups were performed within 30 minutes prior to dosing and at 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, and 12 hours after dosing on day 1, prior to dosing only on days 2, 3, 4, 5, and 6, and prior to dosing on day 7, as well as at 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24 (day 8), 48 (day 9), and 72 (day 10) hours after dosing. result
[0400] Treprostinil PK is linear (i.e., CL / F, Vd / F, and t 1 / 2 The systemic exposure was linearly related to dose with low to moderate interindividual variability. No accumulation was observed at steady state. max and long t 1 / 2 (7-12 hours) were observed with both single and multiple daily doses. PK profiles for the single and multiple dose groups are provided in Tables 30A (single dose group) and 30B (multiple dose group). max , AUC, and t 1 / 2 may range from 80 to 125% of the values provided in Tables 30A and 30B. [Table 38] [Table 39] For Tables 30A and 30B: AUC, area under the plasma concentration versus time curve; CL / F, apparent total drug clearance after oral administration; CV, coefficient of variation; C max , maximum observed plasma concentration, PK, pharmacokinetics, QD, once daily, t 1 / 2, terminal phase half-life; TPIP, treprostinil palmityl inhalation powder; Vd / F, apparent volume of distribution after non-intravenous drug administration. a AUC for the single dose group = AUC extrapolated from time 0 to infinity, b n=5. c AUC for multiple dose groups = AUC from 0 to 24 hours at steady state.
[0401] Single and multiple doses of TPIP-B were generally well tolerated in healthy adults. A dose-escalation strategy in the multiple-dose groups improved tolerability. Treatment-emergent adverse events (TEAEs) were dose-related and generally mild (80.6%). No serious or severe TEAEs were observed. TEAEs are shown in Tables 31A (single-dose group) and 31B (multiple-dose group). [Table 40] [Table 41]
[0402] While the invention as described has been described in connection with specific embodiments thereof, those skilled in the art will recognize that various modifications can be made and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process step(s), to the spirit and scope of the invention as described. All such modifications are intended to be within the scope of the claims appended hereto.
[0403] All patents, patent applications, patent application publications, journal articles, and protocols referenced herein are incorporated by reference in their entirety for all purposes.
Claims
1. (a) from about 0.1 wt % to about 5 wt % of formula (I); [Formula 1] In the formula, R 1 is tetradecyl, pentadecyl, hexadecyl, heptadecyl, or octadecyl, or an enantiomer, diastereomer, or a pharma- ceutically acceptable salt thereof; (b) about 10 wt % to about 50 wt % leucine; and The remainder (c) is a sugar selected from the group consisting of trehalose and mannitol; A dry powder composition, the total of (a), (b), and (c) being 100 wt %.
2. R 1 2. The dry powder composition of claim 1, wherein is hexadecyl.
3. R 1 3. The dry powder composition of claim 2, wherein is linear hexadecyl.
4. The dry powder composition of claim 1, wherein (a) is a compound of formula (I), or a pharma- ceutically acceptable salt thereof, and the compound of formula (I), or a pharma- ceutically acceptable salt thereof, is present in an amount of from about 1 wt. % to about 2 wt. %, or from about 0.5 wt. % to about 1.5 wt. %, of the total weight of the dry powder composition.
5. 5. The dry powder composition of claim 1, wherein the leucine is present at about 25 wt% to about 33 wt% of the total weight of the dry powder composition.
6. The dry powder composition of any one of claims 1 to 5, wherein the sugar is mannitol.
7. A dry powder composition for treating pulmonary hypertension (PH) in a patient in need thereof, comprising an effective amount of a compound of formula (I): [Case 2] wherein R 1 is tetradecyl, pentadecyl, hexadecyl, heptadecyl, or octadecyl, or an enantiomer, diastereomer, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable carrier, wherein during the administration period, an initial dose of 80 to 160 μg of said compound of formula (I), or an enantiomer, diastereomer, or a pharma- ceutically acceptable salt thereof, is administered once daily in a single administration session, said initial dose being A dry powder composition that is adjusted to the maximum tolerated dose of the patient during the administration period.
8. A dry powder composition for treating pulmonary hypertension (PH) in a patient in need of treatment as described in any one of claims 1 to 6, wherein the dry powder composition is administered to the lungs of the patient via inhalation using a dry powder inhaler.
9. The dry powder composition of claim 8, wherein the dry powder composition is administered once daily during an administration period, and the dose of the compound of formula (I), or its enantiomer, diastereomer, or pharma- ceutically acceptable salt in the dry powder composition is titrated from an initial dose to a maximum tolerated dose for the patient, the initial dose being well tolerated by the patient and less than the maximum tolerated dose for the patient.
10. 10. The dry powder composition of any one of claims 7 to 9, wherein the PH is pulmonary arterial hypertension (PAH).
11. 10. The dry powder composition of any one of claims 7 to 9, wherein the PH is PH associated with interstitial lung disease (ILD).
12. 12. The dry powder composition of claim 11, wherein the ILD comprises one or more pulmonary conditions selected from the group consisting of idiopathic pulmonary fibrosis (IPF), idiopathic interstitial pneumonia (COP), desquamative interstitial pneumonia, nonspecific interstitial pneumonia, hypersensitivity pneumonitis, acute interstitial pneumonia, interstitial pneumonia, connective tissue disease, sarcoidosis, or asbestosis.
13. 13. The dry powder composition of any one of claims 7 and 9-12, wherein treating comprises improving the exercise performance of said patient during said administration period compared to the exercise performance of said patient prior to said administration period.
14. 14. The dry powder composition of claim 13, wherein improving exercise performance comprises increasing the patient's walking distance in a six minute walk test (6MWT) during said administration period by at least about 5 meters, at least about 10 meters, at least about 20 meters, at least about 30 meters, at least about 40 meters, or at least about 50 meters compared to the patient's walking distance in the 6MWT before said administration period.
15. 15. The dry powder composition of any one of claims 7 and 9-14, wherein treating comprises decreasing a pulmonary vascular index (PVRI) of said patient during said administration period compared to said patient's PVRI prior to said administration period.
16. A dry powder composition described in any one of claims 7 and 9 to 15, wherein the dose is adjusted to a higher dose after the patient has tolerated the dose for two or more days.
17. The dry powder composition of claim 16, wherein the two or more days is selected from two days, three days, four days, five days, six days, or seven days.
18. The dry powder composition of any one of claims 7 and 9 to 17, wherein the dose is adjusted to a lower dose after the patient experiences an adverse reaction to the compound of formula (I), or an enantiomer, diastereomer, or pharma- ceutically acceptable salt thereof.
19. The dry powder composition of any one of claims 7 and 9 to 18, wherein the patient is administered two or more different doses of the compound of formula (I) during the administration period.
20. The dry powder composition of claim 19, wherein the patient is administered three different doses of the compound of formula (I) during the administration period.
21. The dry powder composition of claim 19, wherein the patient is administered four different doses of the compound of formula (I) during the administration period.
